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Abstract 
This thesis concerns the clinical epidemiology of HIV infection in Zimbabwean 
adolescents. Without treatment, there is a very high risk of death in the early 
years of life in HIV-infected infants. However, in recent years increasing 
numbers of adolescents have been presenting to health care services with 
symptomatic HIV infection and with features suggesting longstanding disease. 
Population-based surveys in Southern Africa have shown HIV prevalence rates 
among older children and adolescents to be much higher than would be 
anticipated if HIV-infants were not surviving early childhood. 
The burden and spectrum of HIV-associated morbidity among adolescents was 
investigated with two studies at secondary and primary care level, respectively. 
The main finding was of an extremely high prevalence of HIV infection at both 
levels of the health system, with HIV infection being the single most common 
cause of hospital admission and death among adolescents. Mother-to-child 
transmission was the most likely source of HIV infection in the majority, 
suggesting a substantial epidemic of older survivors of vertical HIV infection. 
Other countries with severe HIV epidemics may be experiencing a similar trend 
as their HIV epidemics mature. 
The lack of awareness of the possibility of survival to older childhood and 
adolescence with maternally-acquired, untreated HIV infection results in many 
missed opportunities for diagnosis, with HIV infection frequently not diagnosed 
until presentation with a severe HIV-related illness. The median CD4 count in 
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HIV-infected adolescents in primary care was 350cells/µl compared to a 
median CD4 count of 151cells/µl among hospitalised adolescents, suggesting 
that HIV testing in primary care identifies HIV-infected adolescents at an earlier 
stage of infection. Provider-initiated HIV testing and counselling in primary 
care was highly acceptable to adolescents and guardians. 
Provision of care has been adversely affected by under-appreciation of the 
numbers of surviving adolescents living with HIV, and the special needs of this 
age-group have not been distinguished from those of younger children. Young 
people who have acquired HIV perinatally are stigmatised by society who 
assume they must have acquired it through "bad" behaviour themselves, since it 
is not widely appreciated that long-term survival following vertical infection is 
possible. Immediate priorities are earlier diagnosis of HIV infection and 
improved management of HIV-infected adolescents. Possible areas of 
intervention are discussed in the final chapter. Similar studies are needed in 
neighbouring countries to investigate the generalisability of these findings. 
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1 Introduction 
1.1 Background 
The HIV pandemic has been established for nearly thirty years and 
approximately 33 million people worldwide were estimated to be living with 
HIV infection in 2008.1 HIV has had a dramatic demographic impact in 
countries with generalised epidemics, where adult mortality has doubled or 
trebled, life expectancy has fallen to levels typical of the 1950s and up to one in 
four children have become orphaned as a result of parents dying of HIV/AIDS. 2-3 
Southern Africa is the worst affected region, with HIV prevalence rates 
exceeding 15% in most countries. ' Adult HIV prevalence has been at these 
extremely high rates for the last 10 to 15 years, with even higher rates among 
pregnant women. Without interventions, the risk of mother-to-child 
transmission (MTCT) of HIV is 25-35%, and thus the adult epidemic has been 
accompanied by a regional epidemic of vertically-acquired HIV, with substantial 
impact on child mortality. 14 
Unlike adults, where median time from HIV infection to development of AIDS is 
about 10 years, the natural history of HIV in infants is dominated by a very high 
risk of rapid progression and the probability of survival has been reported from 
prospective studies of vertically HIV-infected babies to be about 50% by age 
two years in African cohorts. 5-7 Survival to older childhood without 
antiretroviral therapy (ART) among HIV-infected infants was thus considered 
exceptional. 
14 
Exact survival probabilities for infants infected by HIV through MTCT are ill- 
defined beyond five years of age as there are no direct cohort data, and in 
developed countries the natural history of HIV has been modified by availability 
of ART. Emerging epidemiological data, however, suggests that up to a third of 
HIV-infected infants do not have rapidly progressive disease, and median 
survival in this subgroup of slow progressors is thought to be at least eight 
years and potentially up to sixteen years. 8-9 As such, overall survival to 
adolescence for all vertically infected infants is likely to be in the range of 10 to 
20% of those infected. Thus an emerging epidemic of HIV-infected long-term 
survivors (LTS) of vertical infection is anticipated in countries with severe 
longstanding HIV epidemics during the coming decade, with profound 
implications for adolescent health. 
Population-based surveys in Southern Africa that have included older children 
have consistently reported high HIV prevalence rates of between 2-6% among 
older children and young adolescents. ' 0-13 Of note, young women are at 
disproportionately higher risk of HIV infection through sexual transmission 
than young men, but these surveys showed no difference in HIV prevalence by 
sex in this age-group, implying a non-sexual route of HIV acquisition. 14 Studies 
from other countries in the region confirm that considerable numbers of HIV- 
infected older children and adolescents with features suggestive of long- 
standing HIV infection are presenting for care. 15-16 
Diagnosis of HIV infection is a prerequisite for accessing care and treatment 
Global coverage of HIV testing and counselling remains low, despite improved 
15 
access to voluntary counselling and testing (CT) services. With increased 
availability of ART internationally, there has been a shift from client-initiated to 
provider-initiated approaches to HIV testing. World Health Organisation 
(WHO) guidelines advise health care providers in countries with generalised 
HIV epidemics to offer HIV testing to anyone attending any health facility as a 
standard part of health care (provider-initiated testing and counselling). 17 
Children, however, face additional barriers in accessing HIV diagnosis. In 
children younger than 18 months, diagnosis of HIV requires expensive 
virological tests which are not always readily available in many parts of the 
world where the risk of HIV in infancy is highest. 18 In adolescents, access to HIV 
diagnosis is difficult because of paucity of diagnostic services aimed at this age- 
group and the perception that only sexually active adolescents are at risk of HIV 
infection. 
1.2 Project starting points 
The observation that adolescents were increasingly presenting to health care 
services with symptomatic HIV infection and features of longstanding disease, 
was the initial observation that led to the current work. 15 The findings from 
population-based surveys in Southern Africa, which showed higher than 
anticipated HIV prevalence rates among adolescents, raised the possibility that 
long-term survival of children following MTCT might be a phenomenon of 
greater public health significance than had previously been appreciated. 10-13 
The identification of a population with slow progressing infection would 
provide the potential to advance the understanding of the mechanisms involved 
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in the control of HIV infection through studies of the immunological and 
virological aspects of HIV infection. 
Zimbabwe has the 5th highest adult HIV prevalence in the world and less than 
half of HIV-infected pregnant women access interventions for prevention of 
MTCT, so that vertical infection continues to occur. ' 18 Zimbabwe has 
experienced an otherwise comparable HIV epidemic, but with much earlier 
onset than neighbouring countries; HIV prevalence rates peaked at 29% as far 
back as 1997. ART for prevention of mother-to-child transmission (PMTCT) 
started to become available only around 2004.19 Thus Zimbabwe is likely to 
already have a relatively advanced epidemic of adolescent LTS. 
HIV diagnosis and treatment initiatives in Southern Africa have mainly been 
aimed at adults, and more recently at young children. Adolescents have been a 
priority target group for prevention efforts, but there has been little provision 
of HIV testing or treatment services for this age-group. Delay in diagnosis may 
compromise treatment outcomes and contribute to unwitting onward HIV 
transmission. Identification of strategies to facilitate HIV testing and entry into 
care in adolescents will help focus attention on the needs of this age-group that 
have so far not been considered. 
1.3 Aims and objectives 
The overall aims were to investigate the clinical epidemiology of HIV infection 
among adolescents in Zimbabwe, a country with a long-standing, severe HIV 
17 
epidemic, and to explore how earlier diagnosis and entry into HIV care in this 
age-group can best be achieved. 
The specific objectives were to investigate: 
1. the prevalence of HIV infection among adolescents presenting 
acutely at different levels of health care services 
2. the relative importance of HIV infection as a cause of morbidity and 
mortality among adolescents 
3. the likely modes of HIV acquisition among adolescents 
4. the most common clinical consequences of late diagnosis of 
vertically-acquired HIV infection 
S. the uptake and acceptability of provider-initiated testing and 
counselling among adolescents in primary health care 
6. an approach to creating a diagnostic algorithm for HIV infection 
and evaluating its potential performance in low and high HIV 
prevalence settings 
1.4 Outline of thesis 
In Chapter 1, the starting point that led up to the project, the aims and 
objectives of the research and the plan of the thesis are outlined. In Chapter 2, a 
review of published literature relating to the epidemiology, natural history and 
clinical aspects of HIV infection in adults and children is presented. Studies 
relating to long term survival in children following vertical HIV infection and 
morbidity in HIV-infected older children in the pre-ART era are also reviewed. 
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Methods that are common to more than one study are described in Chapter 3. 
The methods specific to individual studies are described in the respective 
chapters in which the study is described. 
Chapters 4 and S refer to a study conducted in the two public hospitals of 
Harare. In Chapter 4, the prevalence of HIV infection and the causes of 
admission among 301 hospitalised adolescents are reported. In Chapter 5, the 
likely mode of HIV acquisition among these hospitalised adolescents is 
explored. 
Chapters 6 to 8 refer to studies conducted in two primary health care 
polyclinics in Harare among 594 adolescents, 506 attending for acute primary 
care (APC) and 88 attending for antenatal care (ANC). In Chapter 6 the burden 
of undiagnosed HIV infection among adolescents presenting acutely for primary 
care is reported and the mode of HIV transmission is further explored by 
comparing prevalence of characteristics consistent with vertical transmission 
among APC attendees with sexually active adolescents (i. e. adolescents 
attending for ANC). The perception of risk of vertically-acquired HIV infection 
and the acceptability of provider-initiated HIV testing among adolescents and 
their guardians was investigated through a qualitative study and is reported in 
Chapter 7. In Chapter 8a simple algorithm using clinical and demographic data 
that could be used by health care workers at primary care level to identify 
adolescents at risk of being HIV-infected in low and high HIV prevalence 
settings is described. 
The main conclusions, recommendations for further research and potential 
intervention strategies are discussed in Chapter 9. 
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2 Literature review 
2.1 Human Immunodeficiency Virus infection 
2.1.1 Origin of the HIV pandemic 
HIV is a retrovirus that primarily infects monocytes and CD4+ T-helper 
lymphocytes (CD4 cells), resulting in a lifelong infection characterised by 
progressive immunodeficiency and the occurrence of opportunistic infections. 20 
The HIV epidemic was identified in 1981 in the United States when cases of 
unusual tumours and opportunistic infections (Kaposi's sarcoma and 
Pneumocystis pneumonia [PCP]) in previously well homosexual men were 
recognised as being due to a new form of acquired immune deficiency 
syndrome or AIDS, associated with a selective depletion of CD4 cells. 
Epidemiological investigations indicated that the disease was sexually 
transmitted and could also be acquired from administration of infected blood 
products and exposure to blood-contaminated needles. 21-22 HIV was identified 
as being the cause of AIDS in 1983, and the development of a serological test to 
identify HIV infection in 1984 was followed by the discovery that AIDS was not 
only a western disease but also occurring in the heterosexual population of 
central African countries. 23 In Kinshasa, Democratic Republic of Congo (DRC), 
the annual number of cases of Kaposi's sarcoma diagnosed in a large public 
sector hospital tripled from 1970 to 1984, and epidemic increases in the 
wasting syndrome (termed "Slim disease"), a sentinel marker of AIDS, were 
noted in the late 1970s in Uganda and DRC. 24-25 HIV is now recognised to have 
originated in Africa, which remains the worst affected continent. 
20 
HIV arose through cross-species transmission of the related simian 
immunodeficiency virus (SIV), which is widespread in old world non-human 
primates. 26 The virus was probably first introduced to human in the 1950s, and 
the hypothesis that Central Africa was the origin of the HIV epidemic is 
consistent with the retrospective identification of an HIV positive man living in 
Kinshasa in 1959.27 The existence of two distinct HIV species, HIV-1 and HIV-2, 
was recognised in 1985. Molecular phylogeny studies show that HIV-1 evolved 
from a strain of SIV in a particular sub-species of chimpanzees (Pan troglodytes 
troglodytes), with each of the three groups of HIV-1, M, N and 0, arising from 
geographically distinct chimpanzee populations. 28-29 HIV-2 infection is most 
commonly found in West Africa and originated from a separate monkey species, 
the sooty mangabey (Cercocebus atys). 26 More recently, a new HIV-1 variant 
called Group P, distinct from the three main groups of HIV-1 and thought to be 
derived from SIV in gorillas, has been identified, further supporting the 
hypothesis that zoonotic SIV transmission to man occurs periodically in this 
part of Africa. 30 Simian studies have confirmed that, as in HIV, both sexual 
(horizontal) and perinatal (mother-to-child) transmission are the main modes 
of transmission of SIV. 31 
The ability of HIV to evolve rapidly as a result of error-prone transcription and 
high rates of mutation per replicative cycle and the selection pressure by the 
human population with their own HLA-restricted cellular immune response, 
has resulted in exceptional genetic diversity and led to selection of viral 
adaptations to facilitate human-to-human transmission over a relatively short 
period of time. 32 Notably, Group M HIV-1, which has given rise to the global 
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pandemic, has numerous clades or subtypes A-K as well as circulating 
recombinant forms, and has relatively high person-to-person infectivity. 33-34 
The resulting pandemic has so far infected an estimated 60 million people and 
caused over 25 million deaths. 
2.1.2 Pathogenesis of HIV infection 
Primary infection via the mucosal or parenteral route results in rapid viral 
replication which initially overwhelms the body's immune response resulting in 
extremely high viral loads in blood. Viral replication is partially controlled to a 
quasi-steady lower "viral set-point". 35 The level of the set-point is predictive of 
the rate of subsequent disease progression and response to treatment with 
higher levels having a worse prognosis. 36 The picture in the blood is however, a 
poor reflection of the much higher activity in lymphoid tissue, with the gut- 
associated lymphoid tissue being the most active site of HIV replication. 37-38 
HIV replication results in a substantial depletion of CD4 cells in lymphoid 
tissue. 39 The immune response to HIV is multifaceted: cytotoxic (CD8) T- 
lymphocytes play an important role in controlling infection but are unable to 
eliminate the infection; 40 the humeral response allows infected individuals to be 
identified with antibody detection methods and also plays a role in controlling 
primary infection. 41-42 
The replication of HIV involves an enzyme common to all retroviruses called 
reverse transcriptase, that catalyses the synthesis of a DNA copy of the viral 
RNA. Being an RNA virus with a reverse transcription step, HIV is subject to a 
high mutation rate during replication. Mutants that are recognised with a low 
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affinity by the immune response have a replication advantage and selectively 
replace the initial infecting strain. Eventually the capacity for immune 
regeneration is exhausted and immune function against other pathogens 
becomes increasingly compromised as a consequence of CD4 cell depletion. 40 
Without the intervention of antiretroviral drugs, progressive 
immunosuppression leads to an increasing frequency of opportunistic 
infections, ultimately resulting in death. 20 
HIV infection however, is characterised not only by immune suppression but 
also by chronic immune activation. 43 Infection is accompanied by persistent 
CD8 T-lymphocyte stimulation and increased pro-inflammatory cytokine 
production and lymphocyte turnover, leading to accelerated immunological 
senescence 44-45 Long-term disease can result in fibrosis and scarring of 
supporting lymphoid tissue which is unable to adequately generate CD4 cells 
despite viral suppression. 46 Chronic stimulation of the immune system may be 
a response to ongoing release of HIV antigens from the latent pool of infected 
cells and/or to bacterial antigens from the gut that are able to translocate as a 
result of damage to mucosal lymphoid tissue during early infection. 43 47 Even in 
individuals where HIV levels in plasma are "optimally" suppressed by ART, 
persistent immune activation contributes to residual immune dysfunction and 
may be a factor in the pathogenesis of non-AIDS disease such as cardiovascular 
or lung disease. 48 
2.1.3 HIV Epidemiology in Africa 
HIV-related illnesses are projected to continue as leading global causes of 
premature mortality in the next two decades. Sub-Saharan Africa is by far the 
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worst affected region in the world; 70% of global incident HIV infections and 
deaths attributable to HIV worldwide occurred in this region in 2008.1 
Unlike industrialised countries, the majority of Africans living with HIV are 
women, and HIV prevalence is typically much higher among young women than 
young men. Age-trends suggest very high HIV incidence in the late teens and 
early 20s for women, with peak incidence in men occurring in the late 20s and 
early 30s. These differences are likely to reflect younger age at sexual debut for 
women and their greater exposure to older partners who have had longer to 
acquire HIV infection themselves. There may also be greater biological 
susceptibility to acquiring HIV following exposure to an infected partner among 
women. 14 The prevalence of HIV among women in child-bearing age reaches 
more than 15% in some parts of Southern Africa, with major implications for 
mother-to-child HIV transmission. ' 
The region's epidemics vary significantly in scale: Southern Africa is 
disproportionately affected with adult HIV prevalence rates of 15% or more in 
most countries, in contrast to less severe epidemics in Western Africa and the 
Sahel countries 49 In Eastern and Central Africa HIV prevalence is intermediate, 
typically in the 5-10% range. Studies addressing the question of why the HIV 
epidemic is so much worse in Southern Africa have identified sub-regional 
differences in the following critical aspects: 
i) A greater prevalence of concurrent partnerships in Southern Africa 
than in East and West Africa which allows multiple partners to be 
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infected, particularly during the period of high infectiousness that 
characterises acute HIV infection, when HIV may be introduced into any 
given sexual network; ' 50 
ii) A much higher prevalence of a second sexually transmitted infection 
(Herpes Simplex Virus-2 [HSV-2]) than in West Africa that greatly 
increases individual susceptibility to acquiring HIV infection; 51-52 
iii) A lower prevalence of male circumcision in Southern Africa. Male 
circumcision has been shown to be highly protective of HIV 
transmission to men and, when widely practised, may limit the 
magnitude of the HIV epidemic by indirectly protecting women too. 
53-54 
Following introduction of HIV into a previously unexposed population, there is 
first a period of rising prevalence with relatively little morbidity and mortality, 
as most infected individuals have been relatively recently infected. This is 
followed by a phase of rising morbidity and mortality, typically accompanied by 
stabilisation of HIV prevalence rates, with the proportion of infections among 
people in stable low-risk partnerships increasing. Eventually, HIV prevalence 
begins to decline, with falling prevalence now being reported from most of the 
worst affected countries in sub-Saharan Africa. ' 
Both behavioural change and rising mortality among infected persons as the 
HIV epidemic matures are likely to have contributed to true declines in HIV 
prevalence in some countries. 55 However, there have also been a number of 
fundamental changes to the methodologies used for producing national 
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estimates, contributing to apparent declines especially in the highest HIV 
prevalence countries. The major changes have been greater use of population- 
based national HIV prevalence surveys with less reliance on antenatal surveys, 
upward revision of the assumed median survival from HIV infection to death in 
untreated individuals from 8 to 11 years and a downward adjustment (X0.8) 
from antenatal clinic HIV prevalence estimates when these are used to 
extrapolate HIV prevalence in the general population in urban areas, based on 
studies that have shown a consistent trend towards overestimation of HIV in 
the general population without this adjustment. 56-57 Expanded surveillance 
systems have yielded more representative data and national population-based 
HIV prevalence surveys, adjusted for non-response and other biases, have 
shown considerably lower HIV prevalence rates than extrapolations obtained 
from sentinel site surveillance. 58 
Since 2003, there has been an unprecedented increase in access to HIV 
treatment in resource-limited settings, which is helping to drive a decline in 
HIV-associated mortality. It is likely that the effect of improved access to 
treatment will be an increase in HIV prevalence rates in Africa, as has occurred 
in high-income countries where ART has been available for much longer 
periods. 59 
2.2 Paediatric HIV infection 
Since its identification in 1981, HIV has spread rapidly through sub-Saharan 
Africa mainly through heterosexual transmission. HIV prevalence rates have 
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been particularly high among pregnant women and the adult HIV epidemic has 
thus been followed by an HIV epidemic among children, acquired 
predominantly through MTCT. The global epidemiology of paediatric HIV 
mirrors that of women: 90% of paediatric infections occur in sub-Saharan 
Africa and the improvements in child health outcomes observed in the 1970s 
and 1980s were reversed during the 1990s with child mortality rates being one 
third to two thirds higher than they would have been in the absence of 
HIV/AIDS. 60 
2.2.1 Mother-to-child (vertical) HIV transmission 
MTCT can occur in utero, during delivery and postnatally through breast- 
feeding. Without interventions, the rate of MTCT ranges from 25-35%, with 
differences in rates between populations due to the additional risk through 
breast-feeding. 4 61 Transmission during late pregnancy and the intrapartum 
period contributes relatively more to the overall rate of vertical transmission 
than the early intrauterine period. 61.62 The risk of MTCT is increased by high 
maternal plasma HIV viral load, advanced immunosuppression in the mother, 
vaginal delivery and conditions during labour that increase the risk of the infant 
coming into contact with contaminated fluids in the maternal genital tract 
(prolonged labour, premature rupture of membranes). 63 
Breastfeeding approximately doubles the risk of vertical HIV transmission in 
populations where breast-feeding is the norm compared with areas where 
breastfeeding is uncommon. 63-64 Transmission can occur at any point during 
the breastfeeding period, although there is evidence that this is highest in the 
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first three months postpartum. 65-66 It is not possible to confidently distinguish 
perinatal from early breast-feeding acquisition of HIV, but after the first three 
months the risk of transmission appears to be relatively constant throughout 
the breast-feeding period so that the longer the duration of breast-feeding the 
greater the risk of late postnatal transmission, with a cumulative transmission 
risk of 12-16% at 24 months 65-66 Risk factors associated with an increased risk 
of breast milk transmission include sub-clinical and clinical mastitis, high viral 
load in breast milk and seroconversion of the mother during breastfeeding, 
reflecting increased infectiousness during early HIV infection. 67-68 Mixed 
feeding (adding other foods or fluids to the infant's diet in addition to breast 
milk) carries an increased risk compared to exclusive breast-feeding, possibly 
because exposure to pathogens in non-sterile foods and fluids results in 
intestinal inflammation and increased intestinal epithelial permeability. 69-72 
2.2.2 Prevention of mother-to-child HIV transmission 
Recommended interventions to reduce the risk of MTCT include ART during 
pregnancy, labour and in the early neonatal period, elective Caesarean section 
delivery in women with detectable viraemia, and avoidance of breast-feeding. 
The rapid widespread implementation of these interventions in industrialised 
countries has reduced MTCT rates to 2% or less. 73 
The first trial to demonstrate the efficacy of ART in reducing mother-to-child 
HIV transmission was the ACTG 076 randomised, placebo-controlled trial in 
1994 which showed a 67% reduction in MTCT with a regimen of antepartum 
and intrapartum zidovudine for the mother and six weeks of zidovudine for the 
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infant. 74 Initially it was suggested that ART during pregnancy was too complex 
and costly for low-resource settings, and possibly also more toxic due to higher 
prevalence of nutritional deficiencies and anaemia. Alternative strategies for 
prevention of mother-to-child HIV transmission (PMTCT) with shorter course, 
inexpensive single ART drug regimens were subsequently developed. 75-76 A 
single dose of nevirapine for the mother during labour and for the newborn in 
the first 48 hours decreased transmission by nearly 50% and was 
recommended as a PMTCT strategy for resource-limited settings. 77 However, 
development of resistance to nevirapine is a major concern with the use of 
monotherapy, as this may compromise the subsequent maternal and infant 
response to nevirapine-based ART. 78-8° Guidelines have also recommended 
exclusive breastfeeding in resource-limited settings as use of breast milk 
substitutes was not culturally acceptable or affordable, and mortality risk from 
replacement feeding exceeds the risk of MTCT through breast-feeding, due to 
lack of access to safe water and poor hygiene. 77 81-82 Using simple ART regimens 
and/or exclusive breastfeeding, it is possible to reduce MTCT rates to about 
12% at 6 weeks of age. 61 75-76 
2.2.3 Challenges in controlling the paediatric HIV epidemic 
HIV prevalence rates are disproportionately high among young women of 
reproductive age and there is a high incidence of HIV seroconversion during 
pregnancy and the postpartum period. 83 In one study in South Africa HIV 
incidence was 10.7% per 100 pregnant patient years in women who had tested 
HIV-negative earlier in pregnancy. 84 There is also an unmet need for family 
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planning, which results in high rates of poorly planned and unintended 
pregnancies. 85 
Despite well-evidenced biomedical interventions to reduce the risk of MTCT, 
there are an estimated 1000 new paediatric infections daily, the vast majority 
acquired through MTCT in sub-Saharan Africa. 1 Unlike the rapid widespread 
implementation from the mid-1990s in developed countries, implementation 
and scaling up of PMTCT programs in sub-Saharan Africa has been hampered by 
inadequate funding, weak health systems, and socio-cultural and institutional 
barriers. There is a relatively low HIV testing rate during pregnancy in sub- 
Saharan Africa and only 45% of pregnant women and 30% of exposed infants 
received ART for PMTCT in 2008.18 
Although trends are now changing towards greater effort to provide more 
holistic care, PMTCT was initially conceptualised and rolled out as a simple 
intervention, accomplished during one antenatal visit. In high-resource settings 
Highly Active ART (HAART) has gradually become the mainstay for PMTCT, but 
in Africa attention remained focused on finding short-course, cheap, easy 
regimens. ART was delivered as an intervention to reduce MTCT transmission 
risk, funded and supported by HIV prevention rather than treatment 
programmes that often failed to concurrently identify and treat women who 
met ART eligibility criteria from the perspective of their own health. 86 HIV 
testing in the antenatal setting has not been routinely linked to CD4 cell count 
testing, unlike other HIV testing programs. PMTCT effectively ends at delivery 
and there has been poor linkage between PMTCT programs and maternal and 
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child health services. This has resulted in limited attention being paid to infant 
follow-up and postnatal interventions such as early infant diagnostic testing 
and cotrimoxazole prophylaxis. 87 
There remains an ongoing risk of transmission through breast-feeding, with 
most HIV-infected women breastfeeding their infants for prolonged periods of 
time. 88-89 Clinical trials clearly indicate the efficacy of ART prophylaxis during 
breastfeeding in reducing the risk of MTCT and guidelines are currently being 
modified to provide ART for the infant during the breastfeeding period, as well 
as lowering the CD4 count threshold of providing ART for pregnant women 
from 200 to 350cells/µl, as national ART programmes expand. 90-92 
2.3 Natural history of HIV infection 
2.3.1 Adults 
The first clinical signs and symptoms of HIV infection occur at the time of the 
initial immune response to HIV infection ("seroconversion illness"), which has 
variable severity but usually consists of a self-limiting infectious 
mononucleosis-like syndrome, with symptoms starting about six weeks after 
the primary infection. Primary HIV infection is followed by a variable period of 
clinical latency, usually lasting several years, during which most individuals 
remain well despite sustained viral replication at a high rate, a rapid turnover of 
CD4 cells and continued inflammation. 20 During this stage the CD4 count 
declines at a variable, but usually slow and steady, rate of approximately 40- 
60cells/µl per year. Immune function becomes progressively compromised as a 
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consequence of CD4 cell depletion, leading to an increasing frequency of 
opportunistic infections. 20 
Most studies have reported similar HIV disease progression rates in Africa to 
those reported in developed countries before the use of ART, with a median 
time from seroconversion to AIDS of about ten years. 5 93-94 However, survival 
after diagnosis appears to be shorter in African countries and this may be partly 
due to more advanced immunodeficiency at diagnosis of HIV infection in 
Africa. 95-96 The risk of death is highest in those individuals with a CD4 count of 
less than 200cells/µl, with a steep rise in risk among those with a CD4 count of 
less than 50cells/µ1.95 97 
The spectrum of infections during the course of HIV infection varies with the 
degree of immunosuppression. In the early stages, increased susceptibility to 
infection is limited to high grade pathogens such as Mycobacterium tuberculosis, 
whereas individuals with advanced immunosuppression (particularly when the 
CD4 count drops below 200cells/µl) are at risk of life-threatening disease 
following infection with low grade pathogens such as Pneumocystis jirovecii. 
The extent of exposure to potential pathogens also influences the pattern of 
HIV-associated disease, so that the incidence and relative frequency of the 
common opportunistic pathogens differs markedly between different 
geographical regions and also by age (as discussed below) 98-101 Thus, the main 
causes of HIV-associated morbidity and mortality should ideally be investigated 
for each distinct region and subpopulation in which prophylaxis against 
opportunistic infections is being considered. 
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The two most frequent opportunistic infections of developed countries, PCP and 
Kaposi's sarcoma, are less prevalent among African hospitalised patients. 98102 
Clinical and autopsy studies show that the commonest causes of HIV-associated 
mortality in Africans are tuberculosis (TB), wasting syndrome, pneumonia, 
cryptococcal meningitis, and bloodstream infections (BSI). 94 103-108 The most 
frequent isolates in patients with BSI are M. tuberculosis, Streptococcus 
pneumoniae, Salmonella spp and Cryptococcus neoformans. 105 109-111 Minor 
mucocutaneous problems, respiratory tract infections, severe bacterial 
infections, chronic fever and chronic diarrhoea are common before patients 
develop AIDS. 94 112 However, prevalence of specific conditions are affected by 
referral patterns, the study population (outpatients versus hospitalised 
patients), diagnostic methods used and the diseases reported. 98 
2.3.2 Infants and children 
Infants who acquire HIV infection from their mothers develop 
immunodeficiency much faster than adults. In Europe and the US, 
approximately 20-25% of HIV-infected children progressed to AIDS or died in 
infancy in the pre-ART era while the median incubation period in adults is 
about 10 years, with only a minority developing AIDS in the first three years 
after infection. ' 13-114 This may be explained by the immaturity of the immune 
system at the time of HIV acquisition in infants (as discussed in section 2.4.1). 
In general, an early onset of HIV-related conditions is associated with an 
increased risk of death. 115-116 The most frequent AIDS-defining conditions are 
PCP which has a peak incidence between three and six months of age, 
cytomegalovirus (CMV) infection, and progressive encephalopathy (PE) 
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associated with loss of brain growth, developmental delay and motor 
abnormalities. 117-122 HIV-infected infants are exposed to primary infection with 
opportunistic organisms, which differs from the reactivation of such infections 
that occurs in adults. These manifestations may also be a result of the newborn 
macrophage system being particularly susceptible to HIV infection (and to other 
pathogens), leading to dissemination to the central nervous system and to other 
sites such as the lung, when infected monocytes migrate as tissue 
macrophages. 123-124 
Failure to thrive, oral candidiasis, hepatosplenomegaly, unexplained persistent 
fever and diarrhoea are also common findings. 116 119 125-130 HIV-infected 
children are less likely than adults to develop opportunistic infections such as 
toxoplasmosis, TB, cryptococcosis, and histoplasmosis but more likely to 
develop serious bacterial infections. 119 131 Pneumonia, meningitis and 
septicaemia are especially common, tend to recur and have higher rates of 
treatment failure. 132 The main causative agents are similar to the main causes 
of infectious disease in HIV-uninfected children namely Streptococcus 
pneumoniae, Salmonella spp and Haemophilus influenzae but morbidity and 
case-fatality rates are higher. 132 Malnutrition and hospitalisations for serious 
bacterial infections predict mortality independently of immunosuppression. 16 
The overall rate of disease progression in HIV-infected infants has been thought 
to be more rapid in Africa. Table 2.1 summarises studies that investigated 
mortality rates in children by infant and maternal HIV status. As discussed 
above, in European and American cohorts approximately 25% of HIV-infected 
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infants progress to AIDS or death in the first years of life, while median survival 
is about two years in most African cohorts.? This may be due to more intense 
exposure to pathogens such as malaria and enteric pathogens, and a 
background of undernutrition. Outside these relatively small observational 
studies there is a lack of data on mortality rates of HIV-infected children at 
population level. A major constraint has been the difficulty in confirming HIV 
status among infants, as passively acquired maternal anti-HIV antibodies 
persist for up to eighteen months, precluding the use of antibody testing 
methods. Thus, prevalence estimates of HIV infection in babies have been 
obtained indirectly from estimates of adult HIV prevalence, using assumptions 
relating to fertility and HIV transmission rates and mortality in women of 
childbearing age. 133 Maternal death is an additional independent risk factor for 
child mortality, and there is evidence that maternal HIV infection also impacts 
on child mortality regardless of the HIV status of the child. 134-136 This is likely to 
be due to a combination of poor care given by a sick mother, poverty due to 
parental illness, increased exposure to infections from immunocompromised 
parents, and also the potential for subtle immune dysfunction in HIV-exposed 
but uninfected infants that may arise from suboptimal maternal imprinting of 
the neonatal immune system. 
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2.4 Long-term survival following untreated vertical HIV infection 
Two patterns of disease progression in infants, rapid and slow progression, 
have been described which in part reflect timing of HIV infection. 
Approximately 20-30% of infected infants are rapid progressors and mortality 
approaches 100% by two years of age in this group. In the remainder, 
progression is much slower, with a substantial minority expected to survive 
childhood even without diagnosis and treatment. 118122 130144-148 
2.4.1 Timing of HIV infection relative to birth and course of infection 
Several lines of evidence suggest that timing of infection is critical in influencing 
the subsequent course of disease, with in utero or intrapartum HIV 
transmission having a worse prognosis than later postnatal transmission. The 
peak viral load and the viral set-point are significantly higher, a poor prognostic 
sign, in infants infected during birth or the first few weeks of life (early 
infection) than in those infected after 3 months of age. 149.153 Furthermore, 
epidemiological studies have consistently shown at least a two-fold higher risk 
of progression to AIDS or death by 12 months of age in those with early 
infection compared to those infected later, even after controlling for later time 
of infection and duration of follow-up while infected.? 154-158 
A number of congenital and perinatal infections, such as CMV, Toxoplasma 
gondil and rubella virus, result in more severe disease when these agents are 
acquired early during gestation. It is well established through experimental 
studies in animals that the timing of exposure to pathogens and antigens 
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relative to birth can have a critical impact on the nature and effectiveness of the 
subsequent immune response, with infections in utero and the first few weeks 
of life tending to elicit a suboptimal and/or dysfunctional immune response. 
For example, domestic cats have a naturally occurring retrovirus (Feline 
Immunodeficiency Virus [FIV]) that, like HIV, can be transmitted vertically in 
utero, intrapartum or through breastmilk. 159 Depending on the timing of 
infection, cats can either develop a chronic infection characterised by high level 
viraemia, and a high burden of morbidity and mortality from viral-associated 
cancers and a syndrome of degenerative and infectious disease, or a self- 
limiting acute infection that can occasionally be fatal but is more typically 
accompanied by an effective immune response that leads to near-complete 
eradication with undetectable viral loads and a strong and persistent cytotoxic 
T-cell response. 160-162 
The immune system of the foetus is adapted towards self-tolerance in order to 
avoid destructive autoimmune responses. 163 Although T-cells capable of 
activation are detectable in the foetus as early as 20 weeks of pregnancy, there 
is polarization of T-cells towards a dominance of T-helper cell-2 (Th-2) and 
regulatory T-cell (T-reg) responses which suppress a broad spectrum of 
immune responses. 164"167 The neonatal immune system is antigenically 
inexperienced and characterised by a profound T-cell maturational defect with 
ineffective cytokine production and cytotoxic T-cell responses, slower 
interaction with B-cells and delayed rejection of foreign antigens. 147 163 168-169 
Fundamental changes to the immune system occur in the first few weeks of life 
(e. g. down-regulation of T-reg and Th-2 responses in favour of Th-1 responses 
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which are required to control HIV infection) as development of the immune 
system switches from one adapted towards self-tolerance to one predominantly 
adapted towards mounting effective innate and acquired responses to external 
pathogens. 163 Maturation of the immune system starts from birth onwards in 
response to environmental pathogens and continues particularly during the 
first two years of life. '70 As such, it is not surprising that timing of infection has 
a major prognostic significance for HIV infection, with HIV-infected neonates, 
who are immunologically relatively less mature, likely to be at higher risk of 
rapid progression than infants who are infected later. 168 
There are several other possible factors besides timing of infection that may 
influence the course of infection in infants, such as genetic susceptibility, 
characteristics of the infecting virus, gestational age and maternal health 
status. 171-173 However, unlike timing of infection, the association of these 
factors with disease progression has been less consistently shown in 
epidemiological studies. Investigation into the genetics of long-term survival in 
adults has so far shown relatively little beyond confirming that HLA 
polymorphism plays a major role in the chances of mounting a successful 
response to HIV infection. 32 
2.4.2 Early epidemiological data 
Although accounting for only about 2% of vertical transmission globally, data 
on long-term survival comes mainly from cohorts in industrialised countries. 
Data from prospective cohort studies in industrialised countries with follow-up 
beyond five years of age in the pre-ART era also supports the existence of two 
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distinct prognostic groups: "fast" and "slow" progressors. These data showed 
that rates of AIDS/death in the pre-ART era are at their maximum in the first 
two years of life but decline thereafter among survivors of this early period, 
such that at least a third of vertically-infected children are alive by 13 years of 
age. 118 130 138 141 174-177 Population surveillance data confirmed this and showed 
an overall median survival of at least 8 years in untreated HIV-infected 
infants. 178 Slow progressors run a more chronic course and have a variable 
pattern of disease progression with some developing clinical signs and 
immunological alterations after two to three years of age, while other remain 
alive and symptom-free for a decade or more. 138141 147179-181 
Data from a five-year prospective natural history study of HIV-infected children 
from Rwanda was the first study to support the possibility of two patterns of 
disease progression in Africa. 140 The cumulative incidence of AIDS was 28% at 
two years and 35% at five years, with the risk of death being 5.1 times higher in 
those who were HIV-infected in the first three months of life than in those 
infected later. However, the study was based on small numbers with large 
losses to follow up. 
2.4.3 Epidemiological data from Africa 
In Africa, there have been no natural history cohort studies assessing disease 
progression beyond five years of age, and so the epidemiology of HIV in older 
African HIV-infected children remains unclear. Based on extrapolation from the 
high mortality rates observed during the early years of life among HIV-infected 
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infants, the widely-held perception has been that without ART survival to older 
childhood in Africa was likely to be infrequent. 
Recent national population-based surveys in Southern Africa, however, have 
consistently reported high HIV prevalence rates of between 1-5% among older 
children (Table 2.2). Up to the age of 14 years there was no difference in HIV 
prevalence by gender. However, after this age, HIV prevalence was 
disproportionately higher in females than in males, reflecting the higher risk of 
HIV infection through sexual transmission in younger women compared to 
men. 14 In a survey of public health facilities in South Africa in 2005, HIV 
prevalence was 15% in older children (aged 2 to 9 years) attending health-care 
services for any reason with investigations supporting vertical transmission as 
the source of infection for the majority of children. 182 Almost all HIV-infected 
children had HIV-infected mothers and the major, albeit rare, risk factor for 
mothers having an HIV-infected child if HIV-negative themselves was a history 
of the child having been breast-fed by another woman. Studies from other 
countries in the region show that considerable numbers of older HIV-infected 
children are presenting for care. 15 183 Among 514 HIV-infected and ART-naive 
children aged 1-14 years recruited into the CHAP trial in Zambia during 2001- 
2003,38% were aged 10 years or older, 16 However, studies have discounted 
the possibility of long-term survival as an explanation for the observed HIV 
prevalence rates in older children and it is notable that older children have not 
until recently, been included in most national population-based HIV prevalence 
surveys. 184 
41 
Table 2.2 HIV prevalence among children in Southern Africa 
Location Sample and Age Prevalence 
and year participation rate (%) (years) 
N (%) 
Comments 
2-5 330 2.7 
Chimanimani Household survey; 6-8 189 5.8 Dried blood spots; no 
District, 68%-74% participation 9-11 170 1.3 difference in HIV prevalence 
Zimbabwe 200511 (by age, 2-24 years) 12-14 601 3.0 by sex 
15-18 301 5.3 
South Africa 
Household survey; 
13 2004 
65% participation 
(all ages) 
South Africa 
Household survey; 
2005185 
55% participation for 
children 2-14 years 
Household survey; 
South Africa 59% participation for 
2008186 children 2-14 years; 68% 
for 15-24yrs 
Health facilities: 57 
Free State, South 
primary clinics, 25 Africa 
2002187 
hospitals; 99% 
participation 
2-9 1,377 
10-14 973 
15-18 945 
2-4 
S-9 
10-13 
15-19 
2-14 
15-24 
2-5 
6-9 
729 
1,341 
1,745 
2,154 
6.2 
4.7 
5.0 
5.1 
4.4 
1.7 
5.9 
Oral mucosal transudate for 
HIV testing; no difference in 
HIV prevalence by sex 
Dried blood spots for HIV 
testing; no difference in HIV 
prevalence by sex below 15 
years of age 
Dried blood spots for HIV 
5809 2.5 testing; no difference in HIV 
5344 8.7 prevalence by sex below 15 
years of age 
Rapid test kits with 
confirmation by ELISA; No 
2,737 14.9 difference in HIV prevalence 
1,347 14.6 by sex; Hospital prevalence: 
21.5%; Primary care facilities 
prevalence: 13.7% 
1.5-4 6.3 Oral mucosal transudate for National Household AIDS 
5-9 Not 6.0 HIV testing; No difference in Botswana 200410 indicator survey; 61% 10-14 stated 3.9 HIV prevalence by sex below 
participation (all ages) 15-19 6.6 15 years of age 
Serowe and 2-11 351 6.0 HIV test not specified; HIV 
Kweneng District, 
Household survey; 12-14 110 5.5 prevalence not stratified by 
Botswana 200S188 participation not stated 15-24 302 12.3 gender 
Demographic and Health 2-4 820 5.1 Dried blood spots for HIV 
Swaziland 200612 
Survey; 85-90% 5-9 1,367 4.2 testing; no difference in HIV 
participation (by age, 2- 10-14 1,402` 2.6 prevalence by sex below 10 
19 years) 15-19 2,438 5.8 years of age 
Older children are at risk of acquiring HIV through sexual transmission (i. e. 
sexual abuse or early sexual debut). However, while not discounting the high 
rates of sexual abuse reported from African countries, penetrative forced sex 
during childhood occurs at a much lower frequency at a population level than 
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exposure to HIV at birth and in infancy in this region, with the possible 
exception of South Africa. 189-191 The use of unsterilised needles or other skin- 
piercing instruments for medical or ritual purposes has potential for HIV 
transmission. Although studies have shown an association between 
hypothesized parenteral risk factors such as scarification and injections, the 
potential relevance of these factors need to take into account cultural factors. 
Patients in Africa often express a strong preference for parenterai rather than 
oral therapy and a belief that parenteral medication is more effective than oral 
medication. Thus, causality between hypothesized parenteral risk factors and 
HIV is difficult to establish. 23 The lack of association between HIV seropositivity 
and childhood vaccinations probably reflects the wider use of properly 
sterilised injection equipment in immunisation programs. 192 Furthermore, 
while practices for collecting and transfusing blood vary throughout the 
continent, routine screening of blood products has been established for well 
over a decade in most countries. Investigation in Uganda among more than 
5000 children aged 0-12 years showed no evidence for post-natal transmission 
other than through breastmilk. 193 
As discussed above, infants infected postnatally from breast milk appear to have 
a better prognosis than those infected perinatally or in utero. 7 154-155 In 
industrialised countries HIV-positive mothers almost all formula-feed their 
babies, while in Africa most mothers breastfeed their babies even if they know 
themselves to be HIV-infected. Furthermore, unlike in industrialised countries, 
scale-up of ART for children began relatively recently and coverage remains 
limited. 18 The African paediatric epidemic may thus have a natural history 
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quite unlike that in developed countries, with a higher proportion of untreated 
slow progressors who have acquired their HIV post-natally. 
2.4.4 Current understanding 
Survival estimates among vertically infected infants in Africa have been 
successively revised upwards in recent years as evidence for better prospects of 
long-term survival emerge. 9 A pooled cohort analysis estimated that at least 
13% of such children will survive to 10 years and that the available data are 
most compatible with about one third being slow progressors whose median 
survival is at least 8 years with no upper limit to this estimate possible from the 
existing data. 8 A survival model that combined the estimate of a third of 
vertically-infected infants being slow progressors with an assumption that 
median survival among this group will approximate that observed in children 
infected horizontally in Western Europe (mostly haemophiliacs who received 
infected blood products early on in the HIV pandemic) provided the most recent 
UNAIDS estimate that 17% of HIV-infected African infants infected at birth 
would survive to age 15 years. 9 114 Using similar assumptions (i. e. median 
survival of 16 years among slow progressors), a substantial epidemic of older 
vertically-infected children is predicted in countries with early and severe 
heterosexual epidemics. 194 
The main limitation of these projections is that the median survival is 
extrapolated from that of children from developed countries infected through 
parenteral transmission, whose survival may well be quite different from those 
of vertically-infected slow-progressors in Africa. However, the projections are 
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compatible with observed epidemiological data, suggesting that the model 
estimates provide a reasonably close approximation of the true natural 
history. 194 
Figure 2.1 Estimated number of HIV-associated deaths per year by time 
and age among vertically-infected children who are A) fast- 
progressors and B) slow-progressors in South Africa, assuming 
no PMTCT or ART. Courtesy of Dr Brian Williams 
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The dynamics of the epidemic of slow progressors are such that numbers of 
vertically-infected adolescents build up slowly after the onset of the adult 
epidemic in any given country, reflecting the time needed for infants to reach 
older childhood. However, because of this same time-lag, the epidemic of slow- 
progressors will continue to grow for a decade or more after the adult epidemic 
declines or effective PMTCT has been put in place. 194 Furthermore, mortality 
and morbidity among slow progressors is relatively spread-out in time 
compared to that of fast-progressors, occurring over a much wider age-range, in 
contrast to the more immediately obvious and visible epidemic of infant deaths 
among fast-progressors, as shown in Figure 2.1. These dynamics may partly 
explain why international guidelines for HIV care provision have been focused 
on infants and younger children. 184195-196 
2.5 HIV-associated morbidity in older children 
Although the spectrum of HIV-associated morbidity is a continuum with 
infections predominating in all age-groups, HIV results in certain manifestations 
particular to children. These manifestations occur as a consequence of the 
damaging effects of HIV infection on the body during a period of physiological 
development as well as during a period when the immune system is not fully 
mature. Additionally, timing of persistent viral infections such as Epstein Barr 
virus (EBV), CMV and Human papilloma virus (HPV) in relation to timing of HIV 
infection may also be important in pathogenesis of chronic complications. 
Unlike in adults, infections with viruses such as CMV, EBV and HPV are usually 
acquired after acquisition of HIV infection and onset of immune dysfunction, 
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resulting in increased likelihood of development of virus-mediated pathology. 
Once established, these conditions result in complications in older children 
which may not be fully reversible with ART. 
The data on effects of longstanding HIV infection in children, however, are very 
limited. Most studies that have hitherto been carried out on chronic conditions 
have been largely cross-sectional in nature, often lacked controls and enrolled 
small numbers of children mainly from developed countries, many of whom had 
received prior ART. 
2.5.1 Chronic lung disease 
Lung disease is the commonest cause of morbidity and mortality in HIV-infected 
children with an estimated 80% of HIV-infected children presenting to health 
care with a respiratory problem. 197 As children get older, they have an 
increased risk of developing HIV-associated chronic lung disease. In one cohort 
from USA chronic lung disease was present in 58% of HIV-infected children 
who died. 198 The range of conditions includes chronic infections, a condition 
seen almost exclusively in HIV-infected children known as lymphoid interstitial 
pneumonitis (LIP) and bronchiectasis. 199-201 The spectrum appears to be 
similar in industrialised countries as in resource-limited countries with the 
exception of TB being more common in resource-limited settings. 202 
In children, malnutrition and the immaturity of the immune system results in a 
tendency to develop frequent respiratory infections and HIV infection further 
increases the risk of pneumonia. 132 203 The severity and protracted course of 
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infective episodes in HIV-infected children favour the progression of pulmonary 
infections to chronic lung disease. Viral infections, such as influenza A and B, 
parainfluenza 1-3 and adenovirus, occur more frequently, persist for longer and 
the outcome is poorer, which may be because co-existing bacterial pneumonia 
is more common in HIV-infected children. 204 The burden of hospitalization for 
viral-associated pneumonia is 2-8 times greater in HIV-infected children and 
can be lead to development of a destructive immunopathological condition, 
bronchiolitis obliterans. 201 In high HIV-prevalence settings, TB is an important 
cause of chronic respiratory disease. Studies have estimated that HIV infection 
increases the risk of TB disease by a factor of 20.205 The increased risk of TB 
among HIV-positive children is mainly attributable to immunosuppression, but 
also to the fact that HIV-infected children are more likely to be exposed to TB 
within their families. 206 TB can be complicated by fibrosis, chronic atelectasis 
and bronchiectasis. The inherent difficulty in confirming TB in children in 
resource-limited settings, compounded by reduced sensitivity and specificity of 
clinico-radiological diagnostic criteria from concurrent HIV, means that HIV- 
infected children with chronic lung disease are frequently diagnosed as having 
smear-negative pulmonary TB and given multiple courses of anti-TB treatment 
based on clinical symptoms of chronic cough and failure to thrive and non- 
specific radiological abnormalities 200 
The prevalence of LIP was 20-30% in the developed world in the pre-ART era 
and similar prevalence rates have been observed in clinical, bronchoscopy and 
necropsy studies in African children. 207-209 LIP is characterised by lymphocytic 
and plasma cell infiltration of the inter-alveolar and inter-lobar septa and 
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hyperplasia of pulmonary lymphoid tissue. Pathogenesis is most likely due to 
EBV, which may initiate an abnormal lymphoproliferative response in the 
context of prior immune dysfunction. 210-211 There is also infiltration of other 
organs, manifest as generalised lymphadenopathy, bilateral non-tender parotid 
enlargement and enlargement of the liver and spleen. The diagnosis is 
supported by a chest radiographic pattern of diffuse reticulonodular infiltrates, 
which may be difficult to distinguish from pulmonary or miliary TB and often 
results in incorrect utilisation of prolonged and repeated courses of anti-TB 
therapy in HIV-infected children with chronic respiratory symptoms 
particularly in settings where TB is endemic. 20° 
Of note, LIP was associated with a relatively slow rate of disease progression in 
HIV-infected children in the pre-ART era. 140 Thus LIP may be over-represented 
among children with slow-progressing HIV infection. Although LIP has an 
improved survival compared with other AIDS indicator diseases, it is associated 
with considerable respiratory morbidity; the incidence of recurrent episodes of 
lower respiratory tract infections is double that of HIV-infected children 
without LIP, and there is a high risk of pulmonary fibrosis, cystic lung disease, 
failure of the lungs to grow, and bronchiectasis. 207212 
Bronchiectasis, an abnormal and permanent dilatation of the bronchi, occurs as 
a late sequel of infection or as a result of healing of lung tissue with fibrosis. It 
is a disease-entity in its own right, causing increased susceptibility to lower 
respiratory tract infections regardless of age or aetiology. As discussed above, 
HIV infection in childhood is a strong risk factor for bronchiectasis, and leads to 
49 
a further increased risk of recurrent bacterial pneumonia and to chronic 
respiratory symptoms. 213 In one series of HIV-infected children with chronic 
respiratory symptoms, the prevalence of bronchiectasis was about 15%. 213 As 
in other systemic causes of diffuse bronchiectasis, such as 
hypogammaglobulinaemia, cystic fibrosis and ciliary disorders, failure to 
manage the respiratory condition aggressively leads to a vicious cycle of 
superinfections that accelerate the rate of bronchial wall destruction and 
pulmonary function decline, leading to progressive respiratory failure. Over 
time, involvement of the pulmonary blood circulation results in pulmonary 
hypertension and right heart failure (cor pulmonale). This is associated with 
secondary growth failure, wasting, and a very high mortality. 212 214 Although 
preventable, there are a limited range of treatment options for established 
chronic lung disease, and so children with this complication of HIV infection are 
likely to have reduced quality of life and life expectancy even when started on 
ART. 
2.5.2 Cardiac disease 
Although cardiac disease in the context of HIV infection is well-recognised, most 
studies have been done in adults and the risk in children is generally under- 
appreciated. Cardiac disease as an underlying cause of mortality shows a 
significant age-related trend in children; the risk of dying from cardiac disease 
is virtually nil in infancy, but cardiac abnormalities were directly responsible 
for death in 12% of HIV-infected young American children with this figure 
increasing to 25% in children aged over ten years. 198 215 
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Estimates of the incidence of cardiac disease in HIV-infected children vary 
widely depending on the methods of ascertainment. Subclinical abnormalities 
are commonly detected on electrocardiographyi or echocardiography'i. These 
abnormalities develop early in life and are persistent. 216-217 The main limitation 
of these early studies has been the cross-sectional design and lack of controls, 
making it difficult to ascertain the clinical significance of these abnormalities. 
The most commonly reported abnormality is left ventricular (LV) dysfunction, 
indicated by a low shortening fraction (SF). 216 SF is a measurement made on 
echocardiography and represents a summation of factors that affect LV function 
including contractility, pre-load and after load. LV dysfunction can be due to 
decreased contractility, dilatation and impaired relaxation due to hypertrophy 
of the muscular wall of the LV. Asymptomatic LV dysfunction may ultimately 
progress to dilated cardiomyopathy, with hypotensive hypoperfusion of the 
systemic circulation due to pump failure. 
In the P2C2 cohort, a natural history study of cardiopulmonary complications of 
vertically-acquired HIV infection in USA, between 5-8% of children had a low 
baseline SF, and the cumulative incidence of LV dysfunction after five years was 
28%. 218-220 The risk of cardiac disease increased as the level of 
immunosuppression increased. 221 The cause of myocardial damage in HIV 
infection is likely to be multi-factorial, with infections as well as direct 
immunological effects of HIV infection playing a role. The virus itself has been 
detected in myocardial cells as well as pericardial fluid in HIV-infected 
A non-invasive recording of the electrical activity over time of the heart captured by skin 
electrodes 
A non-invasive ultrasound technique that provides two-dimensional images of the heart 
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children. 222 Possible mechanisms include direct mononuclear immune cell 
activation, cytokine effects or immunopathology that may be potentiated by co- 
infections. 
The prevalence of cardiac abnormalities among HIV-infected children in 
resource-poor settings appears to be even higher than in industrialised 
countries for reasons that are as yet unclear. In a cross-sectional study in 
Uganda, where mean age was 6.8 yrs, 17% of children in care had left 
ventricular systolic dysfunction, a finding similar to that of a study of 
hospitalised children in South Africa. 223-224 The symptoms of cardiac disease 
are non-specific and may often be attributed to non-cardiac pathologies 
particularly pulmonary infections. 223 225 Thus cardiac abnormalities are 
probably under-diagnosed and may have an impact on morbidity and mortality 
as children grow older. Early LV dysfunction can only be diagnosed by 
echocardiography and the skills needed limit the availability of 
echocardiography and so preclude diagnosis in most HIV-infected children. 
2.5.3 Growth failure 
Growth failure, defined by a growth rate that is below the appropriate growth 
velocity for age, is reported in up to 30-80% of HIV-infected children. 226-227 The 
exact prevalence is difficult to ascertain due to the different case definitions 
which have been used for investigative and surveillance purposes. Growth 
failure is distinguished from weight loss or wasting which is primarily due to 
inadequate calorie intake. Disturbances in growth patterns, although very 
variable, become apparent by 3-4 months of age, persist and increase with 
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time. 226 228 In one retrospective study, 42% of vertically-infected children over 
five years old had a growth velocity of less than the 5th centile, an indication of 
severe growth failure, and growth faltering in terms of both height and weight 
was observed for at least up to 10 years of age in the European Collaborative 
Study as well as in a cohort of Ugandan children. 141 183 229 HIV-infected children 
experience nearly proportional declines in both height and weight such that 
normal "height-for-weight" is maintained, and wasting may become apparent 
only as children develop more advanced immune deficiency. 229 Similar 
stunting, with normal height-for-weight, is also reported in HIV-positive 
haemophiliac boys infected through contaminated blood products. 230 
Growth can be exacerbated by a variety of nutritional, endocrine and 
immunological disorders. The pattern of concurrent impairment of weight and 
height suggests that other mechanisms underlie HIV-related growth failure 
other than nutrition, as weight tends to fall off before height in conditions of 
protein energy malnutrition. Also, in contrast to children with protein energy 
malnutrition, increasing nutritional intake in children with HIV-associated 
growth failure improves weight but has no effect on linear growth/height 
velocity or lean body implying that it cannot be solely explained by inadequate 
nutrition. 231 Furthermore, the alteration in body composition in HIV-infected 
children with growth failure includes disproportionate decreases of fat-free or 
lean body mass, a characteristic pattern that is distinct from that in children 
with nutritionally based stunting, but similar to the lipodystrophic pattern of 
weight loss and redistribution observed in adults with HIV infection. 232-233 
There is no consistent relationship between Vitamin A or other micronutrient 
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deficiencies and growth failure, or between gastrointestinal (GI) disease and 
malabsorption and growth. 234-237 However, these associations were 
investigated using cross-sectional studies which did not assess risk of poor 
growth in the future. Various neuroendocrine abnormalities that have the 
potential to affect growth have been identified, including abnormalities in the 
thyroid axis and adrenal axis and elevated glucagon levels, although no single 
endocrine abnormality is consistently encountered in HIV-infected children 
with growth retardation. 229 Primary growth hormone deficiency is found only 
occasionally and insulin-like growth factor-1 (IGF-1), the main determinant of 
linear growth velocity after infancy, is variably reduced, although reduced 
tissue sensitivity to IGF-1 may be an important factor. 238-239 
Virological response to ART is highly correlated with rates of growth in 
children, with ART regimens that result in optimal suppression of HIV viral load 
having the best growth responses. 240 This suggests that HIV itself may 
contribute to the pathogenesis of growth impairment. Linear growth 
retardation is a major complication of several childhood inflammatory diseases. 
For example, Crohn's disease, characterised by transmural inflammation of the 
GI tract, severely inhibits growth in about a third of affected children with a 
significant proportion becoming short adults. 241-242 Although growth failure in 
Crohn's disease used to be attributed chiefly to undernutrition, there is 
increasing evidence that the inflammatory process itself may directly inhibit 
growth through cytokines such as IL-6 that are induced by intestinal 
inflammation and that suppress IGF-1.243-244 The GI tract is one of the most 
important sites of HIV replication and a central element in the immune 
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dysregulation accompanying HIV infection. 245 Hence, growth retardation in HIV 
infection may also be related to the pro-inflammatory milieu, as has been 
observed in Crohn's disease. 246 Malnutrition, increased metabolic requirements 
and an adverse social environment are likely to exacerbate faltering growth and 
thus the degree of growth impairment may be more marked in resource-limited 
settings. 247 
Growth is not only related to height and weight gain. HIV infection is also 
accompanied by skeletal abnormalities, including decreased bone mineral 
content and bone mineral density. 248-249 This is a result of both decreased bone 
accrual as well as increased bone turnover during growth. Childhood is a 
critical period for bone mineral acquisition and a compromised bone mass level 
poses a risk of development of osteoporosis and its complications in the future. 
The pathogenesis of abnormal bone metabolism is not clear and is probably 
multifactorial related to both nutritional deficiency e. g. Vitamin D, and HIV- 
related processes. 250 Osteogenic cells are targets of HIV infection, and cytokines 
such as IL-6 and tumour necrosis factor (TNF) activate osteoclasts and are over- 
expressed in HIV infection. 251-254 ART, particularly tenofovir, may contribute 
further to bone loss. 255 
HIV infection also interferes with sexual maturation and pubertal delay is 
common among children entering adolescence. 256-257 Among haemophiliac 
boys pubertal delay is associated with diminished androgen production and 
subsequent growth hormone secretion, but little is known about the association 
between HIV infection and endocrine dysfunction in vertically-infected 
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children. 230 258-259 Some studies suggest that age at onset of puberty is not 
related to the clinical or immunological status, a finding also observed in other 
childhood chronic conditions such as cystic fibrosis, juvenile chronic arthritis 
and inflammatory bowel disease. 256 260-261 However, other studies show that 
degree of HIV-related immune suppression is associated with delayed initiation 
of pubertal development. 257 
Delay in pubertal development is likely to influence final adult height and cause 
significant psychological morbidity and possibly contribute to social stigma of 
HIV infection. The final extent of catch-up growth and pubertal development is 
likely to be age-dependent, with less good outcomes reported when ART is 
started in older children and adolescents. 262-263 Furthermore, growth 
responses to ART in resource-limited settings are blunted compared to those in 
industrialised countries, potentially reflecting higher background malnutrition 
and infection rates. 263 
2.5.4 Encephalopathy 
PE, characterised by a stepwise or continuous deterioration, has been well 
documented in HIV-infected infants and young children. Older children who 
experience an early AIDS-defining illness are also at risk of impaired cognitive 
functioning, even after controlling for environmental variables, but the pattern 
of impairment is usually consistent with a static encephalopathy with neuro- 
developmental deficits being fixed and non-progressive. 264-265 It is not clear 
why one subgroup of HIV-infected infants develops a more severe PE whereas 
another subgroup does not, but it has been suggested that this may be related to 
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the timing of central nervous system HIV -- infection with early infection of the 
developing brain in utero being associated with a more aggressive course --, the 
accompanying viral load and genetic vulnerability. 266-267 The mechanism of 
brain impairment due to HIV is not well understood, but proposed mechanisms 
include direct neuronal injury, macrophage destruction resulting in 
neurotoxicity, co-infection by other agents, and integration of the virus into the 
central nervous system cell lines. 268 
In HIV-infected children who survive to older childhood without major illness, 
overall cognitive function appears to be within the normal range, although 
studies vary significantly with respect to methods and often lack controls, 
making comparisons of findings difficult. 183 However, even in seemingly 
asymptomatic older children there are deficits that are not easily identified by 
routine testing. These include deficits in fine motor function, memory, 
perceptual performance, quantitative abilities and mental processing and 
language abilities. 269-272 These skills are critical as children approach adulthood 
particularly with respect to adherence to medication, education and career 
planning and risk behaviours as well as to overall quality of life. 
In older children, psychiatric morbidity, which is rare in younger children, is 
more frequent. There is a significantly higher incidence of psychiatric 
hospitalization among HIV-infected older children and adolescents compared 
with the general paediatric population in industrialised countries, the most 
common reasons for hospitalization being depression and behavioural 
disorders. 273 However, it is often difficult to determine whether aetiology is 
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attributable to organic or psychosocial factors. There are few data from 
resource-limited settings where exposure to HIV occurs in the context of 
different environmental factors which may result in a different risk profile for 
cognitive, neuropsychiatric and behavioural problems. 
2.6 Diagnosis and Treatment of HIV Infection 
2.6.1 HIV diagnosis 
HIV counselling and testing (CT) is a prerequisite for access to care and 
measures to reduce risk of onward transmission, such as PMTCT. For adults 
and children older than 18months, diagnosis of HIV infection relies on detecting 
antibodies to HIV in blood. HIV testing has become more convenient in recent 
years with the availability of rapid tests. These do not require invasive 
procedures, specialised equipment or laboratory technicians and the result is 
available within an hour. Because of the passive transplacental transfer of 
maternal HIV antibodies to the infant, newborn infants and children younger 
than eighteen months test positive for the presence of HIV antibodies even in 
the absence of true infection. Therefore, definitive diagnosis of HIV infection 
requires the use of HIV-specific RNA or DNA nucleic acid tests to detect the 
virus itself, instead of the inexpensive and readily available serological assays 
used in older children and adults. 274 
There are two methods of CT provision: client-initiated and provider-initiated. 
The former corresponds to what is usually referred to as voluntary CT or VCT 
and requires individuals to actively seek testing and counselling at a facility that 
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offers these services. Until a few years ago, most countries used a client- 
initiated approach to provide HIV testing through stand-alone facilities, 
facilities integrated in health settings, mobile services and community-based 
settings. Evidence has also shown that providing tests in convenient locations, 
such as workplaces and home-based testing, contributes to increased uptake of 
HIV testing. 275-276 Provider-initiated HIV testing and counselling (PITC) requires 
health care providers to initiate and offer CT. With widespread availability of 
treatment for HIV infection, there has been a notable shift in recent years from 
client-initiated to provider-initiated HIV testing which has much lower costs per 
HIV-positive person tested than alternative strategies. 277-278 International 
guidelines recommend routine PITC to all people seen in all health facilities in 
generalized epidemics as part of access to universal testing and care, and in 
selected health facilities used by populations that may be at special risk of HIV 
in low-level and concentrated epidemics. 17 
Although the availability and uptake of CT has continued to increase, under- 
diagnosis of HIV infection remains a significant issue globally. Up to 60% of 
individuals remain undiagnosed globally, with wide differences across 
countries and across at-risk population groups. 18 Uptake of HIV testing is 
limited by fear, stigma, underestimation of risk, negative reactions to disclosure, 
and limited access to treatment services. 279 Health system factors, including 
lack of human resources and adequate training for health care providers, create 
obstacles to effective PITC implementation. In children younger than 18 
months, virological tests required for HIV diagnosis are expensive and complex 
to perform, and not available in many parts of the world where the risk of HIV 
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in infancy is highest. Late diagnosis prevents the timely initiation of ART, 
resulting in higher early mortality after starting treatment, and poorer 
outcomes. 
2.6.2 Treatment of HIV infection 
The goal of HIV treatment is to suppress HIV replication and to prevent or 
reverse HIV-related symptoms and immunosuppression. Treatment is life-long 
as current drugs are not curative. Following the licensing of zidovudine as an 
antiretroviral drug in 1987, the difficulties in treating HIV were demonstrated 
in the coming years as drug resistance rapidly developed to mono- and to dual 
therapy. Development of HAART, a combination of three drugs that resulted in 
sustained suppression of viral replication, in 1996, led to marked reductions in 
HIV-associated morbidity and mortality in industrialised countries. 28° 
However, adherence to treatment is critical to durable treatment success and 
sub-optimal adherence results in "breakthrough" viral replication and 
development of drug-resistant mutant virus strains. Furthermore, prolonged 
use of ART is associated with dyslipidaemia, insulin resistance and disturbances 
in bone metabolism. Co-morbidities such as diabetes and cardiovascular 
disease are now more common causes of morbidity and mortality than 
opportunistic infections among HIV-infected adults in industrialised countries, 
where HAART has been available for over a decade. 281 
During the past ten years there has been an unprecedented drive to scale up 
access to treatment for people living with HIV infection in low and middle- 
income countries as a public health emergency. Following the 2001 United 
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Nations General Assembly Special Session on HIV/AIDS (UNGASS) Declaration 
of Commitment to control the spread of HIV, the WHO launched the "3 by 5" 
initiative in 2003 to provide ART to three million people by 2005. 
Subsequently, at the United Nations General Assembly High-Level Meeting on 
AIDS in 2006, countries committed to work towards universal access to 
comprehensive HIV prevention and treatment by 2010. Political commitments 
have been backed by international initiatives such as US President's Emergency 
Plan for AIDS Relief (PEPFAR) and The Global Fund to fight AIDS, TB and 
Malaria (GFATM) and other bilateral, national and nongovernmental or private 
funding sources to support global scale-up of ART. Access to ART has continued 
to expand rapidly with an estimated coverage of ART in low and middle-income 
countries of 40% in 2008, a marked improvement but still leaving a large 
treatment gap. 18 
Although high levels of adherence to treatment and virological suppression 
have been achieved in treatment programmes, early mortality following ART 
initiation are several fold higher among patients in resource-limited settings 
compared to that of patients in high-income settings, even after adjusting for 
baseline immunodeficiency. 282 Up to a quarter of patients in sub-Saharan Africa 
die in the first year of ART, contributing to substantial losses in overall patient 
retention. 283 Although several factors contribute to mortality, the key issue is 
presentation with advanced HIV disease, and the early deaths reflect the 
spectrum of causes of death prior to ART initiation such as TB, sepsis, 
cryptococcal meningitis and HIV wasting syndrome. 283 
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Treatment of children lagged behind that of adults because of difficulties in 
getting appropriate drug formulations and palatable drugs, and determining 
practicable criteria for starting HIV treatment. 284 Like adults, infants show a 
strong immunological response to treatment, although they have a higher risk 
of persistent viraemia, possibly reflecting difficulties of giving medicines 
consistently and at the required doses to young children. 285-287 The risk of 
developing drug resistance is a major concern in children who will hopefully be 
taking treatment for a greater proportion of their lives than adults. As access to 
ART improves and prolonged ART use becomes more common, morbidity from 
a similar range of treatment-related non-infectious conditions as adults may 
become a particular concern for children, who will be taking ART during the 
critical years of physiological development. 288 
2.7 Adolescent Health 
2.7.1 Context of adolescence 
Adolescence (from Latin: adolescere meaning "to grow up") is a transitional 
stage of physical, mental and psychological development generally occurring 
between the onset of puberty and maturity. The supposed start and end of the 
period of adolescence varies in different countries and cultures and hence it is 
difficult to rigidly define the time frame in which adolescence occur and the age 
at which an individual is considered to be chronologically and legally mature. 
The World Health Organization defines adolescents as young people between 
the ages of ten and eighteen years and this is the definition used in the thesis. 
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Adolescents currently constitute the largest age group in the world, making up 
approximately a fifth of the world population, with 85% living in resource- 
limited settings. Adolescence is a period of life during which a large proportion 
of key life-course events are experienced including completing school, attaining 
puberty, becoming sexually active and becoming economically productive. This 
can be a personally and socially problematic period: an age group too old to be 
entirely dependent but with few skills and little experience in navigating an 
adult world. Adolescence is universally recognised as the link in the life cycle 
between childhood and adulthood, and most societies mark this stage through 
rites associated with prospective adult roles such as reproduction, 
responsibility, occupation and more autonomy. 289 This transitional period from 
childhood to adulthood involves multiple interactions between biological and 
socio-cultural influences. The physical and psychosocial changes that occur 
during adolescence reveal the impact of generational and early-childhood 
factors on development and predict potential threats to health and well-being in 
adulthood. 289 
2.7.2 Morbidity in adolescence 
In developed countries the major causes of morbidity among adolescents have 
behavioural aetiologies, such as substance and alcohol abuse, self-harm and 
interpersonal violence and risky sexual behaviour. 290 In hospital, chronic 
diseases, trauma, oncology and mental disorders account for the majority of 
admissions. 291 In Africa, research on adolescent morbidity has been limited and 
focused on reproductive health, reflecting the high incidence of STIs including 
HIV, and obstetric problems among young people. 292-293 A South African study 
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in the pre-HIV era found that the disease profile on the paediatric wards 
differed markedly by age, with the most frequent diagnoses in young children 
being infectious while chronic diseases and mental health problems were the 
commonest causes of admission among adolescents. 294 
2.7.3 HIV and adolescent health 
Adolescents are highly susceptible to adverse consequences of HIV infection 
through parental death and impoverishment (Figure 2.2). The orphanhood 
epidemic in Africa, which has accompanied the HIV epidemic, has "aged" along 
with the HIV epidemic, and as a result over 50% of AIDS orphans are 
adolescents. Adolescent HIV orphans have a higher likelihood of being HIV- 
infected themselves through maternal transmission, and are more likely to 
suffer from psychological problems, to drop out of school and to experience 
forced sex and engage in risky sexual behaviour, resulting in disproportionate 
risk of acquiring sexually transmitted HIV infection. 3 295-298 
The recognition that young people are at high risk of HIV transmission has 
resulted in this age group being a priority target for HIV prevention efforts for 
many years. However, less attention has been paid to care of adolescents who 
are already HIV-infected. In industrialized countries, an increasing proportion 
of vertically-infected children survive into adolescence as a result of ART, and a 
similar trend is expected in resource-limited settings as infant diagnosis and 
ART become increasingly available. 299 Furthermore, clinicians from countries 
with severe HIV epidemics report the presentation of HIV-infected adolescents 
with features of longstanding infection and estimates of survival from infancy to 
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adolescence following HIV infection have been successively revised upwards in 
recent years, as discussed in Section 2.4. 
Whilst the epidemiology of sexually-acquired HIV infection among 15-24 yr olds 
is well-described, there are few data on the burden and disease patterns of 
vertically-acquired HIV infection in older children and adolescents, especially in 
sub-Saharan Africa. The proportion of children requiring HIV care who are 
adolescents is expected to increase considerably due to a combination of large 
numbers of LTS reaching adolescence with undiagnosed or recently diagnosed 
HIV and, in future, growing numbers of children who have been taking ART 
from infancy. Thus, the need for appropriate care services for HIV-infected 
adolescents will become an increasingly important part of HIV care in Africa. 300 
Figure 2.2 Potential ways in which the HIV epidemic may affect 
adolescent health 
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2.7.4 Health needs of HIV-infected adolescents 
As well as interfering with the normal physiological and psychosocial 
development that occurs during this period, HIV infection places additional 
stressors on the life of an adolescent. During childhood, caregivers are often 
heavily involved in managing their child's illness. As children reach 
adolescence, expectations for them to take increasing responsibility for 
themselves emerge. Whilst often deferred in childhood (and not plausible in 
infants), disclosure of HIV status is crucial during adolescence as individuals 
approach cognitive maturity and puberty. Young adults have to make decisions 
about sexual relationships and their treatment and plan for the future, and 
these decisions can only be made with an accurate understanding of the nature 
of their illness. 301 Although the benefits seem considerable, disclosure of HIV 
status is typically delayed because of lack of skills in discussing HIV with minors 
and emotional unpreparedness of primary care-givers. 302-303 Reluctance of 
parents and caregivers to disclose HIV status is often due to fear of 
discrimination and stigma toward both the adolescent and the family as a 
whole, the concern that their child will not be able to deal with their HIV 
infection, the inherent disclosure of the mother's HIV status to their child, and 
possibly because of the painful feelings of guilt at having infected their child. 304- 
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Over and above HIV-related issues that are common to any age-group, 
adolescents are likely to face "recurrent and cumulative" psychological distress 
including illness and death of parents and siblings, the fear of being "abnormal" 
and confronting mortality and an uncertain future. 297 306.307 There are also 
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issues with schooling such as absenteeism due to illness or clinic appointments, 
disclosure of HIV status to school officials, and possible stigmatisation from 
classmates and teachers. 308 Many live in poor households with HIV infection 
often perpetuating the cycle of poverty. The emotional effects of coping with 
HIV infection are severe, with high rates of psychiatric morbidity among HIV- 
infected adolescents in industrialised countries, although it is likely that this is 
due to a combination of the neuropathological effects of HIV infection and 
environmental factors. 309 These factors affect treatment adherence and 
undermine success of ART. 310-311 With sexual maturity comes the anxiety about 
relationships, and the risks associated with being sexually active i. e. unwanted 
pregnancies, acquisition of STIs, the risk of rejection if they disclose their HIV 
status to their sexual partner, and the risk of onward transmission of HIV. 312 
2.7.5 Health Services for adolescents 
While many paediatricians see young children as their "core business", a high 
proportion of time is spent looking after adolescents. 313 In some developed 
countries adolescent medicine exists as a separate speciality in recognition of 
the fact that this age-group has differing, and often complex, health needs from 
those of younger children or adults. In Africa, the health needs of adolescents 
are addressed mostly at primary care level and dedicated health care services 
for young people are the exception rather than the rule. Transition from 
paediatric to adult care occurs early, typically between ages of 8 to 12 years, 
and adolescents are variably managed by paediatricians and adult physicians, 
with little emphasis on their specific health needs. 
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The particular context of adolescence impacts on utilisation and delivery of HIV 
services and on adherence. Access to HIV diagnosis and care is likely to be 
particularly difficult in adolescence because of financial dependence, 
orphanhood and paucity of CT services aimed at this age-group. Uptake of HIV 
testing is low among adolescents, with even fewer engaging with care. 185 314 
Without appropriately tailored services, young people are likely to fall through 
the cracks of paediatric or adult-orientated HIV care. 
2.8 Zimbabwe 
Zimbabwe is a land-locked country bordering South Africa, Mozambique, 
Zambia and Botswana, with Harare being the capital city. It is divided into 8 
provinces and the population in 2006 was approximately 12 million with 55% 
of the population aged below 20 years and 22% being aged between 10 and 19 
years. 315 The economy has more than halved over the past decade with 
GDP/capita now around $400. This has had a considerable negative impact on 
the education sector, with declining school enrolment rates, and on all aspects 
of the health sector. Mortality rates were among the lowest in the region prior 
to the HIV/AIDS epidemic but have since increased and the life expectancy at 
birth in 2002 was 45 years. 316 
2.8.1 HIV in Zimbabwe 
Zimbabwe has a wealth of published and unpublished HIV data. HIV sentinel 
surveillance in ANC has been ongoing since 1989. Two population based sero- 
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surveys were conducted in the last six years, with behavioural data collected in 
both surveys. 317-318 
Zimbabwe has experienced an otherwise comparable HIV epidemic of earlier 
onset than neighbouring countries. There is relatively little inter-province and 
urban-rural difference with respect to adult HIV prevalence rates. 318 HIV 
prevalence fell substantially in Zimbabwe over the past decade from 29.3% in 
1997 to 15.6% in 2007 (Figure 2.3). 
Figure 2.3 Adult (15 to 49 years) HIV prevalence (red), HIV incidence 
(green) and HIV-related mortality (blue) rates in Zimbabwe 
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Although it may be expected that prevalence would decline in a mature HIV 
epidemic such as that in Zimbabwe due to increasing AIDS-related mortality 
and a fall in incidence as a result of saturation of infection within high-risk 
groups, these trends are partly attributable to changes in sexual behaviour 
leading to reduced incidence rates. 319 Firstly the decline in prevalence was 
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observed among young women among whom AIDS-related mortality is low. 
Secondly, declines in prevalence were observed in longitudinal studies where 
trends could not be generated through shifting biases in fertility or 
representativeness of antenatal clinic surveillance estimates, and HIV incidence 
rates have declined in the same period. Thirdly, national and regional surveys 
indicated reductions in sexual risk behaviour, especially men forming fewer 
casual sexual partnerships and visiting commercial sex workers less frequently 
and sustained levels of condom use. 320 The extent of recent international 
migration from Zimbabwe is substantial albeit difficult to quantify. 55 Available 
data show that selective migration of HIV-infected individuals is unlikely to 
have contributed significantly to the decline in HIV prevalence. 319 
Zimbabwe was one of the few sub-Saharan African countries to implement 
interventions aimed at controlling the spread of the HIV epidemic, including 
scaling up of condom distribution programs, treatment services for STIs and 
HIV screening of donated blood, early during the HIV epidemic. Zimbabwe has 
maintained a strong blood safety record despite recent economic difficulties, 
and thus parenteral transmission is unlikely to contribute significantly to the 
spread of HIV infection. 
Although HIV incidence has declined in Zimbabwe, it still has one of the highest 
prevalence rates in the world. 19 Given the early onset of the HIV epidemic, 
Zimbabwe is likely to have a relatively advanced epidemic of untreated 
adolescent LTS. To obtain projections of HIV burden among older children, we 
modelled demographic, HIV prevalence, MTCT and child survival: 3.4% of 10 
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year olds were estimated to be living with HIV acquired through MTCT in 
2007.194 The age-profile of HIV-associated mortality is evolving towards a point 
where HIV deaths among vertically-infected adolescents are likely to 
outnumber those among infants within a few years. 194 As is typical for the 
region, however, routine HIV programme data are reported for only 3 age 
categories: 0 to 4,5 to 14 and 15 to 49 years, providing no clear age-profile of 
HIV infection in adolescents. 
Although testing of pregnant women was introduced in 2001, only about 40% 
of HIV-positive pregnant women were receiving ART prophylaxis for PMTCT in 
2008, so that vertical transmission continues to occur. 18 Nearly one in three 
children are orphaned, the majority aged over 10 years, and about 120,000 
children are estimated to be HIV-infected. 321 ART started to become available 
in the public sector only around 2004 and in 2008,36% of children in need of 
ART in Zimbabwe were receiving it. 18 ART is usually initiated in hospital HIV 
services, with on-going care decentralised to local primary care services where 
possible. 
2.9 Summary 
The severe adult HIV epidemic in Southern Africa has been followed by an 
epidemic of vertically-acquired HIV among children. There is increasing 
recognition that a substantial minority of HIV-infected infants have a slow 
course of HIV disease and thus can survive to adolescence and beyond even 
without prior treatment. As the HIV epidemic has matured, the first 
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presentation of vertically acquired HIV in older childhood and adolescence has 
been increasingly observed, and a major epidemic of previously untreated 
vertically-infected adolescents is now anticipated in high HIV burden countries. 
The early onset of the HIV epidemic in Zimbabwe combined with the relatively 
late availability of PMTCT and ART provides an opportunity to investigate the 
clinical epidemiology of HIV infection among adolescents, and to contribute to 
understanding about the contribution of HIV to morbidity among adolescents, 
who have hitherto been poorly represented in studies. 
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3 Methods 
The individual studies described in the following chapters relied on a common 
approach to investigate HIV prevalence, mode of HIV acquisition and morbidity 
among adolescents. The methods used that are common to more than one 
study and specific procedural issues arising as a consequence of conducting 
research on adolescents are outlined below rather than in individual chapters. 
3.1 Clinical methods 
3.1.1 Anthropometric assessment 
The anthropometric assessment included measurement of height, weight, mid- 
upper arm circumference (MUAC) and stage of pubertal development. MUAC 
was measured to the nearest millimetre, weight was measured to the nearest 
0.1kg and height was measured to the nearest 0.1cm. Height was measured 
using a stadiometer, with the participant standing upright (a point on the upper 
and lower back against the stadiometer), feet placed in the tracing on the 
stadiometer base and with socks and shoes removed. Weight was measured 
using a digital scale which was calibrated before each measurement. 
Participants were weighed with their clothes on but any heavy clothing, such as 
coats and jumpers, socks and shoes removed. 
Growth was assessed by using a standardized age- and sex-specific growth 
reference to calculate height-for-age Z-scores (HAZ), weight-for-age Z-scores 
(WAZ) and body-mass-index-for-age Z-scores (BMIZ). Z-scores of less than -2 
for height- and weight-for-age were considered to represent stunting and 
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wasting, respectively. Each z-score expresses the anthropometric value as 
standard deviations below (-ve) or above (+ve) the mean of the reference 
growth curve. 
The z-score scale is linear and hence summary statistics such as a mean, 
standard deviation and standard error can be computed from z-score values. 
These were compared with a reference set that has an expected mean z-score of 
0 and a standard deviation of 1.0 for all normalised growth indices. Although it 
would have been ideal to use the 2006 WHO global child growth standards as 
reference, these were only available for children up to the age of five years. 
Hence, British growth references were used instead, as these are more recent 
than the alternative NCHS/CDC references. 322 Also, the NCHS/CDC references 
are based on examination of American children where the mean of the weight 
distribution is higher than that in British children and may be even less suitable 
for comparison with African populations. WHO growth curves for school 
children and adolescents have, more recently, become available, but these are 
also derived from the 1977 NCHS growth references for the 5-19 year age- 
group which have been merged with the WHO Child Growth Standards (0-5 
years), and weight-for-age standards for children aged over 10 years are not 
available. 323 
Pubertal development was evaluated using Tanner's Staging, based on breast 
size and shape, and pubic hair growth and on size of external genitalia and 
pubic hair growth in boys. 324 Tanner Puberty Stage 1 or 2 in those aged over 13 
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years was considered to represent pubertal delay. Onset of menarche in girls 
was also documented. 
3.1.2 Classification of clinical conditions 
Pre-set diagnostic algorithms were used to define the cause of admission to 
hospital and any underlying chronic conditions, or reason for attendance to 
primary care. These were adapted from previous studies of HIV-associated 
morbidity and from case definitions used in the 2005 WHO HIV Staging 
Classification. 105 108 32S Among hospital admissions, case definitions of clinical 
conditions were defined as "definite", "probable" or "possible" and were based 
on a combination of specific symptoms, clinical signs and investigations 
(Appendix A). Diagnoses of chronic conditions that had been made in the past 
following specialist investigations and were documented in the case notes, were 
also recorded. At primary care level, the classification of the presenting 
complaint was broadly adapted from the WHO Integrated Management of Adult 
and Adolescent Illness (IMAAI) guidelines. IMAAI comprises a series of 
guidelines for syndromic classification and management at primary care level 
for use in high HIV prevalence settings. 326 The 2005 Adult WHO Classification 
was used to stage HIV infection. 325 The WHO Performance Scale was used to 
assess functional state: 
Stage 1- Asymptomatic, normal activity 
Stage 2- Symptomatic, normal activity 
Stage 3- Bedridden, <50% of the day during the last month 
Stage 4- Bedridden, >50% of the day during the last month 
75 
3.2 Laboratory methods 
3.2.1 HIV testing and CD4 counts 
Unreported (anonymised) HIV testing was carried out for study purposes and 
diagnostic HIV testing was offered at the same time with pre- and post-test 
counselling, to all participants. 
Unreported HIV tests were run using a dedicated HIV test number, and results 
were recorded on a form that used the dedicated HIV test number only and had 
no other personal identifiers or the Study ID number. HIV test numbers and 
results were entered into a dedicated database, containing no other data except 
for the date of the test, the type of test kit used and the test results. The file that 
linked HIV test numbers and individual study ID numbers was maintained in a 
separate database. A STATA computer program was written that allowed files 
containing individual study data to be merged to HIV test results by linking 
study ID numbers and HIV test numbers while simultaneously dropping all 
personal identifiers, so that HIV test data could be used without compromising 
individual confidentiality. Numbers of participants were sufficiently large so 
that the potential for individual identification on the basis of results alone was 
not possible. 
For participants who wished to know their results and accepted diagnostic 
testing, HIV tests were carried out according to national testing guidelines. Two 
rapid HIV antibody tests (Abbott Determine and SD Bioline) were run in parallel 
using the participant's Study ID number, and discordant or indeterminate 
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results were resolved using an ELISA assay (Vironostika). An ELISA test was 
required for 0.4% of samples. 
CD4+ lymphocyte (CD4) counts were determined by flow cytometry (CyFlow® 
Counter: Partec). CD4 count blood samples were processed within six hours of 
venepuncture. 
3.2.2 Herpes simplex virus-2 serology 
HSV-2 is a sexually transmitted infection (STI), highly prevalent in Africa. 327 HSV-2 
is synergistic for HIV acquisition and is a good biological marker of sexually- 
acquired HIV. 52 328 The initial infection is followed by seroconversion 4-6 weeks 
after infection, and antibodies persist for life. 
HSV-2 antibodies were detected using a type-specific ELISA assay (HerpeSelect, 
Focus diagnostics, Cypress, USA) that detects antibodies to the HSV-2 
glycoprotein G2 antigen. This test was chosen because it has a high sensitivity 
(98%), particularly for detecting early seroconversion, compared to the other 
widely used G2 ELISA assay, (Kalon). 329-330 The incidence of HSV-2 is highest 
among young people and in the population studied for this project, many 
participants would have been infected recently. Thus, the assay with the 
shortest time to detecting antibodies following seroconversion was used 
(median time to detection: HerpeSelect 21 days vs. Kalon 120 days, p<0.001). 33° 
HerpeSelect appears to have a lower specificity than Kalon in African 
populations, although a study showed 100% concordance with the Western blot 
using sera from a Zimbabwean population. 331-332 Specificity is increased when a 
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higher cut-off of 3.5 for positivity is used, instead of the 1.5 cut-off 
recommended by the manufacturer. However, given that HSV-2 serology was 
used for exploring mode of HIV transmission and given that Harare has low 
rates of the infectious conditions such as malaria and intestinal and blood 
stream parasitic diseases that can cause false-positive serological reactions, the 
manufacturer's recommended cut-off was used to maximise sensitivity. 331333 
3.3 Consent and disclosure procedures 
Participants who were aged 16 years old and above were presumed competent 
to give consent. Where neurocognitive impairment was suspected, consent was 
sought from the guardian to participate in the study. Those under the age of 16 
years were considered minors and consent to participate in the study and to 
undergo HIV testing was sought from the guardian and assent sought from the 
participants. However, emancipated minors i. e. participants under the age of 16 
years who were married or had children could give consent independently. If 
there was no designated guardian, consent was sought from two physicians 
responsible for the clinical care of the participant. In primary care, eligible 
minors who were not accompanied by their guardian were followed up at home 
to get consent from a guardian. If there was disagreement between the 
guardian and adolescent about participating in the study or undergoing 
diagnostic HIV testing, both were counselled until consensus was reached. 
A flyer containing brief information about the study in the local language, 
Shona, was given to eligible adolescents and their guardians, before inviting 
them to take part in the study. A more detailed information sheet was given to 
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those who agreed to participate. Written consent (in Shona) was obtained from 
participants and their guardians. For those participants and/or guardians who 
were unable to read, consent was obtained verbally in the presence of a witness. 
Participants were encouraged to have a guardian present when HIV test results 
were given but the participant could refuse permission to have their test result 
disclosed to the guardian. In reality, refusal to have test results disclosed to a 
guardian did not occur. The participant's HIV status was not disclosed to any 
health care worker without the consent of the participant. In cases where 
participants had tested HIV-positive prior to the study but did not know their 
HIV status, guardians were encouraged to disclose the HIV status to the 
participant and this was done in all cases with the counselling and support of 
the study nurses. 
3.4 Ethical approval 
Ethical approval to conduct studies was obtained from the London School of 
Hygiene and Tropical Medicine Ethics Committee, the Medical Research Council 
of Zimbabwe, the Joint Research Ethics Committee of the University of 
Zimbabwe and the Biomedical Research and Training Institute Institutional 
Review Board. For the studies conducted among hospitalised adolescents, 
ethics approval was also obtained from the respective hospital ethics 
committees. 
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3.5 Data management 
Data were entered into a Microsoft Access database using EPI-Info 2002, which 
was used for data storage and manipulation. Data were analysed using STATA 
10.0 (STATA Corporation, Texas, USA). Data analysis methods for each study 
are described in the relevant chapters. 
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4 The burden of HIV infection and spectrum of HIV-associated 
morbidity in acute hospital admissions among adolescents 
4.1 Introduction 
As discussed in Chapter 2, symptomatic HIV in older children and adolescents 
has increasingly been observed in clinical practice in African countries. 15 183 334 
These observations, along with the relatively high HIV prevalence in this age- 
group in recent national surveys in Southern Africa, raises the potential for HIV 
to be an important cause of ill-health and mortality among adolescents. The 
spectrum of HIV-related disease varies considerably with age, but adolescents 
have been poorly represented in clinical studies of HIV infection, and thus 
distinctive features of HIV-associated morbidity in this age-group may be 
missed. 
This chapter presents data from a cross-sectional hospital-based study 
assessing the burden and clinical manifestations of HIV in hospitalised 
adolescents in Harare. This design was chosen as the initial study for this thesis 
because similar studies have shown high HIV prevalence in hospitalised 
patients even when the corresponding prevalence rates of HIV infection in the 
general population were relatively low, thus providing good statistical power at 
a manageable sample size for the estimated population prevalence of 
adolescent long term survivors of MTCT of 2 to 4% in Zimbabwe. 105.106 
Previous hospital studies have also provided important data on the main age- 
specific causes of HIV-related illnesses and deaths, stimulating further research 
on the specific disease entities as well as contributing to the development of 
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interventions aimed at prevention of opportunistic infections. Furthermore the 
existence of previous adult and child studies of a similar design from several 
African countries provided a good basis for identifying the specific 
distinguishing features of morbidity among adolescents. 105 335 
4.2 Methods 
4.2.1 Participant recruitment and assessment 
Harare Central Hospital and Parirenyatwa Hospital are the two public sector 
hospitals in Harare and cater to two-thirds of Harare's population, the 
remaining one-third using private health care facilities. The cost of 
hospitalisation in public sector facilities is partially subsidised by the 
government. Malaria transmission does not occur in Harare. Between 
September 2007 and April 2008, patients admitted to either hospital were 
enrolled consecutively the following day. Recruitment was limited to weekdays 
and to a maximum of five patients per site per day in order to maintain a 
manageable flow of clinical and laboratory work. 
Patients aged between 10 and 18 years admitted with any acute medical or 
surgical condition, including trauma, were eligible. Patients were excluded if 
moribund, requiring intensive care admission, or admitted for obstetric or 
elective reasons, or previously enrolled into the study. Obstetric admissions 
were excluded because pregnancy is a physiological state, albeit one that carries 
a high risk to health, and also because pregnant adolescents are 
unrepresentative in many respects for e. g. being all female, sexually mature and 
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sexually active and with a disproportionately high risk of horizontally-acquired 
HIV infection. 
Standardised assessment included social and clinical history, height, weight, 
and Tanner puberty staging, and laboratory investigations (full blood count, 
PITC, and CD4 count for HIV-infected participants). Onward referral for HIV 
care services was made for all testing HIV-positive. Where diagnostic HIV 
testing was declined, participants and their guardians were asked to consent to 
unreported (anonymised) HIV-testing for study purposes. In addition, all 
participants with febrile, wasting, or respiratory illness had a standardised 
infectious screen (blood culture, blood films for malaria, cryptococcal antigen 
(CrAg) testing, two sputum specimens, and chest radiography). If PCP was 
suspected, patients underwent sputum induction with nebulised hypertonic 
saline. 
Otherwise investigations followed standard hospital guidelines including 
lumbar puncture for suspected meningitis and cerebral computed tomography 
(CT) for focal neurological signs or suspected encephalopathy. Participants 
were followed for the duration of their hospital stay. 
4.2.2 Case definitions 
Pre-set diagnostic algorithms defined the definitive or presumptive cause of 
admission and any underlying chronic conditions (see Appendix A). The Adult 
WHO Classification was used to stage HIV infection. 325 
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4.2.3 Laboratory methods 
The Myco/F Lytic (MFL, Becton Dickinson) system, which can detect 
bacteraemia, fungaemia and mycobacteraemia, was used for blood culture. 336 
Blood cultures were inspected daily for seven days and then once weekly for 
eight weeks or until growth was observed, using a handheld UV Woods lamp 
(Figure 4.1). The sensor at the bottom of each bottle fluoresces in the presence 
of UV light if there is a decrease in oxygen concentration, reflecting microbial 
growth. Media was then withdrawn, and investigated using microscopy and 
culture. Bacterial growth was identified through Gram staining and culture at 
37°C on conventional media (blood, chocolate and MacConkey agar), with 
biochemical tests for confirmation (Table 4.1). Fungal and mycobacterial 
growth was investigated as described below. 
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Figure 4.1 Fluorescence of a blood culture bottle under a UV Woods lamp. 
Table 4.1 Tests used for confirmation of the identity of cultured bacterial 
and fungal pathogens 
Appearance on Suspected organism Identification Test 
culture on culture 
Gram +ve cocci " 
Catalase, coagulase and ONAase test: to distinguish 
(clusters) Staphylococcus spp between Staph aureus and coagulase-negative 
Staphylococcus 
Gram +ve cocci " 
(Haemolysis pattern on culture agar: a vs. 6 vs. none) 
(chains) ) Streptococcus spp Optochin test to distinguish between Strep 
pneumonia and Strep viridians 
" Carbohydrate utilisation to distinguish between 
lactose fermenting (LFC) vs. non-lactose fermenting 
Gram -ve bacilli Coliforms 
coliforms 
" Indole, Kligler Iron tube (carbohydrate utilisation, gas 
production, H2S production) to distinguish between 
Salmonella spp, Escherichia. coli, Enterobacter spp 
Gram -ve bacilli Pseudomonas spp " Oxidase test 
Gram -ve bacilli Salmonella spp " Serological testing (0 & H) 
Gram +ve yeast " Urease test to identify Cryptococcus spp 
" Germ tube test to identify Candida albicans 
Concentrated decontaminated sputum specimens and positive blood cultures 
were examined under fluorescent microscopy (Auramine-0) and cultured for 
mycobacteria (Lowenstein-Jensen media [LJ]). Species identification used 
MBP64 lateral flow antigen capture tests (Capillia), microscopic cording, and 
culture morphology and growth characteristics at 37 deg C (one LJ slope and 
one PNB-containing LJ slope), room temperature and 45 deg C. Cerebrospinal 
fluid (CSF) and positive blood cultures were investigated for Cryptococcus using 
India ink contrast staining, culture on Sabouraud media, and CrAg detection. 
CrAg was detected using latex agglutination (IMMY, Alpha Laboratories), with 
agglutination at a serum dilution at 1: 8 being considered positive. Induced 
sputum was stained with Grocott's silver stain. Thick blood films for malaria 
were examined under a microscope after Giemsa staining. 
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4.2.4 Sample size calculations 
We estimated that between 2 to 4% of all Zimbabwean 10 year olds were likely 
to be HIV-infected LTS based on a forward projection from a demographic 
model of the Zimbabwean general population that included UNAIDS estimates 
of the magnitude and time course of the adult HIV epidemic, the risk of mother 
to child transmission, and an estimated 36% likelihood of survival to 
adolescence with untreated maternally acquired HIV. 194 Studies estimating the 
relative rate of all-cause hospitalisation and death by HIV status in other age- 
groups have given incidence rate ratios in the region of 15 to 25 leading us to 
project a likely HIV prevalence in acute adolescent admissions of 25% to 
50%. 105 335 A sample size of 310 was chosen to detect an approximate 5% 
confidence interval (CI) around the estimated HIV prevalence at a 95% 
confidence level. This would provide 80-90% power to detect differences 
between the HIV-infected and HIV-negative group for the considered exposures 
(orphanhood, stunting, pubertal delay, previous TB) with 95% confidence, in 
the considered range of HIV prevalence (Table 4.2). 
Table 4.2 Sample sizes required to detect an association between HIV 
status and the considered exposure at the given power. The 
table gives the expected range of frequency of exposures 
Overall HIV 
prevalence 
Prevalence of exposure 
HIV+ve HIV-ve 
Sample size Power 
50% 25% 265 90% 
30% 10% 293 90% 
25% 
15% 2% 294 80% 
20% 5% 297 80% 
50% 30% 303 90% 
30% 15% 309 80% 
50% 
15% 2% 254 90% 
20% 5% 261 90% 
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4.2.5 Data analysis 
Continuous variables were compared using Student's t test for normally 
distributed variables and Mann Whitney U test for variables not normally 
distributed. Categorical variables were compared using the chi-squared (Xz) or 
Fisher's exact test as appropriate. 
Multivariate logistic regression was used for analysis of risk factors for 
mortality using a conceptual framework. 337 Potential risk factors were 
considered in two groups: socio -demographic (sex, age, orphanhood, difficulty 
raising clinic fees, TB or illness in a household member, food shortage, type of 
care-giver) and clinical (stage of HIV, previous TB, ART status, stunting, wasting, 
pubertal delay, chronic disease, anaemia, poor performance scores, self- 
perceived poor health, broad diagnosis category). An initial model retained all 
socio-demographic factors that reached statistical significance at p<0.05 on 
multivariate adjustment for confounding with other variables in this subgroup. 
Independent risk factors from the clinical variables were then assessed by 
adding each one into the socio-demographic multivariate model. The 
multivariate model was developed further by excluding single factors 
sequentially (starting from the least significant) until all remaining factors were 
statistically significant. 
4.3 Results 
Of 1,025 total adolescent hospital admissions, 340 were eligible. 301 
participants were recruited, with a refusal rate of 6% (Figure 4.2). 
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Figure 4.2 Study recruitment procedure 
Adolescent Hospital Admissions during study recruitment 
" Obstetric 516 
" Elective Admissions 72 
" Moribund/Intensive care 65 Eligible 305 
" Readmissions 32 
" Patient not found on ward 14 Participants excluded 4 
" No consent 21 
" No HIV test results 
Enrolment 301 
" Social/clinical history 
" Full blood count 
" Confidential HIV test + CD4 count (if HIV+ve) 
" Known HIV+ve (confirmed by study team) 86 
" Provider-initiated testing and counselling 215 
Accepted PITC 197 Declined PITC 18 
" Test HIV+ 50 " On confidential testing 
" Test HIV- 147 " Test HIV+ 3 
" Test HIV-15 
Results given + post-test 
counselling 
" Including disclosure 
to 17 previously 
tested 
Referral for HIV care to 
Adolescent HIV Clinic 71 
" New diagnoses 28 
. Previously known 
diagnosis but not 
in care 43 
" Including 7 where 
no previous 
disclosure 
Doctor Assessment All 
" Clinical history and examination 
Fever / Respiratory Symptoms 154 
" Sputum for TB microscopy/culture 
(173 samples) 93 
" Cryptococcal antigen (CrAg) 143 
" Thick blood film for malaria 120 
" Blood culture: 148 
I No Fever/ Respiratory 
Symptoms 147 
Management according to National Clinical Guidelines 
by Hospital Clinical team plus if clinically indicated: 
" Lumbar puncture if meningitis suspected 
" Cardiac ultrasound if cardiac disease suspected 
" Sputum induction if PCP suspected 
" CT brain if localizing neurological signs/clinical 
encephalopathy 
" Fine needle aspiration if pleural effusion or 
lymphadenopathy 
Day 2& Day 5: Doctor assessment 
Weekly follow-up to discharge/death 
Categorization using preset case definitions 
" Acute condition 
" Chronic condition 
88 
4.3.1 Socio-demographic and clinical characteristics 
Table 4.3 Baseline demographic, clinical and growth characteristics of 
adolescents admitted to hospital (n = 301 unless specified 
otherwise) 
Characteristic 
No. (%) of Participants 
HIV+ve HIV-ve 
N=139 N=162 
p-Value 
Demographic 
Age (years) 
<12 41(29) 47 (29) 0.025 
12-15 69 (50) 60 (37) 
>15 29 (21) 55 (34) 
Female 65 (47) 65 (40) 0.25 
Orphan 
Maternal or double 88 (63) 25 (15) <0.001 
Paternal 24 (17) 34 (21) 0.41 
Married 1 (1) 8 (5) 0.041 
Currently attending school 97 (70) 116 (72) 0.73 
Previously tested for HIV 103(74) 20(12) <0.001 
HIV status already known by participant 86 (62) 20 (12) <0.001 
Clinical 
Previous TB treatment 61(44) 3 (2) <0.001 
Self-rated general health "fair" 120 (86) 49 (30) <0.001 
or "Door" 
Poor performance scores 64 (46) 20 (12) <0.001 (WHO scale 3/4) 
Growth and sexual development 
Weight-for-age z< -2 (n = 266)b 88 (72) 29 (20) <0.001 
Height-for-age z< -2 (n = 263)c 63 (52) 32 (23) <0.001 
Body mass index z< -2 (n = 263)c 74 (73) 28 (27) <0.001 
Median MUAC, mm (IQR) (n = 296) d 172.5 (147-190.5) 204.5 (180-231) <0.001 
Pubertal delay 20 (14) 4 (2) <0.001 
Occurrence of menarche (females only) 18 (28) 34 (52) 0.005 
a Scale 3: bedridden, <50% of the day during the last month; scale 4: bedridden, >50% of the 
day during the last month. 
b Data missing for 35 patients due to inability to stand: 20 too ill, 8 fractured lower limb, 4 
chronic disability, 3 pathology in lower limb (2 joint infection/1 soft tissue infection). 
`Data missing for 38 patients: 35 as for b plus 2 unable to stand upright and 1 acute confusion. 
d Data reported as median, not as percentage of patients 
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Figure 4.3 Stunting (Height-for-age z-score -3.54) in a 14-year old HIV- 
infected male participant shown next to the study research 
assistant 
Participants and their guardians consented to having their pictures taken 
and the images being used for scholarly contributions. 
4.3.2 Burden of HIV infection 
The prevalence of HIV was extremely high, but within our anticipated range, at 
46%. The median age at diagnosis of HIV infection was 12 years (IQR 11-14). 
Of the 139 participants who were HIV-positive, 86 (62%) had tested HIV- 
positive prior to admission and knew their HIV status. Fifty participants tested 
positive following PITC; of these, 17 had tested HIV-positive previously but had 
not been told of their HIV infection. The median age of the participants who had 
previously tested HIV-positive but were unaware of their diagnosis was 13 
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years (IQR: 12-15 years). All guardians, however, agreed to disclosure to the 
participants with assistance of study counsellors. Only 18 (6%) participants 
declined PITC, of whom three were HIV-positive on unreported HIV testing and 
are likely to remain unaware of their HIV infection. 
Of the 103 HIV-infected participants who had tested HIV-positive prior to this 
admission (with or without their knowledge), the median age at testing was 12 
years (IQR 10-14) and 88 (85%) had tested within two years of this admission. 
Ninety four (91%) participants cited either chronic ill-health and/or 
hospitalisation with an HIV-related illness as a reason for HIV testing. Of the 
103 participants, 78 (75%) were taking cotrimoxazole (9 of whom were 
unaware of their HIV status), and 44 (43%) were taking ART (3 of whom were 
unaware of their HIV status) fora median duration of 121 days. 
4.3.3 Stage of HIV Infection 
HIV-infected participants were profoundly immunosuppressed at presentation: 
115 (83%) participants had WHO stage 3 or 4 disease and the overall median 
CD4 count was 151cells/VI (IQR 57-328). Interestingly, there was no significant 
difference in CD4 count by ART status (p<0.59): this may reflect the short 
length of time that patients had been on ART. 
4.3.4 Causes of hospitalisation 
The most frequent diagnosis among HIV-infected participants was infection 
with TB, pneumonia, cryptococcosis, and septicaemia being the most common 
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diagnoses (Table 4.4). Among HIV-negative participants, the commonest cause 
of admission was trauma, followed by acute exacerbations of chronic medical 
conditions, predominantly cardiac (Table 4.4). The median duration of stay in 
hospital for HIV-infected participants was 9 days (IQR 6-16) and for HIV- 
negative participants 7 days (IQR 4-18). 
4.3.4.1 Disease-specific microbiological findings 
113 (81%) and 41 (25%) of HIV-infected and HIV-negative admissions (p < 
0.001) met criteria for the standardised infectious screen, of whom 20 (18%) 
and two (5%) had positive blood cultures, respectively. The most frequently 
identified pathogens in HIV-infected participants were non-typhoidal 
Salmonella species (7 patients) and M. tuberculosis (4 patients). 
Cryptococcus spp were identified in blood culture in three participants, in 
cerebrospinal fluid (CSF) culture in five patients, and seven participants had a 
positive serum CrAg only. 
There were 27 TB diagnoses of which 13 were pulmonary TB: six were sputum 
smear- positive, one was culture-positive only, and six were radiological 
diagnoses (smear- and culture-negative pulmonary disease with failure to 
respond to broad-spectrum antibiotics, but response to TB treatment at 1 
month). M. tuberculosis was identified in blood culture in five participants, and 
the remaining nine had TB meningitis (n=2), pleural TB (n=3), TB arthritis 
(n=1), pericardial TB (n=1), military TB (n=1) and intra-abdominal TB (n=1). 
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Table 4.4 Causes of admission among adolescents admitted to hospital 
Cause of Admission 
(Up to Four Causes Allowed) 
No. (%) of Participants 
HIV+ve HIV-ve 
p-Value 
n= 139 n=162 
Infection 96 (69) 30 (19) <0.001a 
Mycobacterial disease 
Any mycobacterial disease 25 (18) 3 (2) - 
TB 24 3- 
Mycobacterium avium-intracellulare disease 1 0- 
Bacterial infection 
Any bacterial infection 65 (47) 20 (12) - 
Acute pneumonia 24 1- 
Bronchitis 9 2- 
Meningitis 9 2- 
Soft tissue or bone/joint infection 2 5- 
Enteritis 5 3- 
Urinary tract infection 1 1- 
Ear, Nose and Throat infection 0 2- 
Sexually transmitted infection 1 1- 
Septicaemia 12 1- 
Organ abscess' 2 2- 
Fungal Infection 
Any fungal infection 35 (25) 0 (0) 
Cryptococcosis 15 0- 
Oesophageal candidiasis 21 0- 
PCP 1 0- 
Other infection 
Any other infection 8 (6) 10 (6) - 
Malaria 2 5- 
Viral 3 3- 
Otherb 3 2- 
HIV wasting syndrome 15 (11) -- 
Traumatic injury 4 (3) 53 (33) <0.001 
Road-traffic accident 0 19 - 
Assault 1 4- 
Accident in the home 3 30 - 
Complications of previous trauma 1 6- 
Overdose/other psychiatric disorder 1 (0.7) 18 (11) <0.001 
Acute surgical 2 (1.4) 15 (9) 0.004 
Acute medical non-infectious 53 (48) 52 (38) 0.080 
Stroke 4 0- 
Cardiac failure 9 12 - 
Exacerbation of chronic condition other 1 16 
than cardiac/respiratory 
Malignancy 8 6- 
Severe anaemia (Hb < 7g/dl) 34 14 - 
Drug toxicity` 4 0- 
Malnutrition 3 1- 
Otherd 4 12 - 
Data in shaded bars indicate numbers and percentages of participants with >_1 diagnosis in 
that category 
a HIV+ve: empyema 2; HIV-ve: intracranial abscess 2 
b HIV+ve: scabies 2; self-limiting fever 1; HIV-ve: rhe umatic fever 1; sel f-limiting fever 1 
`Stevens-Johnson syndrome due to cotrimoxazole 2; hepatitis due to nevirapine 1; lactic 
acidosis due to stavudine 1 
d HIV+ve: anal fissures 1; renal condition 2; deep vein thrombosis 1; HIV-ve: renal condition 
5; dysfunctional uterine bleeding 3; gastritis 2; hepatitis 1; pellagra 1 
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4.3.4.2 CD4+ counts by diagnostic group and outcome 
Figure 4.4 Box-and-whisker plot showing median and range of CD4+ T 
lymphocyte counts in HIV-positive adolescents (regardless of 
ART status), according to cause and outcome of admission 
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Anaemia (112) 
Surgical (628) 
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2 
Trauma (403) 
- -------- - ------ 
Fatal outcome (74) 
Non-fatal outcome (183) 
CD4 count (cells/µl) 
Lower and upper line bars show the minimum and maximum CD4+ T lymphocyte counts 
and the lower, middle and upper points on the solid bars denote the 25th, median and 
75% centile respectively. Median values are also shown in parentheses after admission 
categories. Values are based on CD4 T-lymphocyte counts recorded at admission for 10 
participants with HIV wasting syndrome (67%), 16 participants with oesophageal 
candidiasis (76%), 11 participants with septicaemia (92%), 30 participants with anaemia 
(88%), 12 participants with cryptococcosis (80%), 21 participants with pneumonia (88%), 7 
participants with malignancy (88%), 23 participants with TB (96%), 3 participants with 
trauma (75%) and 2 participants with surgical conditions (100%); and 23 participants with 
fatal outcomes (72%) and 102 participants with non-fatal outcomes (95%). 
*p-value <0.003 for difference in median CD4 count in those with fatal vs. non-fatal 
outcome 
4.3.5 Chronic clinical conditions 
84 (28%) participants had underlying chronic medical conditions other than 
HIV (26% in HIV-infected versus 29% in HIV-negative, p<0.56). In addition, 
70% of HIV-infected participants had chronic skin complaints, although these 
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were rarely responsible for the admission. Admission as a result of acute 
exacerbation of a chronic condition accounted for 26 (19%) and 44 (27%) 
admissions in HIV-infected and HIV-negative participants, respectively (p 
<0.082). Chronic lung disease and cardiac disease were the most common 
serious HIV-related complications (Table 4.5). In HIV-negative participants, 
rheumatic heart disease was the most common chronic condition. 
Table 4.5 Chronic conditions among adolescents admitted to hospital 
No. (%) of Participants 
Chronic Condition HIV+ve 
N=139 
HIV-ve p-Value 
N=162 
Chronic lung disease 17(12) 0 (0) <0.001 
Cardiac disease 9 (6) 12 (7) 0.82 
Rheumatic heart disease 0 9- 
Cor-pulmonale 9 0- 
Dilated cardiomyopathy 1 1- 
Other 0 2- 
Diabetes 0 (0) 7 (4) 0.016 
Epilepsy 0 (0) 3 (2) 0.25 
Asthma 0(0) 4(2) 0.13 
Chronic skin disease 97 (70) 11(7) <0.001 
Other chronic 23 (17) 25 (15) 0.63 
Neurological 7 2 - 
Malignancy' 8 6 - 
Haematological 1 3 - 
Chronic infection/inflammation 1 5 - 
Blindness 4 0 - 
Polyarthritis 1 2 - 
Congenital 1 7 - 
HIV-ve: 4, Kaposi's Sarcoma; 2, Non-Hodgkins's lymphoma; 1, osteogenic 
sarcoma; 1, cholangiocarcinoma. HIV-negative: 3, haematological malignancy; 
2, intracranial tumours; 1, myxoid neurofibroma 
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Figure 4.5 Chronic complications of HIV infection. Al and A2) Burnt-out 
deforming seronegative arthritis in a 12 year old B) Chronic 
uveitis (complicated by corneal deposits in R eye and corneal 
perforation in the L eye) in a 15 year old 
Al 
A2 
B 
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Figure 4.6 Disseminated Kaposi Sarcoma in HIV-infected participants. 
A) Palatal and lingual disease B) Skin and lymphatic disease 
C) Lung disease 
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Figure 4.7 Chronic skin disease in HIV-infected participants. A) 
Widespread papular pruritic eruption (PPE) B) Onycholysis 
secondary to fungal nail infection C) Molluscum-contagiosum 
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Figure 4.8 Human papilloma virus infection in HIV-infected participants. 
Al) and A2) Verruca plana B) Verruca vulgaris 
Al 
A2 
B 
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4.3.6 Causes of and risk factors for death 
32/139 (23%) HIV-infected participants died in hospital compared with 
11/162 (7%) HIV-negative participants (sex- and age-adjusted odds ratio [OR] 
for death for HIV-infected patients 3.7,95% Cl 1.7-7.8, p<0.001). The median 
time to death was 12 days (IQR 4-2 1) in HIV-infected and 10 days (IQR 6-20) in 
HIV-negative participants. 
Death was significantly associated with low CD4+ T lymphocyte count in HIV- 
infected patients (74 versus 183 cells/µl, p<0.003). The highest case-fatality 
rates among HIV-infected participants were from HIV wasting syndrome (53%), 
any malignancy (50%), and drug toxicity (50%), and among HIV-negative 
participants the highest case-fatality rates were for malignancy (83%). 
Table 4.6 Causes of death among adolescents admitted to hospital 
Cause of Death 
No. (%) of Deaths 
HIV+ve HIV-ve 
(N = 32) (N =11) 
No. Died/Total 
(Case Fatality Rate) 
TB 4(13) 1(9) 5/27(19) 
Pneumonia 3 (9) 1(9) 4/25 (16) 
Meningitis 2 (6) 1(9) 3/11(27) 
Bloodstream infection 2 (6) 0 2/13 (15) 
Other infection' 1(3) 1(9) 2/11(18) 
Cryptococcosis 6 (19) 0 6/15 (40) 
HIV wasting syndrome 8 (25) 0 8/15 (53) 
Drug toxicity 2 (6) 0 2/4 (50) 
Malignancy 4 (13) 5 (46) 9/14 (64) 
Cardiac failure 0 2 (18) 2/21(10) 
a HIV-ve = empyema; HIV-ve = osteomyelitis 
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Table 4.7 Risk factors for death among adolescents admitted to hospital 
(n = 301 unless specified) 
Variable 
No. Died/Total 
(%) 
Univariate 
OR (95% Cl) p-Value 
Final 
Multivariate 
OR` (95% Cl) p-Value 
Sociodemographic 
----- -- --- --- - - --- - Age (years) -- --- --- -- --- -- -- -- -- - - 
> 15 5/84 (6) 1.0 1.0 
12 to 15 27/129 (21) 4.2 (1.5-11.4) 0.005 2.5 (0.8-7.4) 0.11 
<12 Y 
-- ---- -- - 
11/88 (13) 2.3 (0.7-6.8) 0.15 2.0 (0.6-7.0) 0.25 
- -- - ------ - -- --- Primary caregiver - ------ ----------- -- ----- -- ---- ----- 
Biological parent 12/126 (10) 1.0 1.0 
Not biological parent 31/175 (18) 2.0 (1.0-4.2) 0.05 1.3 (0.5-2.9) 0.60 
Clinical 
HIV WHO stage 
HIV-negative 11/162 (7) 1.0 - 1.0 - 
HIV-infected and stage 
1/2 2/24 (8) 1.2 (0.3-5.7) 0.85 1.0 (0.2-5.7) 0.99 
HIV-infected and stage 3 5/36 (14) 1.6 (0.5-5.1) 0.42 1.6 (0.5-5.4) 0.49 
HIV-infected and stage 4 
-- 
25/79(32) 5.1(2.3-11.4) <0.001 2.8 (1.1-7.1) 0.03 
------- --- ----------- Previously treated for TB --- - --- - -- - ---- -- -- - 
Yes 25/237 (11) 1.0 - 1.0 - 
No 18/64 (28) 2.4 (1.2-4.9) 0.02 1.3 (0.6-3.2) 0.53 
Poor performance score (WHO scale 3/4) 
No 12/217 (6) 1.0 - 1.0 - 
Yes 31/84 (37) 8.2 (3.9-17.3) <0.001 6.9 (3.0-15.8) <0.001 
Self-perceived poor health ---- -- -- -- 
No 8/132 (6) 1.0 - 1.0 - 
Yes 35/169 (21) 3.0 (1.3-6.9) 0.01 0.4 (0.1-1.5) 0.19 
-- -- - Pubertal delay -- --- 
No 34/276 (12) 1.0 - 1.0 - 
Yes 9/25 (36) 3.1 (1.2-8.1) 0.021 4.0 (1.4-11.6) 0.01 
--- ---- -- Stunting (n = 263) 
No 11/168(7) 1.0 - 1.0 
Yes 17/95 (18) 3.1 (1.3-7.3) 0.01 1.2 (0.5-3.2) 0.69 
-------- ------- ---- -- Wasting (n = 266) 
No 6/149 (4) 1.0 - 1.0 
Yes 23/117(20) 5.2 (2.0-13.7) 0.001 2.1 (0.6-6.9) 0.23 
----------- Chronic disease (other than ski -- n disease) 
No 22/21 (10) 1.0 - 1.0 - 
Yes 21/84 (25) 2.7 (1.3-5.3) 0.005 2.8 (1.3-6.0) <0.001 
Haemoglobin (n = 282) 
>11g/dl 12/124 (10) 1.0 - 1.0 - 
7.0-10.9 g/dl 13/110(12) 1.0 (0.4-2.4) 0.97 0.4 (0.1-1.1) 0.07 
<7.0 g/dl 14/48 (29) 
, 
3.6 (1.5-8.7) 0.005 0.8 (0.3-2.5) 0.72 
' Univariate ORs adjusted for significant sociodemographic variables (age group and type of 
primary caregiver) 
b Adult WHO staging system 
`Adjusted for HIV stage, chronic disease, pubertal delay, and performance score 
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Of the considered socio-demographic risk factors, younger age and having a 
primary care-giver who was not the parent were associated with an increased 
risk of death (Table 4.7). After adjusting for these factors, advanced HIV 
disease, severe anaemia, TB treatment in the past, poor self-rated health, a 
chronic disease (except chronic skin disease), pubertal delay (Tanner puberty 
stage 1/2 in those aged 14 years or above), poor performance scores, wasting, 
and stunting were all associated with increased risk of death. In the final 
multivariate model, WHO stage 4 HIV infection (OR 2.8,95% Cl 1.1-7.1; p< 
0.032), chronic disease (OR 2.8,95% Cl 1.3-6.0; p<0.009), pubertal delay (OR 
4.0,95% C. I 1.4-11.6; p<0.011), and poor performance scores (OR 6.9,95% C. I 
3.0-15.8; p<0.001) remained independently associated with increased risk of 
death. 
4.4 Discussion 
4.4.1 HIV burden and HIV-associated morbidity 
The main finding of this study high burden was that HIV infection is the single 
most common cause of acute hospital admission and in-hospital death. Nearly 
one in two adolescents admitted to hospital were HIV-infected, the majority 
with profound immunosuppression; the median CD4 count among untreated 
HIV-infected patients (141 cells/µl) was similar to that reported in other 
studies of hospitalised African adults in the pre-ART era as was the spectrum of 
HIV-associated infections. 105 338 However, adolescents had an additional and 
heavy burden of chronic complications such as growth failure, lung disease and 
cardiac disease, typically reported in HIV-infected children. In about a fifth of 
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HIV-infected patients, hospital admission was precipitated by an exacerbation 
of the underlying chronic condition. An underlying chronic disease (excluding 
skin disease) was independently associated with an increased risk of in-hospital 
death. 
4.4.1.1 Chronic lung disease 
More than 10% of HIV-infected patients met the case-definition for chronic lung 
disease and of these, 53% had end-stage complications of secondary right heart 
failure or cor pulmonale. The prevalence of chronic lung disease was felt to 
have been underestimated as a conservative case definition was used and it was 
difficult to distinguish underlying chronic lung disease in patients who were 
presenting with acute-on-chronic complications due to lack of pre-admission 
chest radiographs. 
In order to investigate this possibility further I, therefore, carried out a cross- 
sectional survey for chronic lung disease in stable HIV-infected adolescents 
drawn systematically from two adolescent HIV care clinics in Harare. The 
results are summarised in Appendix B and confirm the impression that 
underlying chronic lung disease is highly prevalent in HIV-infected adolescent 
LTS and is one of the main threats to survival among adolescents on ART. 
4.4.1.2 Skin disease 
Skin disease, although incidental to the need for admission in only a small 
minority of cases, was an extremely common manifestation of HIV infection, 
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and should be a strong indicator for diagnostic HIV testing. Although not 
commonly life-threatening, skin disease is associated with considerable 
psychological morbidity. 339 In communities with a high burden of HIV, social 
isolation is compounded by the strong association of skin disease with HIV and 
subsequent stigmatization. 340 
4.4.2 Delay in diagnosis of HIV infection 
One of the major findings was that diagnosis of HIV infection was frequently 
delayed in this age group until presentation with advanced HIV disease. A 
substantial minority had not been diagnosed with HIV before hospitalisation, 
and most others reported relatively recent diagnosis following a prolonged 
history of recurrent infections and chronic ill-health. The beneficial effects of 
early HIV diagnosis and ART on reducing the risk of opportunistic infections 
and reducing mortality are well-recognised in children. 341 In addition to 
irreversible chronic complications such as those observed in the study, older 
age at diagnosis and delay in starting ART may potentially result in suboptimal 
immune response and blunted catch-up growth and pubertal development. 262 
263 342 
The findings of the study strongly support implementation of PITC for all 
patients in this age group attending health facilities, and stimulated the study at 
primary care level described in Chapter 6, as our data suggest that by the time 
LTS are seen at hospital level they are already critically ill and have a high 
burden of irreversible complications, notably so for lung disease. The high 
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uptake of HIV testing in this study indicates that PITC is acceptable to 
adolescents and their guardians at least in a hospital setting. 
Reluctance of guardians to disclose the true nature of the underlying illness was 
also apparent in that a substantial minority of the HIV-infected participants had 
not been told their HIV test results and some participants were even taking 
cotrimoxazole or ART without knowledge of their diagnosis. Non-disclosure is 
associated with anxiety, reduced likelihood of accepting medical care and 
exclusion from social support. 303 Clear advice to health professionals to not 
only offer PITC but also to assist guardians with disclosure may improve timely 
diagnosis and adherence to subsequent ART. 343 
4.4.3 Other implications of the study findings 
The high prevalence of stunting, pubertal delay and other established 
complications discussed above, as well as the history of chronic ill-health 
(which prompted HIV testing in the majority of cases) are indicative of 
longstanding HIV infection, and consistent with MTCT being the major route of 
infection (as explored further in Chapter 5). 
The widely held perception until recently has been that, due to the high risk of 
rapid progression in HIV-infected infants, survival to late childhood and 
adolescence with untreated HIV was unusual. Thus, adolescents and older 
children have been considered to be at low risk of long-standing HIV infection, 
which has resulted in failure to prioritise this age-group in 11IV testing and care 
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programmes. The findings of this study, however, suggest that long-term 
survival following MTCT is now a major cause of morbidity among adolescents 
in Zimbabwe and likely to be so in other Southern African countries. 194 Given 
the potential implications of the study findings, the mode of HIV acquisition 
among study participants was explored and the results are presented in 
Chapter 5. 
4.5 Limitations of the study and generalisability 
The study was hospital-based and therefore focused on sicker patients and 
more severe HIV-associated complications. One of the study sites was based at 
a referral hospital, which may have resulted in a higher proportion of specialist 
diagnoses such as cancer. 
Both hospitals had ART clinics, but only nine (6%) of the HIV-infected 
participants were admitted from these: instead the vast majority of our 
participants (87%) were referred directly from primary health care clinics or 
through hospital casualty departments and there was a high participation rate 
(94% of eligible subjects). The only local alternatives to these two hospitals are 
private facilities. The results are, therefore, likely to be representative of the 
pattern of acute severe morbidity and mortality in Harare. 
Additional studies in Zimbabwe and the region that lend support to these 
findings being generalisable to the rest of Zimbabwe and most likely the 
Southern African region are that a high proportion of 0 to 19 year olds 
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attending HIV care clinics throughout Zimbabwe (ranging from 25% to 56% in 
the eight provinces of Zimbabwe) are in the 10 to 19 year-old age-group, and 
that similar (although delayed onset) epidemics of LTS were projected for South 
Africa , 194 344 
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5 Mode of transmission of HIV infection among hospitalised 
adolescents: an exploratory study 
5.1 Introduction 
As discussed in Chapters 2 and 4, HIV with advanced immunosuppression and 
characteristics suggesting long-standing infection, potentially dating back to 
infancy, now features as a prominent cause of morbidity in African older 
children and adolescents, having been rarely encountered in the early years of 
the HIV epidemic. 23 This suggests either long-term survival from maternal 
transmission during infancy which would not have been obvious early on 
during the HIV epidemic given the intrinsic time lag between HIV infection and 
reaching adolescence. Alternatively, HIV transmission by sexual or parenteral 
routes is more common during childhood than has been anticipated. This 
Chapter aims to summarise the evidence for and against each of these 
alternatives as being the predominant mode of transmission in the HIV-infected 
adolescent participants from the study described in Chapter 4. 
Investigating the likely mode of transmission was important because natural 
history cohort data from which to directly estimate survival probabilities for 
HIV-infected children growing up in resource-limited settings are limited to the 
first few years of life. As such, indirect approaches have instead been used to 
estimate survival probabilities beyond the age of 5 years. More recent 
estimates have assumed two distinct subgroups of infants: the majority (fast 
progressor group) assumed to have exponential mortality with a median 
survival of less than one year, and the slow progressors assumed to have a 
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much longer median survival in the range of 8 to 16 years. 8.9 194 These have 
superseded earlier models based on extrapolation of infant survival, resulting in 
underestimation of the probability of survival beyond 5 years of age. Similarly, 
there are no good data on the frequency of sexual or parenteral exposure to HIV 
at a young age. 
When the HIV epidemic was initially identified, the routes of HIV transmission 
were established through epidemiological investigations. Unlike in North 
America and Europe, in early studies African AIDS patients rarely reported a 
history of homosexual activity or of intravenous drug use. Several lines of 
epidemiological evidence supported heterosexual transmission in Africa. These 
included demographic factors (1: 1 male to female ratio among cases, younger 
age and single marital status for female cases), sexual factors (higher number of 
sexual partners and sexual exposures and association with STIs in cases). 23 The 
association of HIV seropositivity with blood transfusions and number of 
medical injections particularly in children who had HIV seronegative mothers 
also identified a parenteral route of HIV transmission. 192 Similar data helped 
discount the role of arthropods in HIV transmission; the lack of evidence for 
increased exposure to HIV infection among non-spousal household contacts of 
AIDS suggested that insect transmission did not occur over short distances and 
there was a very low prevalence in children between 1 and 15 years of age in 
Kinshasa, where there is a high incidence of malaria in childhood. 23192 
109 
4 C 
d cJ 
O 
Iti 
.. r 
O 
; 
.r 
H 
it 
rar 
O 
O 
E 
it 
Lr 
CL) 
.. r 
E 
O 
w 
'O 
O 
a+ 
cu 
in 
O 
O 
O 
.. r Rn 
E 
O 
U 
(o 
CL 
N 
0 
0. 
3 x 
d N 
Is 
t 
d 
CL d 
I- 
c 
a, 
Cl. 
I- 
r r O 
E 
ba C Co 
O 
.°C 
1o 1 >" 
NV 
EÖ 
r 
ö0 
C 
0 
41 41 
0 
14- 
aI 
0ö 
E 
E I t w v a a 0 
a 
c (0 C ai 
TE YL 
cu L- m 
> 
d A .0 G 
. Ö to 3 L C IM 00 
) 
0 
Z. c S 
o_D cl 
_. S 2 >" 
0 
Z Zv Z 
d 
0 
0 
f9 
27 N 0 -0 
C 
C 
m 
v C 
7 
aU O N 
CL 0 ' L Ö >«O O 
Y 41 U L) 
_ Cü 
C 
Q) 
M CO üE . - 
"ý wý"" 
ie c ai 'e, a o, c vc wL in a) - Gl .ÖO "la r cC m 
13 
> 
t LO 
0 
Leo r0 
w- 
' ` 
(0 (0 
' ( "tu 
ON . 92 t0 
Z _ Z Z } 
gy p" 
f0 
t o0 bO Q0 
LL ZL J v 
N 
N 
0) 
m 
F+ m (0 0 
(0 
t9 C N 4.. 
0 
L C 
. 
d 
-0 
C 
E N M 0 0 G 0 G C . 
O 
0) U 
C 
yyC NC 
2'i 3 ai c 
vä 
v tß 
a L Y vý fO 'ý 0 $ ýE+ f nOv ,;? 
E 
0 lj Gl r C 
W Z 2 
Jv = 7 >' >C > -0 
In 
vvaN 
O 
ro ö 
o c vC 
O -1 
y" 
3 O 
`O j 
12 m &A 
y 
CL 
C 
,p 
ü 'C G! 
CO= 
a) ~O T ei C a 
'N d Co 
Q7 a) Ö 
L 
. 
U 
C 
O 
'i' > ,Öe ei 
C O tc v rý 
v i 
ö 
T 
äö 0 
a t L 
o > w 
0 
L a> ka 
0 d y 
to 
L0 ' öY "C ý C 
C! 
o a O 2M0 *C) 0 I- NNQ 
a) 
N O 
0 d, T 41 N 
( i 
O 
r- 
ao x wf6 
3 3 m v O °G ö 
L 
ä C_ 
ff . ä° i 3 3 Co > Z x u , v i 
N 
d 
U OC 
dw y ä IA 
C 
OÜ 
CO C 
W 4! C two "' C 
r`o . 
> d 
ý ,ý 
3ö - 
y 
ä> 
Z, 
ci 4- 
°C C > 
(L) 
0 
Z 
Ö m O 
Ö Z cu `. 4 
0 i Z !qC 
"G 
E 
VÖ 
H >_ 
O 
> x 
\ N OCi 
O 
N 
A 
7 
Ct 
O 'O 
x CL x C 00 (A CL) 
0 W 
° ' ° WO ü x x aN l7 V1 , u 
O 
We used a similar approach described above to explore the likely mode of 
transmission among hospitalised HIV-infected adolescents. The putative 
association of demographic, clinical, parenteral and sexual factors with different 
modes of transmission is summarised in Table 5.1. The prevalence of these factors 
were compared in HIV-infected and uninfected participants to explore the likely 
mode of transmission. Although we anticipated that it would not be possible to 
categorise the mode of transmission in any given individual with complete 
confidence, we hypothesised that associated factors may be sufficiently 
characteristic at group level to allow identification of the predominant mode of 
transmission with reasonable certainty. 
5.2 Methods 
The participant selection process is described in the previous Chapter (Section 
4.2.1). 
5.2.1 Exploring route of HIV acquisition 
A self-completion questionnaire (with no personal identifiers except a study 
number) investigating sexual behaviour was given to participants aged 12 years 
and older. The questionnaire was an abbreviated version of one developed, piloted 
and used in the interim survey of a cluster randomized trial evaluating a 
community-based, multi-component HIV and reproductive health intervention 
among rural Zimbabwean youth (Frances Cowan, Lisa Langhaug, Webster Mavhu: 
Regai Dzive Shiri Project). 345 HSV-2 serology was used as a biological marker for 
sexual activity. 328 
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A standardised questionnaire was administered to the participant to ascertain 
history of personal illness and pregnancy, knowledge of HIV, perceived risks of 
personal HIV infection, history of possible parenteral exposure to HIV and reasons 
for previous HIV testing. Responses indirectly indicating previous sexual exposure 
(e. g. previous pregnancy, marriage, and previous testing due to sexual risk or 
pregnancy) were compared with data obtained from the sexual behaviour 
questionnaires for inconsistency in reporting sexual behaviour. 
A detailed family clinical history was recorded for each participant through 
interview with the participant and the guardian. This included vital status, age at 
and cause of death, HIV status and history of TB and prolonged ill-health in 
biological parents and natural siblings (defined as those with the same biological 
mother as participants). 
5.2.2 Data analysis 
The prevalence of factors suggestive of the considered routes of HIV transmission 
(parenteral, sexual, and vertical) was compared between HIV-infected and 
uninfected participants using the chi-squared (x2) or Fisher's exact test as 
appropriate. 
5.3 Results 
Data on personal and family clinical history, sexual history and parenteral HIV risk 
factors is summarised in Table 5.2. Unlike other studies which show a much 
higher incidence of HIV infection among females than males in young people, there 
was no difference in HIV prevalence by gender, and HIV-infected participants were 
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significantly less likely to be married or have experienced sexual debut. Four 
(1.3%) participants tested HSV-2 positive, of whom two were HIV-positive and 
with a history of previous sexual exposure. All partners of married participants 
were alive but their HIV status was not known. 
HIV-infected participants were more likely to be maternal, but not paternal 
orphans and to give a history of death of natural siblings. Additionally, a higher 
proportion of HIV-infected participants reported HIV or TB as the cause of death of 
their parents and HIV infection in their parents compared to HIV-negative 
participants. HIV-infected participants themselves, were more likely to have had 
multiple hospital admissions and frequent clinic visits, suggesting chronic ill- 
health. 
There was no association between HIV status and potential parenteral risk factors 
for HIV infection. It is notable that nearly all participants (96%) were breastfed by 
their biological mother; three participants were also breastfed by a non-biological 
mother. 
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Table 5.2 Factors expected to vary by route of HIV transmission among the 
study population (139 HIV+ve & 162 HIV-ve participants) 
No. (%) unless No. of missing 
Factor otherwise 
specified 
p-value 
responses 
HIV+ve HIV-ve HIV+ve HIV-ve 
Female 65 (47) 65 (40) 0.25 00 
Past Clinical history 
>3 clinic visits/year in 23 of past 5yrs 42 (31) 11(7) <0.001 2 1 
22 previous hospital admissions 39 (29) 21(13) <0.001 6 1 
Cause of 1" ever hospitalisation 
Never hospitalised 51(37) 105 (65) 
Infection/malnutrition/TB 60 (44) 14 (9) 2 0 
Non-HIV related 15 (11) 36 (22) 
Other' 11(8) 7 (4) 
Median (IQR) age of 1" ever 8.5(2-11) 8 (3-11) 0.51 
hospitalisation 
Family history 
Orphan 
Maternal 31(22) 8 (5) <0.001 1 0 
Paternal 24(17) 34(21) 0.41 3 4 
Double 57 (41) 17 (10) <0.001 
Cause of death in mothers (n=113) 
HIV-related/TB/pneumonia 35 (40) 10 (11) <0.029 43 13 
Non-infection related 5 (20) 7 (28) 
rte...... -SA __" :.. s .. L... __ r.. _, ell* -. aU C UI UC II ui ICLIIIa 1II L L) - 
HIV-related/TB/pneumonia 35 (43) 10(20) 
<0.051 
34 31 
Non-infection related 12 (15) 10 (20) 
Mother HIV-infected' 35 (25) 7 (4) <0.001 101 137 
Father HIV-infected' 27 (19) 4(3) <0.001 108 144 
Siblings HIV-infected' 9 (4) 0 (0) <0.001 196 367 
No. of natural siblings who had died' 26 (12) 15 (4) <0.001 1 0 
Sexual history 
HSV-2 seropositive 2 (1) 2 (1) 0.88 0 0 
Married 1 (1) 8(s) 0.041 0 0 
Self-reported sexual debut (n=150)` 6 (9) 19 (22) 0.032 72 79 
Self-reported forced sexual debut 
d 5(8) 4(5) 0.46 
73 74 
(n=149) 
Parenteral risk factors 
Received injections at rural health 20 (14) 31(19) 0.27 00 
clinic 
Received injections from traditional 0.46 00 
healer 1(0.7) 
0 (0) 
Scarification 3 (2) 11(7) 0.10 00 
One or more surgical procedures 12 (9) 33 (20) 0.004 00 
Median (IQR) number of injections 10 (7-15) 8 (5-11) 0.61 00 
Received at least one blood 15 (11) 10(6) 0.15 00 transfusion 
b 
Cardiac failure 5; arthritis 2; stroke 1; acute flaccid paralysis 1; no cause given 9 
Total 627 siblings: HIV-ve participants 225 siblings; HIV-negative participants 407 siblings 
Total 150 participants: 67 HIV+ve; 83 HIV-ve; questionnaire not completed by 151 participants: 
88 under 12 y, 63 too ill. 
d Total 149 participants: 66 HIV+ve; 83 HIV-ve; questionnaire not completed by 151 participants: 
88 under 12 y, 63 too ill, 1 no response given 
' significant difference in missing responses in HIV+ve vs. HIV-ve 
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5.4 Discussion 
5.4.1 Mode of HIV transmission 
Table 5.3 summarises the evidence for each of the considered modes of HIV 
transmission from the data shown in Table 5.2, and supports MTCT as the 
predominant route of HIV acquisition in hospitalised HIV-infected adolescents. 
Low rates of self-reported sexual debut, and a much lower prevalence of HSV-2 
infection than would be anticipated for sexually-acquired HIV in Southern Africans 
were observed in the study. 328 Although HSV-2 seropositivity does not establish 
an individual's source of infection, HSV-2 infection is a highly prevalent sexually- 
acquired infection in Southern Africans that significantly increases risk of HIV 
acquisition. 52 327 346 As such, it serves here as an independent marker of sexually- 
acquired HIV that can be used to corroborate the self-reported data concerning 
likely mode of transmission that was collected from participants. These findings, 
along with the negative association with marriage (given that marriage at young 
age increases risk of HIV for young African girls14), and the equal sex distribution 
of HIV infection in an age-group where females are at much higher risk of being 
HIV-infected through sexual exposure, makes recent sexual transmission very 
unlikely to be the major route. 14 347 
The strong association of HIV infection with chronic ill-health and with maternal 
and sibling (but not paternal) orphanhood or parental and sibling HIV infection are 
all consistent with long-term survival following MTCT as the source of HIV 
infection in most study participants. Of note, there was no association between 
HIV infection and possible risks factors for HIV acquisition through parenteral 
exposure. Zimbabwe is one of the few African countries to have had strong 
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policies to prevent parenteral transmission very early on in the course of the HIV 
epidemic and has an unusually good safety record for preventing percutaneous 
HIV-infection. 348-349 
Table 5.3 Evidence for and against considered modes of HIV transmission in 
HIV-infected adolescent participants 
Observation expected LTS Sexual: pre or 
to vary by mode of following post puberty 
transmission Mid Parenteral Pre Post 
Comment 
Growth +++ + + No 
Severe stunting suggests 
young age at infection 
F=M +++ +++ No No 
Equal F: M ratio inconsistent 
with sexual transmission 
Sexual maturity +++ + +++ No 
Sexual immaturity suggests 
pre-pubertal infection 
Concurrent STI +++ +++ No No 
HSV-2 higher in HIV-ve 
than in HIV-infected 
History of blood transfusion +++ No +++ +++ Guardians/participants 
uncommonly report Scarification/unsafe 
injections +++ No +++ +++ arenteral risk parenteral 
ascertained (Infant 
HBV (blood transmissible) ND ND ND ND HBV vaccination available 
since 1996) 
Lack of acute seroconversion 
illness +++ + No No None diagnosed 
Frequent maternal and 
Family history +++ No No No sibling death/ known HIV 
infection 
Frequent childhood 
Childhood clinical history +++ + + No hospitalisation and TB 
treatment 
Chronic complications of LIP and planar EV-assoclated early childhood (not adult) +++ ++ No warts highly prevalent HIV infection* 
Observation consistency with postulated mode of HIV transmission: +++ =highly consistent; 
+=consistent direction, but not extent, of finding; No=inconsistent; ND=not done 
*Only occurs when HIV precedes infection with a second virus usually acquired In early 
childhood: LIP=lymphoid interstitial pneumonitis following EBV infection; EV=epidermodysplasia 
verruciformis (EV-associated planar warts following HPV Infection) 
5.4.2 Implications of study findings 
If, as strongly suggested by this study, long-term survival following MTCT is the 
main cause if HIV infection in older childhood, then this raises the possibility that 
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survival with HIV infection from infancy is more likely than previously anticipated 
from earlier studies showing high mortality rates in early life among HIV-infected 
infants.? These findings are supported by population-based HIV prevalence 
surveys in Southern Africa (summarised in Chapter 2, Table 2.2) that have 
consistently reported HIV prevalence rates of 1-5% among older children, much 
higher than would be anticipated given the high HIV-associated mortality observed 
in the first two years of life. 
Figure 5.1 Estimated HIV prevalence rate in 15-49 year olds in African 
countries (Source UNAIDS350 353) 
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If MTCT is indeed the predominant mode of transmission, then HIV-infection 
reflecting long-term survival from the paediatric HIV epidemic in the 1990s, is now 
a major cause of adolescent morbidity and mortality in Harare. These findings 
support epidemiological model findings that predict an emerging epidemic of LTS 
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of MTCT in Zimbabwe. 194 Zimbabwe is unusual in having had high HIV prevalence 
rates from the late 1980s with a subsequent decline in HIV incidence (Figure 5.1) 
and so may be a few years ahead of other countries in the region that have had 
otherwise comparable but later onset HIV epidemics, with respect to the 
subsequent epidemic of HIV-infected adolescent LTS. 19 
The magnitude of the epidemic of LTS may be different in other low income 
countries in Africa because Harare has unusual features resulting in low competing 
causes of mortality in childhood. These include a) lack of malaria and b) a public 
service provision and town planning that have been unusually well implemented 
until the past few years, resulting in a low risk of enteric illnesses. 354 Hence, 
vertically-infected infants are more likely to survive childhood to reach 
adolescence. 
5.5 Limitations of the study 
The study was exploratory in nature and was not able to confirm source of HIV 
infection at individual level. There were three main sources of bias: Firstly, data 
on sources of parenteral exposure may not adequately capture the risk of 
transmission through this route, and data relied on recall by participants and their 
guardians; Secondly, the proportion of parents with unknown HIV status was 
significantly higher for HIV-negative than HIV-infected participants. The higher 
proportion of HIV infection in parents of HIV-infected participants may be a 
consequence of more parents of HIV-infected participants having previously 
tested. Similarly, a large proportion of siblings had not been HIV tested although in 
this case there was no difference in the proportions of siblings with unknown HIV 
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status by HIV status of the participant. Thirdly, sexual behaviour data was only 
available from half of the of the study population, the remainder being too ill or too 
young to complete the questionnaire. There is, however, no reason to believe that 
those who did not complete the questionnaire were at higher risk of sexual 
transmission than participants who completed the questionnaire. Participants 
may also have underreported sexual debut, and one (HIV-negative participant) 
who was HSV-2 serology positive denied being sexually active. However, the 
overall low HSV-2 serology rates support low rates of sexual activity. Production 
of antibodies is suppressed with advanced immunosuppression which may have 
resulted in underestimation of HSV-2 prevalence in HIV-infected 
immunosuppressed participants. However, this has not been demonstrated in 
other studies where the same assay was used. 355 Other potential limitations of the 
HSV-2 assay are discussed in Chapter 3 (Section 3.2.2). 
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6 Undiagnosed HIV infection among adolescents seeking 
primary health care in Zimbabwe 
6.1 Introduction 
The study detailed in Chapter 4 showed that hospitalised adolescents in Harare 
had a high burden of HIV frequently accompanied by one or more chronic 
complications typically described for untreated paediatric HIV infection. Inpatient 
mortality was extremely high, and although most cases were known to be HIV- 
infected by the time of admission, the diagnosis had often been made only recently 
but following a prolonged history of frequent minor illnesses managed at primary 
care level. It was thus postulated that there would be a higher proportion of 
undiagnosed HIV-infection and presentation with less advanced disease at 
primary care level compared to secondary care settings. If this were the case, then 
any diagnostic intervention would be best placed at primary care level, providing 
multiple opportunities to diagnose HIV among LTS of vertical HIV transmission 
before the development of life-threatening illnesses. Furthermore, there was a 
large gap between estimates of numbers of adolescent LTS in Zimbabwe in 2008 
(43,357) and the numbers of adolescents in HIV care nationally (10,500), 
suggesting either a high burden of undiagnosed HIV in this age-group or 
alternatively that the projected numbers of vertically-infected adolescents had 
been over-estimated. 194344 
The aims of the study detailed in this Chapter were to extend investigation of the 
prevalence, severity, and clinical manifestations of HIV-infection to primary care 
level. This study also provided the opportunity to further explore the mode of 
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transmission, and to investigate the acceptability of PITC among adolescents 
attending primary health care services in Harare, Zimbabwe. 
6.2 Methods 
6.2.1 Study population 
Participants were recruited from Epworth and Mabvuku Clinics, two primary care 
polyclinics in the high-density suburbs of Harare, Zimbabwe, with catchment 
populations of about 120,000 and 60,000 people respectively. Primary care clinics 
are run by nurses and services offered by primary care polyclinics include acute 
care as well as ANC. ANC attendees, but not all acute clinical care attendees, are 
routinely offered PITC. Single-dose nevirapine to pregnant HIV-infected mothers 
is offered for PMTCT. 
Individuals aged between 10 and 18 years attending the primary care polyclinics 
for any reason were enrolled consecutively on weekdays over a six-month period 
in 2009. ANC attendees were included in the study as a control group to 
investigate the association of factors suggestive of long-term survival following 
vertical transmission (discussed in Chapter 5) among APC attendees. The 
associations between these factors and HIV infection were compared in the ANC 
attendees (where HIV infection was acquired through sexual transmission) and 
among participants attending for APC. 
Clinic attendees were not eligible if they were too ill to take part (defined as those 
who required urgent hospitalisation), had been previously enrolled in the study, or 
were aged below 16 years and not accompanied by a guardian. 
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6.2.2 Provider-initiated HIV testing and counselling 
All participants were asked to consent to providing blood for unreported 
(anonymised) HIV testing for study purposes, and were offered PITC, either 
through study personnel (APC attendees) or as part of the PMTCT programme 
(ANC attendees). Group pre-test counselling and individual post-test counselling 
was given as part of the PITC process. The group counselling lasted for 30 minutes 
and basic facts about HIV/AIDS including modes of transmission, benefits of 
testing and the effects of HIV on the body were discussed. The testing process was 
explained and participants were given the opportunity to ask questions. 
Participants who declined HIV testing following group pre-test counselling were 
offered individual counselling. HIV-positive participants were started on 
cotrimoxazole, and were referred for HIV care to adolescent clinics at one of the 
two central hospitals in Harare, where CD4 counts were performed. 
6.2.3 Mode of HIV transmission 
HIV-infected APC attendees were given a self-administered questionnaire and 
asked to choose the most likely source of their HIV-infection from the following 
options: born with it/from mother; from injections or blood transfusion; from 
boyfriend/girlfriend or husband/wife; or from an unwanted sexual encounter. 
Study nurses assessed mode of transmission based on a case-definition derived 
from the hospital study (longstanding chronic, i11-health, sibling and maternal 
death, growth failure, no history of blood transfusions and sexual debut), but were 
not blinded to participants' responses. HSV-2 positivity was used as a biological 
marker of sexually-acquired HIV infection. 328 
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6.2.4 Clinical assessment 
All participants had MUAC, height, and weight measured and Tanner pubertal 
staging to assess growth. 324 Pre-set diagnostic algorithms were adapted from the 
WHO IMAAI to broadly classify the presenting complaint. 326 
6.2.5 Sample size calculations 
A sample size of 250 was required to detect an approximate 5% Cl around the 
estimated HIV prevalence of 15% at a 95% confidence level, and an assumption of 
a 10% participation refusal rate. The 15% estimate was based on the observed HIV 
prevalence among 2-9 year olds attending primary health care facilities in South 
Africa. 182 The estimated frequency of the exposure variables are shown in Table 
6.1 (extrapolated from the results of the study described in Chapter 4). The 
chosen sample size provided 80-90% power to detect ORs of around 3.0 or higher 
between the considered risk factors and HIV infection, with a Cl of 95%. 
Table 6.1 Sample sizes required to detect a bivariate association between 
the considered exposure variable and HIV infection, with the given 
power, with a confidence level of 95%. The table gives the 
expected approximate prevalence of the considered variables 
Prevalence Power 80% Power 90% 
Variable of variable 
in HIV-ve OR 2.5 OR 3.0 OR 5.0 OR 2.5 OR 3.0 OR 5.0 
Previous TB/skin complaints 5% 972 630 246 1320 858 336 
Maternal orphan 15% 414 282 120 558 372 162 
Stunting 20% 354 240 108 474 318 144 
Poor self-rated health 30% 306 216 108 402 282 138 
The sample size was, however, doubled as the dataset was used to design an 
algorithm for identifying HIV infection among adolescents in primary care 
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(described in Chapter 8) which required the dataset to be randomly split into two. 
An ethics amendment was obtained to be able to recruit 500 participants. 
6.2.6 Data analysis 
A Xz or Fisher's exact test was used as a test for association between categorical 
variables, a Student's t-test for normally distributed variables and a Mann Whitney 
U test for variables not normally distributed. A p-value <0.05 was considered 
statistically significant. 
6.3 Results 
6.3.1 Demographic and clinical characteristics 
Of 626 clinic attendees, 12 were not accompanied by a guardian, 7 were too ill to 
be recruited and 13 refused consent; the remaining 594 adolescent primary care 
attendees were recruited into the study, of whom 506 (85%) were APC attendees 
and 88 (15%) were ANC attendees. Nearly half of all participants were orphaned 
and 35% were not attending school (Table 6.2). ANC attendees were more likely 
than APC attendees to be married (85% vs. 5%, p<0.001) and were older (median 
age 17 vs. 14 years, p<0.001). 
6.3.2 HIV prevalence 
The overall HIV prevalence was 15%. APC attendees had a significantly higher HIV 
prevalence than ANC attendees (6%, p<0.007). Unlike hospitalised HIV-infected 
adolescents, where less than a third tested for the first time, 70 of the 86 HIV- 
infected APC participants (81%) were newly diagnosed by the study team. Newly 
diagnosed HIV-infected APC participants were less immunosuppressed than those 
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who tested for the first time during hospital admission (median CD4 count 329 vs. 
204 cells/µ1). Four newly diagnosed HIV-infected participants died before 
registering for HIV care. 
Table 6.2 Baseline characteristics of participants by HIV status (n=594) 
Characteristic 
No. (%) of participants 
APC attendees (N=S06) ANC attendees (N=88) 
HIV+ve HIV-ve HIV+ve HIV-ve 
p-value p-value (n=86) (n=420) (n=5) (n=83) 
Median Age (IQR) 14 (11-16) 14(11-16) 0.63 16 (15-17) 17 (16-18) 0.09 
Female 48 (56%) 211(50%) 0.35 5 (100%) 83 (100%) - 
Clinic site 
Epworth 35 (41%) 181(43%) 0.69 5 (100%) 74 (89%) 0.44 
Mabvuku 51(59%) 239 (57%) 0(0%) 9 (11%) 
Orphanhood Status 
Maternal orphan 15 (17%) 36 (8%) 0.013 0 (0%) 6 (7%) 0.53 
Paternal orphan 21(24%) 84(20%) 0.39 0(0%) 18(22%) 0.24 
Double orphan 29 (34%) 56 (13%) 0.001 2 (40%) 13 (16%) 0.16 
Attending School 62 (72%) 327 (78%) 0.23 0 (0%) 0 (0%) - 
Married 7(8%) 18(4%) 0.17 3 (60%) 72(87%) 0.16 
Biological parent as 
primary caregiver 
34 (40%) 264 (63%) 0.001 0 (0%) 15 (18%) 0.58 
Median (IQR) MUAC 202 219 
001 0 
250 243 
0.94 (mm) (177-225) (195-247) . (242-255) (234-261) 
Pubertal Delay 15 (17%) 27 (6%) 0.001 0(0%) 0(0%) - 
Median (IQR) Height- -1.7 -0.71 001 0 -0.75 -0.77 0.98 for age z-score (-2.63 - -0.76) (-1.42- -0.01) . (-0.97- -0.11) (-1.3- -0.13) 
Stunting 34 (40%) 51(12%) 0.001 1(20%) 7 (8%) 0.39 
Median (IQR) 
Weight-for age z- -2.03 -0.90 001 0 -0.2 
0.08 0.55 
score 
(-3.13 - -1.14) (-1.64- -0.27) . (-0.64- 0.63) (-0.43- 0.63) 
Wasting 43 (50%) 63(15%) 0.001 0(0%) 0(0%) 
6.3.3 Presenting complaints 
The most common presenting complaints in APC patients were diarrhoea, ear, 
nose and throat (ENT) infection and skin infection: HIV prevalence in patients 
presenting with these complaints ranged between 20 and 24% (Table 6.3), but was 
above that in routine ANC attendees (5%) for all categories except malaria. 
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Participants presenting with possible TB or an STI had the highest HIV prevalence 
(50% and 40%, respectively), with those presenting with malaria (5%), chronic 
lung or heart conditions (7%), trauma (8%) and urinary tract infection (8%) 
having the lowest risk of underlying HIV infection. HIV-infected participants were 
more likely to present with infectious conditions than HIV-negative participants 
(82% vs. 67%, p<0.001). 
Table 6.3 Syndromic classification of the presenting complaints in 506 
adolescents attending APC services and 88 ANC attendees 
Cause of attendance (up to 3 causes allowed) Total HIV prevalence (%) 
Acute primary care attendees (N=506) 
Diarrhoea/ Dysentery 106 (21%) 20 
Ear, Nose and Throat infection 99 (20%) 22 
Skin infection 65 (13%) 23 
Lower Respiratory Tract infection 45 (9%) 24 
Headache 45 (9%) 16 
Other non-infectious cause' 44 (9%) 16 
Urinary tract infection 29 (6%) 7 
Possible TB 26 (5%) 50 
Traumab 38 (8%) 8 
Non specific abdominal pain 24 (5%) 8 
Malaria 22 (4%) 5 
Other infection` 22 (4%) 23 
Surgical problem 22 (4%) 9 
Sexually transmitted infection 20 (4%) 40 
Chronic lung or heart problem, including asthma 14 (3%) 7 
More than one presenting complaint 117 (23%) 30 
Antenatal care attendees (N=88) 
Routine antenatal care visit 79(90%) 5 
Sexually Transmitted infection 5 (6%) 20 
Other infectionsd 4 (5%) 100 
HIV+ve: allergic conjunctivitis 3; suspected pregnancy 2; visual impairment 1; follow-up 
visit 1; HIV-ve: allergic conjunctivitis 14; visual impairment 3; suspected pregnancy 3; 
gynaecological problem 3; requesting HIV test 2; epilepsy 2; arthritis 1; drug allergy 1; 
diabetes mellitus 1; epistaxis 1; follow-up visi t 1; growth on eye 1, limb pain and 
general weakness (no cause identified) 4 
b Includes wound infection following trauma in 3 participants 
HIV+ve: oral candidiasis 3; hepatitis 1; dental abscess 1; HIV-ve: hepatitis 9, dental 
abscess 2; gingivitis 2; eye Infection 2; mastitis 1; worm infestation 1 
d Skin infection 2; possible TB 1; urinary tract infection 1 
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6.3.4 Mode of HIV acquisition 
As shown in Table 6.2, findings were very similar to those presented for 
hospitalised patients in Chapter 5: age and sex did not differ by HIV status in APC 
attendees. HIV-infected APC attendees were significantly more likely to be 
maternal or double, but not paternal orphans, than their HIV-negative 
counterparts and to be stunted. These associations were not observed for ANC 
participants, although numbers were small in this group. HIV-infected APC 
attendees were also more likely to have pubertal delay than HIV-negative 
counterparts. 
Of the 86 HIV-infected APC participants, 69 (80%) selected vertical transmission 
as the most likely source of their infection, 4 (5%) chose injections or blood 
transfusion and 13 (15%) chose sexual transmission. There was a high 
concordance between participant and nurses' assessment of likely mode of HIV 
transmission (Table 6.4). However, nurses were not blinded to participants' 
responses, which could partly explain the high concordance observed. 
Table 6.4 Comparison of self-rated and nurse-rated assessment of most 
likely mode of HIV acquisition among APC HIV-infected 
participants (n=86) 
Nurses' assessment 
Mother-to-child Sexual Parenteral 
Self-rated Mother-to-child 69 00 
assessment Sexual 1 12 0 
Parenteral 211 
95.4% inter-rater agreement; K score = 0.85 
HSV-2 prevalence among ANC attendees was significantly higher than among APC 
attendees (14% vs. 4%, p<0.002). Being an ANC attendee, regardless of HIV status, 
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was associated with an increased odds of being HSV-2 positive (OR 3.6, p<0.001). 
Among APC participants, there was an association between HIV and HSV-2 for HIV- 
infected participants who considered themselves likely to have been sexually 
infected with HIV (24.8, p<0.001, but not in those who considered themselves 
vertically infected (OR 0.40, p<0.38) (Table 6.5). The median CD4 count was 305 
(IQR 174-480) cells/µl in the vertically-infected group. 
Table 6.5 Risk of being HSV-2 positive among participants attending acute 
APC services and ANC services, according to HIV status and self- 
reported most likely source of HIV infection 
OR for HSV-2 
value No. HSV-2+ve (%) 
positivity (95% C. I) 
p-value 
APC 14/420 (3%) 1.00 (Ref) - 
HIV-ve ANC 10/83 (12%) 3.97 (1.7-9.3) 0.001 
HIV+ve ANC 2/5 (40%) 19.33 (3.0-125) 0.002 
Sexually-infected HIV+ve APC 6/13(46%) 24.85 (7.43-83.6) 0.001 
Non-sexual mode of HIV infection: HIV+ve APCa 1/73 (1%) 0.40 (0.05-3.1) 0.38 
°4=parenteral and 69=vertical 
6.4 Discussion 
6.4.1 Undiagnosed HIV infection in adolescents 
The main finding of this study was the substantial burden of previously 
undiagnosed HIV infection across a wide range of presenting complaints among 
adolescents attending APC services in Harare. In contrast, the prevalence of HIV 
infection among adolescents attending routine ANC services was only 6%: similar 
to the national ANC surveillance estimate for 15-19 year olds (6.8% in 2009), and 
consistent with declining HIV incidence in Zimbabwe. 1320 356 
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In common with hospitalised adolescents, HIV-infected APC attendees had a high 
prevalence of features suggesting longstanding infection, such as pubertal delay 
and stunting and little to suggest sexual transmission as the predominant cause. 
There was a strong association of HIV with maternal and double, but not paternal, 
orphanhood suggesting mother-to-child HIV transmission. The high prevalence of 
HSV-2 in acutely unwell HIV-positive adolescents who reported having probable 
sexually-acquired HIV, and positive association between HIV and HSV-2 infections 
in ANC attendees contrasts with the very low prevalence of HSV-2 (below that of 
HIV-negative participants) in acutely unwell adolescents who selected vertical or 
parenteral transmission as their most likely source of HIV infection. If maternal 
transmission is indeed the predominant source of HIV among the acutely unwell 
adolescents in this study, then the main implications are that there is a high 
burden of undiagnosed LTS in Zimbabwe, and that routine testing of this age-group 
at primary care level is strongly indicated. 
6.4.2 Provider-initiated HIV testing and counselling in primary care 
Few studies have focused on the spectrum of morbidity related to undiagnosed 
HIV presenting at primary care level, and none have focused specifically on 
adolescents. As in other studies, HIV infected individuals were significantly more 
likely to present with possible TB or STI, and were also more likely to have 
multiple complaints. 357-358 However, HIV prevalence was high across the entire 
spectrum of common presenting complaints, suggesting that universal PITC should 
be adopted, rather than targeting specific clinical presentations. 
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In contrast to hospitalised adolescents, most HIV-infected adolescents at this level 
of the health system were previously undiagnosed, and their median CD4 count 
was relatively high (329 cells/µl). Studies have shown that HIV-infected adults 
commonly consult primary care with HIV-related symptoms prior to their eventual 
diagnosis, and children consult primary care services with a greater frequency 
than adults. 359 Thus, implementing PITC at primary care level is likely to have a 
much greater impact on reducing diagnostic delay and, if linked to prompt entry 
into HIV care, improving long term prognosis than a similar intervention at 
hospital level. The acceptability of PITC was very high (97%) in this study, with 
both adolescents and their guardians supporting routinely offered HIV testing, as 
has been shown for younger children in South Africa. 360 Thus, PITC at primary 
care level is likely to be a particularly effective strategy in promoting earlier HIV 
diagnosis in this age-group. 
6.4.3 Implications of study findings 
Evidence from Zimbabwe suggests that there are increasing numbers of LTS of 
MTCT reaching adolescence, the majority of whom are not yet in HIV care. 194 344 
This is likely to be generalisable to the region. The current study adds to the data 
presented in previous chapters and existing literature by demonstrating a high 
burden of undiagnosed HIV infection with features suggesting MTCT as the 
predominant source of infection in adolescents presenting to APC services. 
In contrast to our findings in hospitalised patients, however, the results of this 
study raise the hope of being able to diagnose LTS who still have a good prognosis 
if provided with HIV care through a simple facility-based intervention. Most of the 
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newly diagnosed patients had high CD4 counts and relatively minor intercurrent 
illnesses. This makes a strong argument for routine implementation of diagnostic 
HIV testing for older children and adolescents attending primary care services, 
regardless of the presenting complaint. Frontline service providers also need to be 
made aware that the epidemiology of HIV in older children and adolescents is 
changing, and that the main risk of infection in this group appears to be MTCT, 
which has implications for affected adolescents, and their guardians and siblings. 
6.5 Limitations of the study 
Assessment of the likely mode of HIV infection was through a brief questionnaire 
asking participants to report their likely mode of HIV acquisition. Participants' 
perception of personal risk of being HIV-infected may have been influenced by the 
information obtained during pre-test counselling, particularly regarding vertical 
HIV infection. However, the very low prevalence of HSV-2 in participants selecting 
non-sexual transmission concurs with data obtained through self-report. The 
nurses' assessment may also have been influenced by participants' responses, 
although they were asked to provide a reason for their selected choice of mode of 
transmission based on a case definition.. The proportion of HIV-infected 
adolescents who were newly diagnosed may have been overestimated as those 
with known HIV infection may preferentially present to their HIV care clinic with 
complaints. However, this is unlikely to have a significant effect given the 
relatively small numbers of older children in HIV care. 
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7 Perception of risk of vertically-acquired HIV infection and 
acceptability of PITC among adolescents in primary health 
care 
7.1 Introduction 
International guidelines recommend routine PITC to all people seen in health 
facilities in generalized epidemics as part of universal access to HIV testing and 
care, and countries with severe HIV epidemics, such as Zimbabwe, are increasingly 
moving towards provision of PITC in all health facilities. '? The results described in 
the previous chapter showed a substantial burden of undiagnosed HIV infection 
among adolescents attending primary health care services. 
Despite the clear benefits of PITC, a number of considerations around HIV testing 
in adolescents can act as barriers to implementation of PITC in this age-group. 
Firstly, HIV testing of older children has not been emphasized in HIV programs and 
there may be lack of awareness of the burden of HIV in this age-group among 
health care workers. Secondly, HIV testing of under 16 year olds requires consent 
of a legal guardian: a potential barrier that may be compounded by changing or 
informal guardianship due to parental death. 295 361 The ability of children to get 
diagnosed is thus likely to be influenced by guardians' awareness of risk, and their 
willingness to initiate the process of HIV CT. Thirdly, advice to test a child for HIV 
infection may not be acceptable to guardians as it carries with it the implication 
that the child has either been infected vertically (implying that the mother and 
potentially the father and other siblings are HIV-positive), or horizontally, which 
then raises the question of sexual transmission. Guardians may also fear 
stigmatization of the child and other HIV-infected family members if they are 
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known to be HIV-infected, or may fear that the child or other family members may 
themselves be unable to cope with the knowledge and consequences of being HIV- 
positive. 
This chapter presents the results of 3 sub-studies that were nested into the study 
investigating HIV-related morbidity among adolescent primary clinic attendees 
(Chapter 6). These were focused around the themes of 
" exploring acceptability of PITC to adolescent APC attendees and their 
guardians, given the sensitivities outlined above 
" mode of transmission and knowledge, attitudes and perceptions of the risks 
of adolescent HIV infection in the context of MTCT 
" Entry into HIV care and acceptability of family HIV CT following PITC at 
primary care level 
These topics were chosen to clarify and understand issues that arose from the 
hospital-based study described in Chapter 4, in particular the reasons for delay in 
diagnosis and access to care and awareness of risk of HIV infection in this age- 
group. 
7.2 Methods 
7.2.1 Study population 
The participant selection process is described in detail in the previous chapter 
(Section 6.2.1). Consecutive patients aged between 10 and 18 years attending for 
acute primary care (but not the ANC clinics) were invited to take part in the study. 
All participants were offered an HIV test following group pre-testing counselling. 
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Participants and guardians (where available) were asked to complete a 
confidential questionnaire designed to elicit information on acceptability of the CT 
process and reasons for consenting to or declining HIV testing, including the 
perceived advantages of HIV testing and factors in counseling that may have 
influenced the decision whether to undergo HIV testing. The questionnaires were 
completed before HIV test results were known. 
HIV-infected participants were referred to one of two HIV care clinics in central 
Harare, and were provided with a three months follow-up appointment with the 
primary care study team. The follow-up was intended to allow any problems with 
entry into HIV care to be identified and rectified, and also to provide an 
opportunity for HIV CT of the participants' relatives. 
7.2.2 In-depth interviews with participants and guardians 
In-depth interviews were used to explore the acceptability of HIV testing including 
the perception of risk of HIV infection among adolescents, and the benefits and 
disadvantages of HIV testing. Interview participants were sampled purposively 
from the participants of the parent study to include HIV-negative and HIV-positive 
participants, but with deliberate over-sampling of HIV-positive participants; 
participants who had declined and accepted diagnostic testing, respectively; and 
participants from both study sites. Those who had tested HIV-positive prior to 
participation in the study were not interviewed. Interviews were conducted in the 
participants' homes one week after HIV testing had been offered. A professional 
social science consultant was engaged to facilitate this study. Participants were 
interviewed on their own by an experienced professional field worker of the same 
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sex as the interviewee and in the local language, Shona. The interviews lasted 
between 30 to 45 minutes and were recorded and transcribed verbatim. 
7.2.3 Data analysis 
Questionnaires and interview transcripts were translated into English for data 
processing and analysis. Qualitative data was subjected to thematic analysis, 
whereby common themes were identified and topical codes developed and applied 
to transcripts. For quantitative data, a chi-squared test (X2) or Fisher's exact test 
was used as a test for association between categorical variables, a Students' t test 
for normally distributed variables. 
7.3 Results 
The number of participants in the parent and sub-studies is shown in Figure 7.1. 
71 interviews were conducted: 30 with participants who tested HIV-positive, 29 
with guardians of participants who tested HIV-positive, 7 with participants who 
had tested HIV-negative, 4 with participants who declined HIV testing and 1 with a 
guardian who declined consent for their child to be tested. The median age of 
participants interviewed was 14 years (IQR: 11-16years) and 22 (54%) were 
female, similar to the age and sex of participants in the parent study from which 
the sample was drawn. The guardians interviewed were mother (n=9), aunt (n=6), 
sibling (n=6), grandmother (n=3), uncle (n=2), father (n=1), stepmother (n=1) and 
niece (n=1). 
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7.3.1 Acceptability of PITC among adolescents and families 
Of the 506 PHC attendees, 48 (9%) had previously had an HIV test of whom 16 had 
tested HIV-positive. PITC was offered to all 490 participants who were not already 
known to be HIV-infected (Figure 7.1). Only five (1%) participants declined HIV 
testing, and 70 (14%) participants tested HIV-positive. OF the 32 participants who 
had previously tested HIV-negative, one tested positive during the study. 
Figure 7.1 Uptake of PITC among adolescents and families of HIV-infected 
adolescents 
PHC Participants 506 
Previous HIV test 48 11 No previous HIV test 458 
HIV +ve 16 11 HIV -ve 32 
I Participant PITC 490 
Accepted HIV test 485 11 Declined HIV test 5 
HIV+ve70 11 HIV-ve415 
Offered 3 month follow-up I 
and counselling 
Attended 44 1 I. Did not attend 42 
Offered family PITC 
Accepted 28 II Declined 16 
(56 relatives) 
136 
Of the 86 HIV-infected participants, 44 (51%) attended three months later for 
family-based counselling and had all registered for care. Of the remaining 42 
participants, 21 (24%) relocated from the area, 6 (1%) died and 15 declined 
further follow-up. It was not possible to trace whether these participants were 
attending for HIV care. Of the 44 participants who attended, 56 family members of 
28 HIV-infected participants underwent HIV testing: 7/16 siblings, 6/7 mothers, 
3/3 fathers, 2/2 partners and 6/28 other relatives tested HIV-positive (overall HIV 
prevalence 43%). The one participant with a mother who was confirmed to be 
HIV-negative stated that the most likely route of transmission was through the 
bleeding sores of his HIV-infected cousin in early childhood. 
The main reasons for accepting HIV testing among participants and their guardians 
when they attended for APC related to the general importance of knowing one's 
HIV status, to investigate the cause of recurrent or chronic illness and being able to 
access treatment if diagnosed with HIV infection (Table 7.1). HIV-positive 
adolescents and their guardians were significantly more likely than HIV-negative 
counterparts to cite recurrent ill-health as the main reason for testing. 
The remainder of Section 7.3.1 and Section 7.3.2 refer to data obtained through in- 
depth interviews. 
7.3.1.1 Reasons for declining HIV testing 
Of the five participants who declined HIV testing, three were not mentally 
prepared and feared the test outcome. One participant did not test as he did not 
wish to test in front of his father who had accompanied him to the clinic, and one 
participant wanted to test but his mother did not provide consent. The fears 
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Table 7.1 The main reason cited by participants and their guardians for the 
participant accepting HIV testing following PITC, by HIV status of 
the participant 
Guardians' reasons for 
Participants' reasons for 
consenting to have their child 
Reason for accepting 
HIV testing (n=477)* tested (n=310)* 
HIV Testing HIV+ve HIV-ve HIV+ve HIV-ve 
(%) (%) p-value (%) (%) p-value 
N=68 N=409 N=45 N=265 
To know status: peace 41 297 10 140 
of mind and to plan for p (60.3%) 
0.10 
(72.6%) (22.2%) 
0.001 
(52.8%) 
the future 
Urged to test/ Parents 2 1 
Approve (2.9%) 
ND 
(0.24%) 
Recurrent Illness/ Not 22 68 0 005 
24 73 0.001 
Well (32.4%) . (16.6%) (53.3%) (27.6%) 
Parent/s HIV- 0 1 ND 
6 13 0.11 
infected/died (0.0%) (0.24%) (13.3%) (4.9%) 
On TB Treatment - -- 
0 
(0.0%) 
1 ND 
(0.4%) 
Had sex 
Re-test** 
Sexually abused 
01 
ND (0.0%) (0.24%) 
01 ND (0.0%) (0.24%) 
100.001 
(2.2) (0.0%) 
02 ND 
(0.0%) (0.8%) 
Early access to 
treatment if found to 
3 40 0.001 
4 36 0.001 
be HIV positive 
(4.4%) (9.8%) (8.9%) (13.6%) 
ND-not determined 
*Reasons not given by 2 HIV+ve ve adolescents, 6 HIV-ve adolescents, and 3 guardians of 
HIV-ve adolescents 
**Participant tested HIV positive as an infant, participant not aware of status, not in HIV care 
expressed by these five participants were not being able to get married if HIV- 
positive, fear of being beaten at home, fear of dying, fear of other people finding 
out and needing more food. 
"I was tested but my mother refused to get the results. I don't know 
why she was afraid; she didn't explain it to me. After the blood 
sample was taken and we were called in for the results she said she 
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was not prepared to take them and went away. Personally 1 want to 
know my HIV status 1 know how important it is " (12 year old male 
who declined HIV testing) 
"I wasn't ready for it. I only came to treat him for what was wrong 
that day. I wasn't going to accept the results; I was scared to hear. 
No-one can expect something that terrifies you. As a young boy he 
has never thought of anything that can go wrong. Knowing might 
not affect him but it will affect me as an adult" (Mother of 12-year 
old male who declined HIV testing quoted above) 
"1 was afraid to get tested, not because of any bad thing which I was 
suspected to have done. I had some fear inside, how will my parents 
accept it, how am I going to cope with the situation. If only I was 
above 18 years I could stand for myself but now I am dependent on 
my parents; how will they accept it? My health would be affected 
because I would be thinking of that most of the time. " (17 year old 
male who declined HIV testing) 
7.3.1.2 Perceived benefits and disadvantages of HIV testing 
Regardless of the participants' HIV status or whether the participants had accepted 
testing, there was strong support for HIV testing for this age-group. There was 
unanimous agreement among the participants that HIV testing was beneficial, 
regardless of the test result. Participants identified several benefits to HIV testing, 
including earlier access to HIV treatment, access to HIV prevention and motivation 
to stay HIV-negative, and the ability to plan lives around marriage and child- 
bearing. The main concerns about HIV testing were about adverse psychological 
reactions such as stress, depression, worry about premature death, withdrawal 
from society, stigma and the desire to take revenge on their sexual partner that 
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might accompany testing HIV-positive, or complacency following a negative HIV 
test leading to an increase in risk-taking behaviours. 
"You can start thinking too much which is not good, so you keep 
being sick and die early. Also, people you live with might say - you 
and your disease, we can't live together. ' " (HIV negative female, 
aged 15 years) 
7.3.1.3 Concerns regarding PITC in primary health care 
All study participants felt that the information provided during pre-test 
counselling was comprehensible and adequate to make a decision about HIV 
testing. There was no concern that PITC put pressure on participants or guardians 
to accept testing or resulted in loss of confidentiality. At interview, the 
participants noted that counselling had reinforced messages that motivated them 
to consider testing. In particular, the realization that vertically-infected children 
could survive to adolescence was a trigger for some participants to test. 
'1 was surprised to learn about transmission from mother to child 
during breastfeeding and delivery. This alone prompted me to be 
tested because I was not aware of this before. " (11 year old HIV 
negative male) 
"The most important message was that children are still being 
detected positive, even when they are 18 years of age. The virus can 
be in your body for a very long time without any symptoms 
showing. " (12 year old HIV negative male) 
Participants expressed mixed feelings about group versus individual pre-test 
counselling with some participants expressing a preference for an Individual pre- 
test session rather than a group session. 
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"Counselling should be done individually because in a group some 
might be domineering and give all the answers whereas one might 
not understand. " (16 year old HIV negative female) 
"Individually is best because whatever is said will be directed at me. 
If I ask a question, it is about myself and the answers will be directed 
at me, not the group. In a group, one person can say we have 
understood and the others will just follow and some will be afraid to 
ask questions. " (11 year old HIV negative male) 
The main concern regarding the PITC process was the need for more detailed post- 
test counselling and psychosocial support. Participants felt more support was 
needed for those testing HIV-positive, and HIV-negative participants expressed 
concern that PITC might focus on those who had tested HIV-positive with little 
opportunity to reinforce primary HIV prevention messages. Additionally, the 
period when participants waited to be tested and then waited for their results was 
typically filled with fear, highlighting the need for the testing process to be 
reassuring and prompt. 
7.3.2 Perception of risk of HIV infection in adolescence 
7.3.2.1 Prior contemplation of HIV testing 
A third of HIV-positive participants interviewed had contemplated being tested before. 
Seventeen (65%) guardians of HIV-infected participants interviewed had also 
considered getting their child tested and about half had discussed having their 
child tested with others, usually another family member. The main reasons 
mentioned by participants for not having tested previously were lack of money for 
transport or clinic consultation fees, prevarication, and no one to accompany them. 
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"1 must admit I had thought of it before because I was experiencing 
stomach pains, my legs were painful and 1 couldn't walk properly. I 
hadn't gone before because I just kept putting it off, but not for any 
reason in particular. " (HIV-infected 11 year old male) 
"1 wanted to go on my own before I became seriously ill but I had no 
money for transport and to pay at the clinic. " (HIV-infected 17 year 
old male) 
Guardians also mentioned these reasons as well as a lack of awareness of testing 
services and one had been dissuaded by her husband who considered that their 
son was "not all that sick" : 
"7t wasn't common fifteen years ago to test children but he was 
tested and I knew he was positive. Later on he became strong and 
fit and it was then difficult to believe he was positive because he was 
healthy. " (Guardian of 15 year old HIV-infected male, not in HIV 
care) 
"Yes, I thought about it but didn't realize that children were being 
tested for AIDS. I thought only adults were tested. I didn't know of 
any clinic that was offering the service and thought you could only 
go to a private doctor if your child was seriously ill. " (Guardian of 
12 year old, HIV-infected boy) 
"Yes, because she had been coughing a lot. But we kept putting it 
off. " (Guardian of 10 year old HIV-infected female) 
7.3.2.2 Reasons for suspecting HIV infection 
Eight (28%) HIV-infected participants and 19 (66%) guardians of HIV-infected 
participants had strongly suspected that the HIV test results would be positive. 
The main reason for suspecting HIV infection among participants and their 
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guardians was recurrent ill-health, and guardians also volunteered the death or 
HIV status of the child's parents or siblings and poor growth of the child as reasons 
for suspecting HIV infection. Over two thirds of guardians (n=23) identified the 
deaths of parents and siblings or HIV infection in parents as a reason for having 
their child tested and eight guardians reported 14 sibling deaths of whom two had 
died after the age of five years. 
"My father died of TB, my mother is HIV positive and 1 have been 
diagnosed with TB. " (18-year old HIV-infected male) 
"He is really stunted in his growth and is forever sick with a runny 
stomach and severe acne and pimples. " (Guardian of 16 year old 
HIV-infected male) 
"The way I was being affected by headaches with the whole of my 
body feeling weak, I suspected it could be HIV. I had noticed that my 
symptoms were the same as my sister and two brothers who have 
died. " (17 year old HIV- infected male) 
"My child was born with the virus. I could tell from his health as he 
was not fit and strong like other children of his age. By the age of 
two he was not crawling and he was supposed to be running. He 
was tested for HIV at the age of two and was positive but I didn't 
believe it 1 just ignored it. He has been living with the virus from 
that time without any treatment and he is now 17. " (Guardian of 17 
year old HIV- infected male) 
"I got it from my parents; I was infected while I was still young. I 
think I got it in 1998 while I was being breastfed by my mother. 
Yes, I grew up being sick and that's where I think I might have 
acquired it I was never given blood so it can't be from a blood 
transfusion. " (11-year old HIV-infected male) 
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In addition to the HIV-infected participants' and their guardians' own suspicions 
regarding their HIV status, twelve guardians (41%) and nine (31%) participants 
mentioned that others had raised the possibility of HIV infection and suggested 
HIV testing, which prompted them to consider testing. These suggestions were 
given by family members to the guardians, although a third of the group noted that 
friends had also offered such advice. For adolescents, this suggestion had come 
from a parent (38%), other family members (50%), or a friend (22%) but only one 
reported receiving this suggestion from a health care worker. The basis of others' 
suspicions was the poor health state or short height of the adolescent. 
"Two of his siblings have died -a girl who was 21 months old and a 
boy of eleven months. I even relocated because of their deaths 
because I thought people were bewitching me... My sister 
encouraged me to be tested and now I know they died because of 
this disease. " (Mother of 11 year old HIV-infected male) 
HIV-infected participants and their guardians who had expected a negative result 
did so because the child was not sexually active, had enjoyed a general good state 
of health throughout childhood or had illnesses not perceived as typical symptoms 
of HIV/AIDS. 
"I had a very positive mind and thought that if I had the virus from 
birth I would have been dead long back so I was expecting a 
negative result. I was never sick from childhood which would have 
made me suspect I could be positive. " (14 year old HIV-infected 
male) 
"I thought she would be negative because the symptoms of 
HIV/AIDS I have heard about are totally different from what she 
was feeling. She has been complaining of headaches, feeling weak 
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and refusing to eat At one time I thought she was pregnant. " 
(Guardian of 17 year old HIV-infected female) 
7.3.2.3 Lay perception of risk of HIV infection in adolescence 
Although the majority of HIV-infected adolescents and their guardians felt that the 
source of HIV infection was probably from the mother, less than half of those 
interviewed felt that others would believe that this was actually the case. Most 
interviewees mentioned that HIV was associated with sexual intercourse in 
people's minds and eleven (38%) guardians said that people did not expect a child 
infected by its mother to survive early childhood. 
"The general public lacks knowledge because they think that one 
can only be infected through sexual intercourse. They don't think of 
these other means. They say since young ones have not experienced 
sexual matters, they can't be affected. " (16-year old HIV-infected 
male) 
Guardians commented that most people in their communities do not believe that 
adolescents are at risk from HIV and that people believe the only infection route 
for adolescents is through sexual intercourse. Similar views were expressed by 
those who had tested HIV-negative and those who had opted-out of HIV testing. 
These adolescents exhibited negative impressions of those at risk of HIV infection 
and felt they were not at risk of HIV infection, unless they engaged in unprotected 
sex. About half of the participants did not think it possible that HIV-infected 
infants could survive to adolescence and most had learnt of long-term survival 
through the patient information and counselling they had received during the 
study. Some participants remained sceptical that HIV-infected infants could live 
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into their teens and remarked that it would be assumed that an HIV positive 
adolescent would have contracted the virus through sexual intercourse. 
"7t is very difficult for other members of the family to accept that 
one of the children is positive. They would just think I got it from a 
sexual partner even if I have not engaged in that. Very few will 
think of themselves as having infected their children. The 
knowledge about mother to child transmission is not widespread. " 
(15 year old HIV negative male) 
"Some would chase away the child and say -go and stay where you 
got the disease' - because many people still think one gets HIV 
through being mischievous. " (17-year old HIV negative female) 
"The risk is very low for boys compared to ladies. The ladies become 
sexually active early. You find four ladies in love with one man. The 
risk for boys is only if you get a sugar mummy or have used a sharp 
instrument" (17 year old male who declined HIV testing) 
"People who are at risk are those who go to beer halls and pubs - 
prostitutes. They will be after boyfriends and sleep around with all 
sorts of men. " (17 year old female who declined HIV testing) 
"The people who are at risk are prostitutes, promiscuous or 
adulterous people. Also soldiers, because they work away from 
home and end up having extra-marital affairs. No other types of 
people are at risk. " (16 year old female who declined testing) 
7.4 Discussion 
7.4.1 Feasibility and acceptability of PITC 
Contrary to our expectations, the main finding of this study was the very high 
acceptance rate of PITC in primary care among adolescents. Given the results of 
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the study of hospitalised adolescents whereby the vast majority of adolescents had 
tested after presentation with a severe illness, we had anticipated a high refusal 
rate to PITC. A uniform offer of testing, with an explanation as to why the group as 
a whole is being targeted appeared to be highly acceptable and there was strong 
endorsement from adolescents and their guardians that HIV testing for this age- 
group is beneficial and desirable, regardless of the level of perceived risk of being 
HIV-infected and potential implications for the participant and other family 
members. 
The substantial burden of undiagnosed HIV infection among adolescents attending 
primary health care services strongly supports the routine HIV testing in this age- 
group. HIV testing is a means of promoting HIV prevention in an age-group that is 
also at high risk of HIV infection through horizontal HIV transmission. 362 
Additionally, some family members of HIV-infected adolescents underwent testing 
as a result of the adolescent testing, with nearly 50% of relatives who tested being 
HIV-infected. Hence, PITC in children may be an entry point for the whole family 
to access HIV testing and care. However, even at primary care level, six out of 86 
participants died shortly after diagnosis, highlighting the importance of HIV 
diagnosis as early as possible. The observation that such a high proportion of HIV- 
infected biological parents were alive is intriguing and study of this group may 
provide further insight into immune mechanisms involved in control of HIV 
infection. 
Notably, nearly a quarter of HIV-infected participants had relocated from the area 
within three months of HIV diagnosis. Although this is speculative, HIV-infected 
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participants may have been sent to the rural areas (where medical consultation 
fees are lower, and ART is often easier to access than in Harare) or the whole 
family may have departed following a diagnosis of HIV infection in the adolescent 
which may have revealed the HIV status of the child's parents. This may also 
account for the low uptake of HIV testing among family members and highlights 
the need for interventions to facilitate linkage into care following HIV diagnosis 
and for family-based interventions to accompany routine HIV testing for children. 
7.4.2 Knowledge, attitudes and perceptions of HIV risk in adolescents 
Our results show a stark contrast in knowledge and perceptions between HIV- 
infected and HIV-uninfected participants and their guardians regarding possibility 
of HIV infection in adolescence acquired through MTCT. The majority of HIV- 
infected participants and their guardians acknowledged that they had anticipated a 
positive result, and attributed this predominantly to MTCT because of the 
combination of a) failure to thrive in the child and b) known or suspected maternal 
HIV infection or death, and c) deaths among siblings. These spontaneously 
volunteered reasons for suspecting an adolescent to be a long term survivor of 
MTCT were the same variables shown to be most strongly associated with 
underlying HIV infection in our hospital and primary care level data. 
In contrast, however, the perception of personal risk of being HIV-infected was low 
among uninfected and asymptomatic HIV-infected participants. Perceptions of the 
reaction that HIV-infected adolescents could anticipate were more uniform: 
participants and guardians from both HIV-positive and HIV-negative groups stated 
that community members would assume that HIV in an adolescent was sexually- 
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acquired, and that communities would not believe that the infection had been 
present from infancy. Stigmatizing attitudes were commonly expressed by HIV- 
negative participants and their guardians, and were strongly anticipated by HIV- 
infected participants and their guardians. 
7.4.3 Barriers to HIV testing 
Although the majority of the HIV-infected adolescents had suspected HIV and had 
even contemplated HIV testing as had their guardians, they had prevaricated for 
various reasons, including not knowing where to get testing. Lack of awareness of 
VCT services or reluctance of health care providers to discuss risk behaviours 
creates barriers to HIV testing. 363-364 There has been not only a dearth of health 
information and education about long term survival in HIV-infected children, but 
indeed the perception that survival of HIV-infected infants beyond the first few 
years of life is exceptional. These may have contributed to the current 
unsatisfactory situation of missed opportunities for PITC and family-initiated 
testing, with important implications for health education and health provider 
training. Participants reported having received encouragement in the past to test 
from friends and relatives but not from any health care providers. Without the 
knowledge of how to access testing and in the face of information that has stressed 
the low chance of surviving with HIV, families may hesitate to have older children 
tested. 
The study also raises an important possibility that the low awareness of long-term 
survival from MTCT may have a further major deterrent effect, in that the question 
of how the adolescent became infected then automatically arises. The default 
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assumption that HIV' among adolescents is sexually-acquired means that 
adolescents automatically anticipate stigma linked to having acquired HIV sexually 
should they test HIV positive, and this may deter them further from testing. Health 
care providers may be reluctant to discuss HIV infection in a sexually immature 
adolescent with guardians if they are themselves unaware that long-term 
untreated survival is more common than previously thought, as it might mean 
raising the question of sexual abuse. 
7.4.4 Other implications of Study Findings 
As well as systematic under-appreciation of the burden of HIV in this age group, 
adolescents face formidable barriers in accessing HIV diagnosis. Over and above 
ill-health and loss of parental input due to ill-health and death, lack of health 
information and education may be contributing to the high risk of prolonged 
diagnostic delay once signs and symptoms of HIV have developed. 365 The study 
highlights the need to publicise the growing problem of MTCT to general public, 
and health providers alike, and provide information on where families with older 
children who may be at risk of MTCT can seek testing. This may serve the purpose 
of destigmatising adolescent HIV infection in the broader community, while also 
enabling health providers to feel less inhibited about offering diagnostic testing. 
There are operational issues with regards to provision of routine HIV testing in 
healthcare facilities. 366-368 There is a potential for adolescents identified with HIV 
infection to be subjected to exploitation from others who assume behavioural HIV 
acquisition, and adequate counselling will be a critical requirement of PITC scale- 
up. Within primary healthcare services significant attention will need to be paid to 
staff training, motivating staff to offer HIV testing routinely, maintaining patient 
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confidentiality, mechanisms for referral and access to appropriate services for 
those who test HIV-positive, as well as reduction of stigma and discrimination. 
7.5 Limitations of the study 
Given the small numbers of those who opted-out of HIV testing in this setting, it 
was not possible to study possible deterrents to uptake of PITC in adolescents, 
including the influence of guardians on the likelihood of adolescents considering 
HIV testing. However, the extremely high uptake demonstrates that there are 
unlikely to be significant barriers to uptake in this group. Furthermore, there was 
strong support from guardians who are likely to be an important influence on 
adolescents considering HIV testing and whose consent is required for adolescents 
to undergo testing. The uptake of PITC among family members of HIV-negative 
participants may have been lower than that among families of HIV-infected 
participants, but was not assessed. 
HIV CT was carried out by motivated, well-trained research nurses and testing 
rates may well be lower under routine conditions. The perceptions and views of 
health-care workers to PITC were not assessed and the uptake of PITC among 
family members of HIV-negative participants was not determined. The 
questionnaires were given after the pre-test discussion and the information given 
may have influenced participants' responses and acceptability of HIV testing. The 
interviews were conducted some time after the HIV test which may have 
introduced some recall bias. Data on sexual risk factors was not collected and 
sexual abuse as a reason for testing may have been underestimated, as participants 
and their guardians may have been reluctant to divulge this. However, while not 
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discounting the high rates of sexual abuse reported from some African countries, 
the risk of acquiring HIV infection through sexual abuse is limited to penetrative 
forced sex, which occurs at a low rate during childhood and adolescence in this 
region, with the possible exception of South Africa. 189-190 Also, the association of 
HSV-2 infection with self-reported horizontally-acquired but not vertically- 
acquired HIV, further support the validity of the self-reported mode of HIV 
acquisition. 
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8A primary-care level algorithm for identifying adolescents at 
risk of HIV infection 
8.1 introduction 
As described in previous chapters, HIV prevalence was high among adolescents 
accessing both hospital and primary acute care services. Moreover, HIV infection 
was previously undiagnosed in all but a small minority of adolescents accessing 
primary care services. At both health service levels, characteristic features 
suggesting long-standing or maternally-acquired HIV infection were noted to be 
present in most cases, and were spontaneously volunteered by adolescents and 
guardians (Chapter 7). 
In this study, data collected prospectively from primary health care in Harare was 
used to investigate whether or not a simple screening tool could be constructed to 
identify adolescents at high risk of undiagnosed HIV infection in the context of 
populations at high risk of MTCT at the time of their birth. If so, then potential 
applications would include a) screening of adolescents for priority offer of 
diagnostic HIV testing in high HIV prevalence settings with mature epidemics but 
where implementation of routine testing is suboptimal, and b) in low HIV 
prevalence settings where HIV testing and counselling is not routinely considered, 
for example among African immigrants in low HIV prevalence settings. 
8.2 Methods 
8.2.1 Study Population and data collection 
The participant selection process and the sample size justification are described in 
detail in Chapter 6 (Section 6.2.1 and Section 6.2.5). Patients aged 10 to 18 years 
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attending two primary care polyclinics in Harare for any reason except ANC were 
offered an HIV test following group pre-test counselling and asked to consent for 
participation in the study, including an additional HIV test for study purposes, 
regardless of whether they accepted diagnostic HIV testing. A standardised 
questionnaire was used to record demographic details, clinical history and reason 
for clinic attendance. 
8.2.2 Data analysis 
A random number generator was used to divide the dataset into two: a "train" and 
"test" dataset, with an equal number of HIV-positive participants in each dataset. 
The train dataset was used to create and optimise the screening algorithm, which 
was then evaluated in the test dataset. 
8.2.2.1 Algorithm criteria 
The algorithm was designed for use at primary care level and thus variables that 
could be measured by primary health care workers were selected. Candidate 
variables used to construct the algorithm were defined a priori, and were coded as 
binary variables. The considered criteria were defined as in Table 8.1. Other 
criteria that were considered included age, sex, educational level, history of TB, 
self-rated health and history of hospitalisation (at least one night stay in hospital). 
8.2.2.2 Construction and optimisation of the algorithm 
Logistic regression modelling was used to estimate the univariate OR for the 
association of each variable with HIV infection. Variables with a p-value <0.1 were 
included in an initial multivariate model. 369 Variables not independently 
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statistically significant (i. e. with a p-value >0.05) were excluded from the model, so 
the final model included only those variables independently associated with HIV. 
Table 8.1 Definitions of variables predictive of HIV infection among 
adolescents 
Definition used in questionnaire 
Recurrent upper respiratory tract More than two upper respiratory tract infections (URTI) over a 
infections period of at least six months 
Recurrent chest infections 
More than two chest infections over a period of at least one 
year 
More than three episodes of diarrhoea over a period of at least 
Recurrent diarrhoea six months, with at least a week's diarrhoea-free period 
between each episode 
Recurrent skin problems 
More than 3 episodes of skin complaints occurring over a 
period of a year or more 
Wasting Weight-for age z-score <-2 
Stunting Height-for age z-score <-2 
Poor Functional ability Illness affecting ability to function in daily life 
Possible TB 
Suggestive symptoms: Cough >2 weeks, night sweats, weight 
loss, fevers 
Oral candidiasis White spots or plaques in the mouth 
Possible Sexually transmitted Vaginal/urethra) discharge or genital sores infection 
The log of the probability of being HIV-infected (p) was calculated for different 
combinations of variables Vi from the final multivariable model as follows: 
log (p/1-p) = constant + I31Vi+ ß2V2 + ß3V3 ...... ßnVn 
where V; is the binary variable i (coded as 1 if the variable is present and as 0 if the 
variable is absent) and ß; is the log(OR) associated with variable V1. 
The next step was to select a cut-off value of p, which would discriminate which 
individuals should be considered as being at higher risk of HIV infection and be 
referred for an HIV test. Using this cut-off, an algorithm was devised which 
classified individuals into one of two groups: 'high risk for HIV" and "low risk for 
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HIV". To choose the optimal cut-off, the sensitivity and specificity of the algorithm 
against the HIV test result were calculated for a range of cut-offs. The positive 
predictive value (PPV), negative predictive value (NPV) and the likelihood ratio 
(LR) of the algorithm using different cut-offs were also calculated. 
To increase the sensitivity of the algorithm without compromising specificity, 
additional variables with very high specificity (>97%) for HIV infection were 
added as options to the model at the desired cut-off of p. 
8.2.2.3 Evaluation of the algorithm 
The optimised algorithm was applied to the test dataset and sensitivity, specificity, 
PPV and NPV and LR calculated. The PPV, NPV, and number needed to HIV test to 
detect one HIV-positive individual were then calculated for varying HIV prevalence 
levels. 
8.3 Results 
A total of 506 participants (97% of those eligible) were enrolled during the study 
period of whom 86 (17%) were HIV-positive. 251 participants were randomly 
assigned to the train set and 255 to the test dataset. There were 43 HIV-infected 
participants in each dataset. 
8.3.1 Variables associated with HIV infection 
Age, sex and pubertal delay were not associated with HIV infection on univariate 
analysis. Orphanhood, hospitalisation, recurrent skin problems, possible STI and 
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poor functional ability were independently associated with increased risk of HIV 
infection in the multivariable analysis, and were included in the algorithm (Table 
8.2). Under the multivariable logistic regression model, a cut-off of p=0.12 
corresponded to an individual who met more than one of the five criteria in the 
model being considered as "high risk for HIV", and hence would be offered HIV 
testing under the proposed algorithm. 
Table 8.2 Sensitivity, specificity, crude odds ratio and adjusted odds ratio for 
variables associated with HIV infection 
Sensitivity 
(%J 
Specificity 
(%) 
Crude 
OR p-value 
Adjusted 
OR* p-value 
History of TB 9 97 3.45 0.06 4.37 0.08 
Orphan 77 58 4.59 <0.001 3.93 0.002 
Ever hospitalised 35 90 4.77 <0.001 4.05 0.003 
5 Primary education level 63 54 2.01 0.04 1.85 0.14 
Recurrent URTI 44 82 3.66 <0.001 2.41 0.06 
Recurrent chest infections 37 85 3.26 0.001 1.76 0.23 
Wasting 35 85 2.95 0.004 1.91 0.17 
Stunting 28 86 2.39 0.03 1.64 0.34 
Recurrent diarrhoea 53 74 3.20 0.001 1.66 0.25 
Recurrent skin problems 51 82 4.69 <0.001 4.07 0.001 
Self-rated poor health 65 79 7.16 <0.001 2.44 0.06 
Poor Functional ability 51 86 6.47 <0.001 4.82 <0.001 
Possible TB 12 97 3.78 0.03 2.96 0.16 
Possible sexually 12 96 3.29 0.05 5.35 0.015 transmitted infection 
*Adjusted for orphanhood, hospitalisation, chronic skin problems, functional ability and 
possible STI 
8.3.2 Identification of the optimum algorithm 
Using a cut-off of p=0.12, the sensitivity and specificity of the algorithm to predict 
HIV infection in the trainer dataset were 77% and 81% respectively. Lower and 
higher cut-offs resulted in a substantial drop in specificity and sensitivity 
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respectively: for example, using a cut-off of p=0.38 (corresponding to >2 criteria in 
the algorithm being met) resulted in a specificity of 95% but sensitivity dropped 
to 47%. Thus, other cut-offs were not considered further. High specificity 
variables (history of TB, history of herpes zoster and presence of oral candidiasis) 
were tested in various combinations as an option to the original algorithm, but 
resulted in no significant improvement in sensitivity of the algorithm, and thus the 
original model was retained as the final algorithm (Figure 8.1). 
Figure 8.1 Adolescent "HIV suspect" algorithm 
" Have you ever been admitted to 
hospital? 
" Have you had recurring skin problems? 
If _>2 
" Has one or both of your natural answers OFFER 
parents died? YES HIV 
" Does poor health affect your ability to TESTING 
function in daily life? 
" Does he/she have symptoms and/or 
signs of a sexually-transmitted 
infection? 
8.3.4 Test data set 
Applying the algorithm (with a cut-off of p=0.12) to the test dataset gave a 
sensitivity of 74.0% (95% Cl: 64%-82%) and a specificity of 80% (95% CI: 71%- 
87%) with the algorithm correctly classifying the HIV status of 79% of 
participants. As an additional check for internal validity of the model, 
bootstrapping of the dataset was carried out and the sensitivity and specificity on 
the test dataset after 50,000 iterations were 81% (95% Cl: 73-88%) and 77% 
(95% Cl: 68-82%) respectively. 
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8.3.5 Prediction of HIV Status in low HIV prevalence settings using the 
test dataset 
The algorithm had high estimated NPV in both low and high HIV prevalence 
settings and would result in an estimated 60% decrease in the number of people 
needing to test to identify one HIV-infected individual, compared with universal 
testing (Table 8.3). 
Table 8.3 Prediction of HIV status in different HIV prevalence settings 
HIV prevalence in 
Reduction in 
acutely unwell 
NNT+ NNT- NNT+ compared 
adolescents PPV NPV algorithm algorithm 
to universal 
testing 
0.05% 0.1% 100% 754 4380 62% 
0.1% 0.3% 100% 377 2189 62% 
0.5% 1.3% 99.8% 76 437 62% 
1% 2.6% 99.5% 38 218 62% 
2% 5.1% 99.1% 19 108 61% 
PPV = Positive predictive value; NPV = Negative Predictive Value; NNT+ algorithm = Number 
needed to test to identify 1 HIV-infected adolescent after application of algorithm; NNT- 
algorithm = Number needed to test to identify 1 HIV-infected adolescent misclassified by 
algorithm as not at HIV risk 
Using the algorithm in an adolescent clinic population with a low prevalence of HIV 
infection for e. g. 0.1% underlying risk of HIV infection, the algorithm would 
identify 377 adolescents for HIV testing for every one true positive (compared to a 
1000 adolescents screened to identify one HIV-infected adolescents). However, it 
is also important to minimise the number of false negative results (i. e. HIV-infected 
adolescents identified as being low risk): using the algorithm an individual would 
be falsely classified as "not at risk" for every 2189 adolescents screened. 
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8.4 Discussion 
8.4.1 Utility of a diagnostic algorithm 
This study shows that a simple, question-based algorithm can identify underlying 
HIV infection with reasonable sensitivity and specificity in African adolescent 
primary care attendees born into a population in which the adult HIV epidemic 
was at high prevalence at the time of their birth. Existing paediatric algorithms to 
identify children with HIV infection, such as the IMCI/HIV algorithm, tend to focus 
on diagnosis of younger children with symptomatic HIV infection, which may not 
be applicable to older children, and are also less evidence-based. 370 The algorithm 
had a sensitivity and specificity equal to or better than other tools to identify HIV 
infection in children, including algorithms based on clinical signs and symptoms 
and even paediatrician assessment, and requires a very simple assessment that 
could be administered following minimal training. 371-372 Data used to develop the 
algorithm was systematically and prospectively collected, avoiding the biases 
associated with use of retrospective or routine clinical data. Parallel HIV testing 
with two rapid test kits was used, with discordant results resolved by retesting 
stored specimens with the original two tests plus an ELISA test and hence, 
misclassification of HIV status will be minimal. 
Zimbabwe now has a rapidly declining HIV epidemic, and the studies described in 
the earlier chapters have established that vertically-acquired HIV is likely to be 
responsible for most symptomatic HIV infections in this age-group. This may also 
be true for some neighbouring countries, although the decline in HIV incidence and 
prevalence has been more pronounced in Zimbabwe than elsewhere in the 
region. 16194 Current international recommendations are that HIV testing should be 
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routinely offered to all attendees in health facilities, aiming to reduce the risk of 
late presentation with advanced HIV/AIDS and for secondary HIV prevention. 17 
However, in practice not all national policies are in line with the current 
international guidelines and often exclude children, and human resources and 
other constraints may adversely affect implementation. '8 In settings where 
universal testing is not routine for this age-group, a risk assessment based on the 
type of screening algorithm presented here is proposed as a preferable alternative 
to no offer of testing. 
Health care workers in primary care are often reluctant to discuss HIV testing with 
patients, and this may be particularly true for older children and younger 
adolescents where considering a diagnosis of HIV will raise uncomfortable 
questions about the source of their infection. Use of an algorithm may then serve 
to prompt this process in an age-group that is not well served by alternative 
testing services. 
8.4.2 Application of algorithm in low HIV prevalence settings 
Maternally-acquired infection also appears to be the predominant risk-factor in 
older African children and adolescents who present with previously undiagnosed 
symptomatic HIV infection having emigrated from high to low HIV prevalence 
countries, such as the UK. 373-374 For example, there has been a well-publicised 
death in the UK of a previously undiagnosed 10 year old whose parents had been 
diagnosed with HIV six years earlier. 375 Undiagnosed HIV should, therefore, be 
considered in all acutely unwell adolescents from families with known risk factors 
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for HIV (e. g. immigrants from high HIV prevalence settings or intravenous drug 
users). 
In low HIV prevalence countries, most HIV testing is carried out through free- 
standing or sexual health services. However, many newly diagnosed HIV-infected 
individuals report prior consultation in primary care, implying that opportunities 
for earlier diagnosis are frequently missed. 359 376 Facility-based testing is a highly 
cost-effective way of identifying HIV-positive individuals even in low HIV- 
prevalence settings. 377-378 The algorithm has a very high negative predictive value 
in low prevalence settings and, if validated, may be an attractive alternative to 
universal testing as, despite a low positive predictive value, it still results in a 
substantial decrease in numbers of adolescents who would need to be offered HIV 
testing. An additional advantage may be expansion and normalisation of HIV 
testing in primary care, a relatively under-utilised resource for provision of HIV 
testing. 379-380 
8.4.3 Other implications of study findings 
The study has evaluated a tool to identify underlying HIV infection among acutely 
unwell adolescents in whom the predominant risk factor for HIV is maternal 
transmission. It recognises the changing epidemiology of symptomatic adolescent 
HIV infection, thus prioritising high risk adolescents and their families for 
appropriate CT. 
As well as identifying individuals at high risk, the algorithm may serve to raise 
awareness among health providers of the need to consider long-term survival in 
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acutely unwell older children and adolescents at risk of maternally-acquired HIV 
infection. 
8.5 Limitations of the study 
The high prevalence of HIV infection (17%) in the study population, which was 
drawn from otherwise unselected adolescents attending acute care services at 
primary level, provided the statistical power needed to develop this type of 
algorithm in a relatively small sample size. The test-train method provides an 
internal validation of this approach but gives no insight into external validity. The 
algorithm may perform differently in populations with a different mix of sexually- 
acquired, parenterally and vertically-acquired adolescent HIV infection. The 
positive and negative predictive values of the algorithm will vary by background 
HIV prevalence and prevalence of variables in the model for e. g. past TB treatment 
and presentation with an STI may be uncommon in adolescents who have grown 
up in countries where these infections are well controlled, which may decrease the 
PPV of the algorithm. However, the sensitivity and specificity of the algorithm will 
remain unchanged. The algorithm is presented as a promising approach that can 
be adapted and according to local context, and the performance of the algorithm 
should be further validated in other settings. 
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9 Conclusions and recommendations 
As noted in Chapter 1, the starting point for this series of studies was the 
observation of increasing numbers of adolescents presenting to health care 
services in Harare with symptomatic HIV infection and features suggestive of 
longstanding disease. The epidemiological studies described in the previous 
chapters provide strong circumstantial evidence to support our initial hypothesis 
that this is predominantly due to a substantial epidemic of adolescent LTS of 
MTCT. The data are consistent from a number of key perspectives: 
9 Evidence of complications (stunting, pubertal delay, chronic lung 
disease, treatment for TB and chronic skin disorders) that are 
consistent with long standing HIV infection from childhood 
" Lack of any evidence suggesting forced or voluntary sexual debut in 
all but a small minority of HIV-infected adolescents, including HSV- 
2 serology, self-reported sexual history (hospital study), self-rated 
likely mode of transmission (primary care study) and in-depth 
interviews with HIV-infected participants and their guardians 
" Family attributes that are consistent with maternal HIV infection, 
including maternal death or known HIV infection, a high prevalence 
of HIV in family members who were tested as a result of HIV- 
diagnosis in an adolescent, reported sibling deaths, and the 
responses given by HIV-infected participants and their guardians 
on in-depth interview 
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Furthermore, as the risk of parenteral HIV infection is also known to be low in 
Zimbabwe, the rest of this discussion will consider the clinical and regional 
research implications, assuming that MTCT is indeed the dominant mode of 
transmission. 349 
Vertically acquired HIV used to be regarded as an inevitably fatal illness with death 
in early childhood. However, as HIV epidemics have matured, an epidemic of LTS 
of vertical transmission has become apparent in Zimbabwe, with substantial 
numbers of perinatally-infected children who have survived despite lack of 
treatment presenting with symptomatic HIV in older childhood and adolescence. 
Figure 9.1 Evolution of the HIV epidemic in sub-Saharan Africa 
Severe Heterosexual Adult HIV Epidemic 
High risk of sexual " MTCT "'35% risk without PMTCT 1980s 
transmission " Suboptimal PMTCT strategies and 
F»M 
coverage/postnatal transmission 
HIV Epidemic in Infants 
1990s 
Long-term Antiretroviral 
survival therapy 
Growing numbers of surviving HIV-infected adolescents 
2000s 
Risk of transmission to infants of adolescent LTS 
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9.1 Implications of research findings 
The most striking implications follow from the observation that HIV Infection is 
now the predominant cause of serious morbidity among adolescents in Harare. 
The findings underscore the importance of scaling up PMTCT interventions as well 
as early infant HIV diagnosis and immediate treatment of HIV infection in infants. 
These interventions will however, not affect the current cohort of surviving 
children who have slowly progressing HIV infection that was acquired before the 
introduction of PMTCT services. Potentially, current single-dose PMTCT 
interventions may further increase the proportion of vertical HIV infections that 
are acquired after the first few weeks of life (and thus more likely to be slow- 
progressing infections), although reducing the overall burden of infected infants. 
A key question that arises concerns the generalisability of study findings. This 
calls for urgent investigation into whether or not there is a similar trend regionally 
and steps to identify and implement appropriately tailored interventions to 
facilitate earlier diagnosis and entry into care of HIV-infected children and 
adolescents, with the aim of reducing the risk of severe immunosuppression and 
chronic complications. In addition, there is need to consider the special 
management issues that apply to adolescent LTS. 
9.1.1 Generalisability of findings 
The median survival of slow progressors plays a critical role in determining the 
magnitude and duration of the HIV epidemic in older survivors of MTCT in the 
region but cohort studies to estimate this would require a very long follow-up that 
would not now be ethical given the increasing availability of ART. However, it may 
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be possible to obtain indirect evidence of the distribution of survival through much 
more extensive prevalence surveys than have so far been carried out, through data 
from health facilities implementing provider-initiated or routine HIV testing and 
from data on the age distribution of patients entering clinical care with HIV 
infection. 
The magnitude of the epidemic of HIV infection among adolescents may vary 
between countries depending on the severity and duration of the adult HIV 
epidemic and the prevalence of competing causes of mortality in childhood e. g. 
exposure to malaria, enteric illnesses and levels of food insecurity. Hence the 
impact of HIV on ill-health, morbidity, and mortality in adolescence in other 
countries in Africa needs further study. As mentioned in Chapter 2, however, the 
available data concerning the age-distribution of children in care is already known 
to be similar to that of Harare for the rest of Zimbabwe, 344 and in Lusaka, Zambia, 16 
and also in Blantyre, Malawi where 38% of 1,733 paediatric HIV patients drawn 
from an urban population of less than 700,000 are 10 years or older (unpublished 
data, Dr B O'Hare) 344 
Given i) the consistency of the available data, ii) the magnitude of the projected 
epidemic of HIV in older children in Zimbabwe and South Africa (peaks of 3.4% 
and 3.3% of all 10 years being LTS in 2007 and 2020 respectively), and iii) the high 
risk of major preventable complications, notably of chronic lung disease, 
investment in rapid multi-country assessment studies may be already 
warranted. 194 
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9.1.2 Access to HIV testing and care 
HIV testing of older children has not been emphasized in HIV programs and health 
providers and the community lack awareness of the burden of HIV in this age- 
group. Routine health facility-based testing services may not be early or universal 
enough to be an acceptable strategy for this age-group. 365 Other models such as 
youth-friendly testing services, school-linked testing and family-centred testing 
may engage this group more effectively and should be actively explored. 
Similarly, interventions to facilitate access to HIV care for those who test HIV- 
positive are needed, especially in the light of our findings from primary care level. 
Cohort studies from Malawi, South Africa and Mozambique showed that ART 
uptake among eligible individuals was as low as 13 to 56%. 381-383 Outcomes for 
individuals who don't meet eligibility criteria for ART may be even worse, with 
only 4% of such individuals retained in pre-ART care in Thyolo, Malawi. 384 Access 
to care is likely to be even more difficult for adolescents as discussed in Chapter 7. 
The substantial barriers to accessing ART result in initiation of ART at an advanced 
stage of immunosuppression, which in turn is associated with significantly worse 
treatment outcomes. 283 385 A consensus on how care should be optimally delivered 
is also needed to avoid this age-group falling through the net of adult and 
paediatric services. 
9.1.3 Management of HIV-infected adolescents 
HIV interventions to date have mainly targeted younger children who face 
different challenges from those confronting adolescents. 344 These include several 
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unaddressed questions around clinical management, adherence and psychosocial 
and sexual health. 
9.1.3.1 Clinical issues 
The pathogenesis of chronic complications notably lung disease is not clearly 
understood and the optimum management strategies particularly in resource- 
limited settings need to be defined. The other question concerns the use of ART. 
Currently, adult guidelines are used to decide when adolescents should be initiated 
on ART. This may be inappropriate for this age-group as ART may also be 
indicated for prevention and treatment of chronic complications including growth 
failure, regardless of immunological status. Very little is known about 
pharmacokinetics and efficacy of different ART formulations in African 
adolescents. 386 Current international guidelines recommend dosing by weight, 
with the adult regimen from 25kg. Increasing age, undernourishment and pubertal 
and growth delay may each affect drug metabolism for e. g. nevirapine levels in 
African children on fixed dose combinations are reduced in stunted but increased 
in wasted children. 387-389 Vertically HIV-infected adolescents in Africa are 
frequently underweight and stunted, and it is unclear whether age or weight 
should be used to guide ART drug dosage. 
Although ART substantially reduces morbidity and mortality in children, 
irrespective of previous clinical and virological status, the extent of immune 
restoration may be age-dependent. 390 CD4 count recovery has been shown to be 
greater in younger children and this may reflect either greater thymic productivity 
in pre-adolescent children or poorer treatment adherence in older children. 391-392 
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The final extent of catch-up growth and pubertal development may be blunted 
when ART is started at an older age. 262 
9.1.3.2 Adherence 
Evidence is emerging that adolescents are at extremely high risk of early treatment 
failure. Early ART outcomes are much worse in adolescents than in adults, with 
very low self-reported complete adherence and high rates of detectable viraemia, 
nevirapine resistance and clinical disease progression. 392-395 
Table 9.1 Potential risk factors for poor adherence in adolescents 
Gender Contentious but women report more time off ART than men396 
Sexual maturity Tanner's stage 
Disabling Co-morbidity Chronic lung disease and neurocognitive impairment 
Adverse effects of treatment Real and perceived side-effects397 
Poverty Affects clinic attendance and attrition398 
Dependency & carer issues Orphanhood, carer ill-health, lack of supervision, guardian neglect399-400 
Distance from ART clinic Journey time and travel cost40' 
Disclosure and stigma Experienced or anticipated HIV stigma279 
Health beliefs Disbelief in HIV as a biological entity of disease402 
Reluctance to miss school Nondisclosure at school/ teacher's attitudes 
Drug resistance as a result of poor adherence or suboptimal dosing of ART has 
major implications for patients and health systems. Second-line therapy is 
expensive, less accessible, has poor outcomes, and adds substantially to ART 
programme costs even when rates of first-line treatment failure are low. 
9.1.3.3 Sexual and reproductive health 
Accessibility of sexual health services for young people is poor due to reluctance of 
health care workers to provide such services to this age-group reflecting the 
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cultural context in which services are delivered, and lack of confidentiality and 
privacy. 403 
Vertically-infected adolescents are often cared for in paediatric settings where 
reproductive health issues are not often addressed but sexual activity among this 
group is more common than many paediatricians assume. In a study of Ugandan 
HIV-infected adolescents aged 11-21 years, about a quarter of participants 
reported prior or current sexual exposure and barriers to adopting preventive 
behaviours included peer pressure, stigma, partners' ignorance, alcohol use and 
desire to have children. 404 There are several reports of pregnancies in vertically- 
infected adolescents, with three out of ten pregnancies resulting in abortion in one 
series. 405-407 Cervical screening is not standard among HIV-infected adolescents 
although nearly 50% of vertically-infected sexually-active females have persistent 
cervical cytological abnormalities. 408 
9.1.4 Correlates of slow progression 
The identification of a population with slow progressing infection provides the 
opportunity to study disease pathogenesis and mechanisms involved in control of 
HIV infection including genetic, virological and immunological determinants of 
delayed disease progression. This has implications for development of future 
strategies targeted against HIV such as therapeutic vaccines, particularly against 
the clades that are prevalent in sub-Saharan Africa. 
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9.2 Potential interventions and further research 
These are summarised in Table 9.2. 
Table 9.2 Research priorities and interventions concerning HIV-infected 
adolescent LTS 
Aims Research objectives and possible interventions 
Population-based epidemiology and interventions 
Is the Zimbabwean " Confirm facility-based findings elsewhere in the region 
epidemic of LTS typical " Investigate competing cause of childhood mortality: malaria, 
of Southern Africa? poor sanitation and unclean drinking water as potential 
disproportionate hazards to survival of HIV-infected children 
" Prevalence of HIV-infected LTS at community level 
  School surveys 
" Include older children and adolescents in Demographic 
Health Surveys (DHS) 
include questions concerning maternal vital status and whether 
participants already known to be HIV-infected. Repeated 
surveillance until prevalence of undiagnosed HIV infection in 
older children declines 
Can facility-based " Investigate impact of health facility-based PITC on 
diagnostic undiagnosed HIV infection 
interventions reliably " Investigate perceptions of health care workers re. PITC 
identify infected " Investigate feasibility of implementing community-based HIV 
adolescents & older testing and counselling diagnosis through School Health 
children? Programmes using different models e. g. opt-out testing, 
voluntary CT 
" Investigate feasibility of school-based HIV care services 
" Investigate school-based barriers to accessing care 
How can adolescent- Interventions: 
friendly HIV testing   Training of health-care workers and teachers 
and care interventions   Advocacy and health communication to increase general 
be implemented? awareness 
  Family-based counselling services promoted through 
community outlets such as schools, churches 
  Promotion of HIV testing of adolescents e. g. home-based 
HIV testing, adolescent testing days in primary health 
clinics 
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Aims Research objectives and possible interventions 
Biomedical research 
Host and viral " Confirming mother-to-child HIV transmission among LTS 
attributes of LTS (Viral genotyping and phylogenetic analysis of HIV from 
mother, child and sibling samples) 
" Genetic and immunological correlates of slow progression 
of HIV infection (e. g. HLA and KIR typing) 
HIV care 
How can virological " Investigate interventions to promote adherence: Directly 
outcomes following observed therapy, peer-led support, health education, 
ART be improved? economic enablers, community-based provision of ART, once 
daily dosing 
" Pharmacokinetic studies in stunted adolescents to define 
optimal ART dosing 
Complications of HIV " Significance of non-TB mycobacteria in chronic lung disease 
infection: Chronic " Impact of respiratory infections on decline in lung function 
lung and " Investigate interventions effective in other forms of 
cardiovascular bronchiectasis (e. g. cystic fibrosis): i) NSAIDS, ii) inhaled 
disease; antibiotics iii) oral antibiotics iv) TB preventive therapy v) 
neurocognitive phosphodiesterase inhibitors for prevention & treatment of 
complications pulmonary hypertension 
" Investigate approaches to improving infection control in the 
context of chronic cough and heightened susceptibility to 
M. tuberculosis infection 
" Investigate neurocognitive deficits that may affect executive 
functioning, contributing to poor adherence and poor 
learning 
Reproductive &" Mother and child outcomes in female LTS who have children 
sexual health (potential for high maternal mortality and risk of HIV to child) 
" Investigate effectiveness of ART in preventing second- 
generation perinatal HIV transmission given potential for 
transmission of HIV resistant to one or more classes of ART 
Interventions: 
  Cervical screening 
  Health education 
  Family planning and syndromic treatment of STIs 
Psychosocial health " Development of interventions to address stigma directed at 
health providers, families, teachers and HIV-infected 
adolescents (to address self-stigmatisation) 
" Interventions focused on providing life-skills to deal with 
sexual abuse and economic exploitation 
" Training health-care workers in disclosure practices 
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9.3 Summary 
Service provision has been adversely affected by the under-appreciation of the 
numbers of surviving older children and adolescents living with HIV in Africa. 
The need to consider HIV as a cause of ill health in older children has not been 
emphasized to health providers, and little or no provision has been made for the 
special needs of this age group. While awaiting further data of the burden of 
HIV in other countries, there is an urgent need to develop and rapidly 
implement policies and programmes aimed at providing early diagnosis and 
improving the care provided to the expanding numbers of older children and 
adolescents who are growing up with HIV. A model that integrates HIV clinical 
care with sexual and reproductive health, psychological, educational and social 
services will aid this previously neglected age-group to prepare for an 
independent and productive future and help reduce the impact of this 
devastating epidemic at community and societal level. 
Assuming that the high prevalence of older LTS is confirmed through 
population-based studies specifically addressing this phenomenon, then we can 
anticipate the need for clinical trials to address some of the unique features that 
accompany delayed diagnosis of vertically-acquired HIV infection, for example 
prevention and treatment of chronic lung and cardiac disease. 
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Postscript 
In addition to being a special group with unusual needs, we may also have much 
to learn from this previously neglected group. Global eradication of HIV 
infection is unlikely to be an achievable aim, and there are already signs that the 
political will needed to continue to expand international investment in HIV 
prevention and treatment programmes in Africa may be waning. 409 The 
survival to adolescence of a much higher proportion of untreated infants than 
anticipated pays testament to the powerful forces of natural selection that have 
shaped our immune systems and maintained the genetic heterogeneity required 
to cope with previously unencountered pathogens over hundreds of millions of 
years. 41o 
Pathogen-host co-evolution through analogous natural selection processes are 
thought to have greatly mitigated the pathogenicity of SIV strains in their 
normal host species. 411 Although we may feel that we should have no need of 
recourse to natural selection in the fight against HIV/AIDS, neither now in this 
technological age, nor in the future, African populations have already 
experienced huge mortality rates and extremely high life-time risks of dying 
from HIV. The current generation of LTS thus have the unique evolutionary 
significance of being the first to take the critical step of survival to reproductive 
age while living with this novel and deadly virus, and for this, as well as for 
humanitarian reasons, deserve our support, encouragement and investment to 
live their life to its full potential. 
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Appendix A Case Definitions 
The following case definitions were used to define acute and chronic conditions 
among adolescents admitted to hospital. 
A. 1 Acute conditions 
Tuberculosis (TB) 
i) More than five colonies of M. tuberculosis from any specimen or 
ii) AFB on tissue biopsy or at least two positive sputum smears or 
iii) Caseating granulomata on tissue biopsy or 
iv) response to treatment for one of: 
1. pulmonary disease - compatible chest radiograph changes and no 
response to antibiotics 
Z. exudative pleural effusion; 
3. pericardial effusion; 
4. meningitis- CSF lymphocytic pleocytosis, raised protein, low 
glucose, negative CrAg and fungal culture; 
5. intra-abdominal TB- lymphadenopathy on abdominal 
ultrasonography 
6. disseminated disease- febrile illness of more than 2 weeks 
duration, weight loss, pancytopenia and no response to 
antibiotics 
Bacterial pneumonia 
i) Acute onset (5 lweek) of symptoms plus airspace consolidation on 
chest radiograph performed at presentation, plus clinical response to 
antibiotics or 
Three of: 
1. fever 
2. cough 
3. purulent sputum 
4. pleuritic chest pain 
5. leucocytosis 
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iii) Plus evidence of consolidation on examination, plus clinical response 
to antibiotics. 
Lower respiratory tract infection (LRTI) 
Same as definition of bacterial pneumonia, but with no chest radiograph 
changes and/or no consolidation on respiratory examination. 
Pneumocystis pneumonia (PCP) 
i) Pneumocystis organisms detected in induced sputum or 
ii) Subacute onset of cough, exertional dyspnoea, elevated respiratory 
rate at rest (>25/min), diffuse ground-glass or interstitial shadowing, 
radiological and clinical response to high-dose trimethoprim- 
sulfamethoxazole. 
Bacterial meningitis 
Conventional pathogen identified in CSF by microscopy or if CSF leucocytosis 
(>50cells/mm3) that is predominantly (>80%) neutrophils, plus clinical 
response to antibiotics 
Cryptococcosis 
i) Cryptococcus isolated from blood or CSF or 
ii) serum or CSF antigen positive at a dilution of greater than 1: 8 
Septicaemia 
Isolation of clinically significant bacterial pathogen from blood culture plus 
clinical illness compatible with pathogen isolate. 
Enteritis 
Acute onset (s 1 week) of diarrhoea (3 or more loose stools /day). 
Malaria 
i) Visualisation of malaria parasite on thick blood film or 
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Consistent clinical symptoms, appropriate exposure history plus not 
other cause of fever found and response to anti-malarial treatment. 
Drug Toxicity 
i) History of exposure to appropriate drug (51 week before onset of 
symptoms) plus recognised adverse reaction to drug (e. g. 
zidovudine/anaemia) or 
ii) Stevens Johnson syndrome or new rash or anaphylaxis plus no other 
cause for the symptoms. 
Oesophageal candidiasis 
Oral candidiasis and recent onset of retrosternal chest pain on swallowing, plus 
response to fluconazole. 
HIV Wasting Syndrome 
Weight loss or cachexia, with diarrhoea or fever, or both, for at least one month, 
not known to be due to a condition unrelated to HIV infection, plus negative 
investigations for TB. 
Urinary Tract Infection 
Z2 of dysuria, fever, flank tenderness plus no abnormal vaginal or urethral 
discharge. 
Sexually Transmitted Infection 
i) (Women) Vaginal discharge and/or lower abdominal tenderness 
ii) (Men) Urethral discharge and/or dysuria or 
iii) genital sore/ vesicle / ulcer. 
Kapos! Sarcoma 
i) Characteristic gross appearance of erythematous or violaceous 
plaque-like lesion on skin or 
ii) mucous membrane and/or 
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iii) characteristic histological appearance of lesion. 
Stroke 
i) Sudden or rapid onset of focal neurological deficit, 
ii) Plus compatible CT appearance of stroke (bleed or infarct and no 
space occupying lesion) and no history of fevers or 
iii) Constitutional symptoms or 
iv) Chest radiographic features suggesting TB. 
Trauma 
Injury or later consequences of an injury 
A. 2 Chronic conditions 
Cardiac disease 
Clinical finding of cardiac failure and cardiomyopathy, valve lesions or 
pericardial disease on echocardiography. 
Chronic lung disease 
i) Radiological appearance of focal scarring, and/or 
ii) Opacification and/or 
iii) Cystic changes and/or 
iv) bronchial wall thickening, 
v) Plus negative TB smears & cultures from current episode 
vi) Plus two of 
1. Clubbing 
2. History of recurrent (at least 2) episodes of cough productive of 
copious amounts of purulent sputum 
3. Persistent fine basal crepitations on auscultation 
4. Cor pulmonale. 
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Cor pulmonale 
i) Case definition for chronic lung disease met plus 
ii) Either echocardiographic finding of right ventricular enlargement 
iii) Or two of the following: - 
i. Ascites 
2. Hepatomegaly 
3. Raised jugular venous pressure 
4. Ankle oedema. 
HIV-associated encephalopathy 
i) HIV infection 
ii) CT scan appearance of generalised cortical atrophy and no space 
occupying lesion or localised infarct, 
iii) Plus each of the following: - 
1. Two of 
1) Hyperreflexia 
2) Palmo-mental reflex, 
3) Memory loss (e. g. forgets names, places, conversations) 
4) Apathy 
5) Slowness of thinking 
2. No other cause found to explain the clinical findings 
3. Course of illness over weeks to months. 
Diabetes 
i) Previous diagnosis of diabetes mellitus made by a physician or blood 
glucose stix >10mmol/1(for the first time) or 
ii) Ketones in urine, z2+ glucose in urine, shallow and fast breathing, 
polyuria and excessive thirst. 
Bronchial Asthma 
i) History of recurrent wheeze or 
ii) Chest tightness on waking, at night or during exercise 
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iii) Symptomatic relief achieved through use of salbutamol plus audible 
wheeze at examination. 
Epilepsy 
iý Witnessed seizure or fit 
ii) Plus diagnosis of epilepsy made by a physician and 
iii) History of recurrent (at least 2) seizures unprovoked by 
alcohol/drugs. 
221 
Appendix B Chronic lung disease among HIV-infected 
adolescents with vertically-acquired HIV 
infection 
The study investigating HIV-associated morbidity among hospitalised 
adolescents, described in Chapter 4 of this thesis, suggested a high burden of 
chronic lung disease among HIV-infected adolescents, as a complication of 
longstanding HIV infection. However, pre-admission history of chronic lung 
problems was not well documented and past chest radiographs were not 
available, making it difficult to distinguish underlying chronic lung disease in 
patients who were presenting with acute-on-chronic complications. A 
prospective study was thus carried out in collaboration with King's College 
Hospital, London to investigate the burden and clinical features of chronic lung 
disease among stable vertically-infected adolescents (aged 10 to 18 years) in 
HIV care. Preliminary results are summarised in this appendix. 
B. 1 Methods 
Consecutive patients attending two outpatient clinics in Harare were recruited 
with no other inclusion criteria applied. Exclusion criteria were: - horizontally- 
acquired HIV, acute respiratory disease, taking intensive phase of treatment for 
smear-positive TB, lung malignancy, pregnancy, sickle cell disease. Mode of HIV 
acquisition was assessed by a physician, based on history of maternal and 
sibling HIV/death, history of chronic ill-health, pubertal delay and stunting, 
report of sexual activity by participant. Participant assessment included the 
following: 
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" Anthropometric assessment and standardised respiratory examination 
" Oxygen saturation 
0 Exercise testing (brisk 200m walk) 
" Spirometry (spirometric standards were obtained from age, sex and 
height matched healthy Malawian children412) 
" CD4 lymphocyte count 
0 Sputum examination for bacterial and mycobacterial culture, if able to 
expectorate 
" Chest radiography (CXR) 
0 High resolution computed tomography (HrCT) scan (independently 
reviewed by two thoracic radiologists, blinded to clinical and CXR data) 
0 Doppler echocardiography independently reviewed by two 
cardiologists, blinded to clinical and other data 
8.2 Results 
116 participants were recruited. The mean age was 14 years (S. D 2.62) and 
57% were female. The median CD4 count was 384 cells/µl (IQR 180-584), and 
69% were taking ART (median duration 20 months, IQR 5-40 months). Only 
one patient was a smoker. There was a high prevalence of chronic respiratory 
symptoms and severe restriction of exercise tolerance (Table B1), and 
spirometry showed common and severe deficit in lung function (Table B1). 
Symptoms, signs and spirometric indices were not associated with CD4 count, 
taking ART or duration of time on ART. 86% of CXRs were abnormal; the two 
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most common patterns on HrCT suggested obliterative bronchiolitis and 
bronchiectasis. 13% of patients had pulmonary hypertension on Doppler 
echocardiography. 
Table 131. Clinical features of respiratory disease in participants 
Clinical Features N (%) 
Clinical History 
>2 courses of antibiotics for LRTI in past year 48 (41) 
Hospitalised for LRTI in past year 19 (16) 
Symptoms 
Recurrent cough productive of purulent sputum* 77 (62) 
Exceptional chest pain 49 (42) 
NYHA Dyspnoea Scale >1 24 (21) 
Signs 
Respiratory rate >25/min at rest 33 (28) 
Resting oxygen saturation <92% at rest 15 (13) 
Oxygen saturation drop of z5% on exercise testing (n=72)* 21(29) 
Spirometric 
FEV1 % predicted < 80% 52 (44) 
PEFR % predicted < 80% 33 (28) 
*Most days in at least 3 months in the year in past two years 
** 3 not mobile, 8 02 sats<92%, 26 RR>25,7 02 sats<92% and RR>25) 
B. 3 Conclusions 
Vertically-infected African adolescents attending for HIV care have an extremely 
high prevalence of severe and disabling chronic lung disease, with over half of 
the systematically selected adolescents in this clinic displaying features (resting 
tachypnoea, resting hypoxia, drop in Fi02 on exercise, and pulmonary 
hypertension) that have been well documented to carry a poor prognosis of 
medium term (5 year) survival in cohort studies of chronic lung disease from 
non-HIV causes. 413 Extending these studies to investigate the prevalence of 
chronic lung disease in adolescents presenting with HIV at other levels in the 
health system is thus a matter of urgency, as are studies focused on better 
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management and prevention of respiratory disease in HIV infected older 
children and adolescents. 
These findings also support the conclusions from the hospital-based study 
detailed in Chapter 4, namely that current HIV testing and care practice need to 
be much more proactive and aimed at younger patients in the community or 
primary care level if severe and irreversible complications from untreated 
maternally-acquired HIV are to be effectively prevented. Of note, clinical signs 
and spirometric indices were independent of immunological status or HIV 
treatment status, suggesting that once established, ART does not significantly 
reverse the clinical course of lung disease. 
Figure 131. A) Finger clubbing in a study participant B) HrCT showing 
cystic destruction of the lung C) HrCT showing mosaic 
attenuation of the lung, suggestive of obliterative bronchiolitis 
D) Flow volume loop in a 13 year old female showing a severe 
restrictive defect 
A 
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